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Abstract 
 
Results from high-throughput studies of the last decade have shown an 
important connection between regulated pre-mRNA splicing and tumorigenesis 
as well as therapy resistance. To date only relatively few such interactions have 
been studied in depth. The human epidermal growth factor receptor 2 (HER2) is 
an important biomarker in cancer, especially in 20-30% of breast cancer cases. 
This subset of breast cancer patients are treated with HER2-targeting therapies 
in addition to chemotherapy. Although these therapies are very successful, in a 
subset of patients with primary tumours as well as in advanced metastatic 
breast cancer resistance occurs. The underlying mechanisms are not well 
understood; one potential cause is the alternative splicing of HER2 pre-mRNA 
yielding protein variants which can evade or prevent action of these 
therapeutics. This PhD thesis details progress in understanding the 
mechanisms regulating the production of the HER2 variant Δ16HER2, which 
has been shown to have high oncogenic potential. Four key splicing factors that 
regulate this splicing event were identified as well as a specific RNA:protein 
binding site in the Δ16HER2 splicing region.  
In addition, a potential novel HER2 mRNA transcript was identified involving 
retention of intron 25 (termed I25HER2). I25HER2 was shown to be expressed 
in both normal human tissues and breast cancer tissue samples. Interestingly, 
the expression level of I25HER2 is not proportional to wild type HER2 in all 
tissues. Although, I25HER2 would be expected to undergo nonsense-mediated 
decay, this study indicated that I25HER2 mRNA has similar stability to 
Δ16HER2 mRNA.  
An ongoing challenge in both clinical and non-clinical studies is the inability to 
distinguish different HER2 protein variants. Initial results presented in this 
thesis, from a comparative study between immunohistochemistry (using three 
different HER2 antibodies, including the clinically used HercepTestTM) and 
HER2 gene amplification (using HER2 CISH pharmDxTM) in a cohort of primary 
human ductal carcinomas showed a subset of discordant cases. In a few of 
these tumours elevated levels of HER2 splice variants could be detected. The 
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possible implication for successful treatment of these patients’ highlights the 
importance of linking the basic processing of HER2 transcripts and protein 
variants with pathological information from patients.   
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Chapter 1: Introduction 
1 
 
Chapter 1: Introduction 
 
1.1. The Human Breast 
 
The human breast is a bilateral organ overlaying the pectorialis major muscle 
located between the second and sixth rib. The mammary gland, the milk 
producing organ, is surrounded by adipose tissue and structurally stabilised and 
anchored to the pectoralis major muscle by Cooper’s ligaments, a loose fibrous 
connective tissue (Cooper, 1840). The breast is supplied by the internal 
mammary artery and the lateral thoracic artery with blood (Vorherr, 1974). 
Lymphatic drainage occurs primarily through axillary lymph nodes and 
ipsilateral internal mammary lymphatics (Suami et al., 2008). 
The first steps in the development of the human breast occur in weeks seven to 
eight of gestation (Naccarato et al., 2000). At birth the mammary gland consists 
of a basic ductal system. Until shortly before puberty the mammary gland 
remains in this resting state and little difference between the genders can be 
observed. Reaching puberty the female breast increases in size primarily 
through the growth of adipose tissue. More importantly, the hormonal changes 
of the menarche and the subsequent menstrual cycles induce the elongation of 
existing ducts and the branching into secondary ducts. At the termini of the 
secondary ducts lobules, clusters of bi-layered epithelial buds, also known as 
alveoli develop. After initial growth of the ductal system in puberty, a decreased 
growth continues until the age of ~35 (Russo and Russo, 2004; Hassiotou and 
Geddes, 2013).  
Only with completion of the first pregnancy-lactation cycle (PLC) does the 
mammary gland develop into a mature and fully functional organ. The presence 
of competent mammary stem cells accounts for the ability of the mammary 
gland to repeatedly undergo structural and functional rearrangements through 
development, repeated PLC and post-menopausal regression (Hassiotou and 
Geddes, 2013). The increase in circulating hormones especially progesterone, 
oestrogen and prolactin in pregnancy induces the elongation and branching of 
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the ductal system and the differentiation of the alveolar mammary epithelial 
cells into lactocytes (Pang and Hartmann, 2007). Although, a low level secretion 
of milk components can be observed around 24 weeks of gestation, within 48-
72h after parturition the levels of secretion drastically increase. A suckling 
induced neuroendocrine reflex causes the release of oxytocin, which induces 
contraction of the myoepithelial cells surrounding the alveoli. The produced milk 
is drained from the alveoli into the main duct, from which it is transported via the 
lactiferous sinus onto the nipple surface (McManaman and Neville, 2003).  
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Anatomy of the human breast. 
The image shows the structure of the female breast. The different parts are indicated. Image 
adapted from (Anatomy of the human breast). 
As the demand for milk decreases or stops, milk production stops and the 
mammary gland returns to a resting state. This process is called post-lactational 
involution, wherein the mammary alveolar cells are removed (Hurley, 1989). As 
the ovary functions decline with the onset of menopause, the hormonal changes 
trigger post-menopausal regression of glandular tissue, which is replaced by 
adipose tissue (Hutson et al., 1985). 
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1.2. Breast cancer 
 
1.2.1. Breast cancer epidemiology 
 
According to numbers collected by the World Health Organisation (WHO) 
cancer remains one of the leading causes of morbidity and mortality with 14 
million new cases and 8.2 million deaths in 2012 (World Health Organisation, 
2015). Furthermore, the numbers of new cancer cases is expected to 
continuously increase (Maddams et al., 2012; World Health Organisation, 
2015). The most common cancer associated deaths are due to lung, liver, 
stomach, colorectal, breast and oesophageal cancer (World Health 
Organisation, 2015).  
Given the ability of the mammary gland for repeated cycles of growth and 
regression as well as morphological changes, it is not surprising to find it as a 
common site for tumour development. In the UK alone nearly 50,000 women 
are diagnosed every year with cancer and 11,643 women died due to breast 
cancer in 2012 alone (Cancer Research UK, 2014b; Cancer Research UK, 
2014c). Thanks to an early diagnosis and to improved treatment options the 
ten-year net survival rate has increased to 78.4% in the UK (Cancer Research 
UK, 2014d; World Health Organisation, 2014). In many less developed 
countries breast cancer is only diagnosed at a later stage and the five-year 
survival rate is therefore only around 10-40% (World Health Organisation, 
2014).  
 
1.2.2. Breast cancer risk factors  
 
As most forms of cancer, breast cancer develops due to an accumulation of 
multiple genetic and environmental insults. This is also reflected in the 
increased occurrence of breast cancer with age. A steep increase in breast 
cancer cases can be found from the age of 30-34 onwards. In the UK 80% of 
cases occur in the age group over 50. These number are potentially slightly 
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biased as they coincide with the onset of the breast cancer screening program 
(Cancer Research UK, 2014a).  
Common cancer risk factors including lifestyle choices such as increased 
alcohol consumption and smoking, as well as environmental factors such as 
exposure to gamma and x-ray radiation are also risk factors of developing 
breast cancer (Parkin et al., 2011). Another risk factor, is a history of benign 
breast disease with a proliferative lesion or atypical hyperplasia (Tice et al., 
2015).  
Many risk factors for the development of breast cancer are associated with 
mammary gland development and circulating hormone levels. An early 
menarche and late menopause, therefore a long exposure to increased sex 
hormone levels are considered important risk factor for the development of 
hormone receptor overexpressing breast tumours (Collaborative Group on 
Hormonal Factors in Breast, 2012). On the other hand, early first pregnancy 
(<14 years after menarche), multiple PLCs and breast feeding are considered to 
reduce the risk of breast cancer (Collaborative Group on Hormonal Factors in 
Breast, 2002; Kubba, 2003).   
Additionally, increased body weight, especially abdominal fat is considered an 
important risk factor for post-menopausal breast cancer (Gathirua-Mwangi et 
al., 2015). The increased sex hormone production, especially oestrogen by 
adipose tissue is thought to increase breast cancer risk (Key et al., 2003). 
Similarly, oral oestrogen-progesterone contraceptives and hormone 
replacement therapy increase the risk of tumour development. Ten years after 
the use of oral contraceptives is stopped, the risk has decreased back to a 
normal level (Collaborative Group on Hormonal Factors in Breast, 1996; Kubba, 
2003; Gierisch et al., 2013). 
About 90 to 95% of breast tumours are classified as sporadic, with no disease 
relevant inherited genetic alteration. The majority of hereditary tumours, 10-20% 
are linked with mutations of the breast cancer early onset genes BRCA1 and 
BRCA2 (Rizzolo et al., 2011; Aloraifi et al., 2015). The BRCA genes are 
involved in cell cycle, apoptosis and DNA-repair after DNA double strand breaks 
(Yoshida and Miki, 2004). These functions make their deregulation an important 
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step in the development of hereditary breast tumours. Inherited mutations 
increase the risk of developing breast cancer by 79.5% for BRCA1 and 88% for 
BRCA2 (Evans et al., 2008). Mutations in p53, STK11, CDH1 and PTEN 
(phosphate and tensin homolog) are also associated with a higher risk of 
developing breast cancer but are far less common (Aloraifi et al., 2015). A 
moderate increase in risk can also be observed for mutations in proteins that 
are part of regulatory pathways like the BRCA signalling pathways, such as 
ATM (ataxia telangiectasia mutated), CHEK2, PALB2 and BRIP1 (Rizzolo et al., 
2011). Further mutations exist that are common in the population, but only 
confer a low increase in the risk of developing breast cancer (Aloraifi et al., 
2015). 
 
1.2.3. Breast cancer categorisation 
 
Breast cancer is an umbrella term for multiple distinct tumour types originating 
from breast tissue. All tumours can be categorized according as to whether they 
are localised (in situ), if they have invaded surrounding tissue (invasive) or if 
they have formed metastasis at distal sites (metastatic).  
 
Figure 1.2: The development of ductal carcinoma. 
The image shows the stages from a normal duct through hyperplasia and ductal carcinoma in 
situ (DCIS) to invasive carcinoma. Image extracted from (Development of ductal carcinoma, 
2014). 
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The development of cancer is not clearly defined. In most cancer cases multiple 
tumours of different stages surrounded by benign tissue can be observed within 
one breast cancer. Most tumours develop in the terminal ducts, not the lobules, 
making the ductal carcinomas the major type of breast cancer. As shown in 
figure 1.2, the first step in the development of ductal carcinomas is an increased 
proliferation of the ductal epithelial cells (ductal hyperplasia). Next abnormal, 
less well differentiated cells (atypical hyperplasia) emerge. These develop into 
non-invasive ductal carcinoma in situ (DCIS) and in a next step into infiltrating, 
invasive breast cancers. 
Invasive tumours are categorized by their histological features. The major 
subtypes are invasive ductal carcinoma (IDC) (80%) and invasive lobular 
carcinoma (ILC) (5-15%). Further minor groups exist, such as adenoid cystic 
carcinoma, apocrine carcinoma, IDC with osteoclastic giant cells, medullary 
carcinoma, metaplastic carcinoma, micropapillary carcinoma, mucinous 
carcinoma, neuroendocrin carcinoma and tubular carcinoma (Weigelt et al., 
2008). 
Additionally, a small proportion (1-5%) of breast tumours are characterised by 
cancer cells that block dermal lymph vessels and cause redness and swelling of 
the breast. These inflammatory breast cancers are very aggressive and fast 
progressing, and are mostly IDC tumours (Anderson et al., 2005; National 
Cancer Institute, 2012). 
 
1.2.3.1. Breast Cancer Grading and Staging  
 
As part of the clinical assessment of a tumour it is categorised according to 
grading and staging systems. Tumours are graded according to how closely 
they resembles the surrounding normal tissue.  
Grade 1: well differentiated cells with slow growth 
Grade 2: moderately differentiated cells with moderate growth 
Grade 3: poorly differentiated cells with fast growth 
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GX: grade cannot be determined 
If the tumour consists of poorly differentiated cells this also means that the cells 
are more stem cell like and able to multiply and adapt to external influences 
much faster (Rakha et al., 2010; Scimeca et al., 2016). Ductal carcinoma in situ 
is differently graded. The grades are due to the nuclear grade, how abnormal 
the cancer cells appear, and the presence of necrosis (Pinder, 2010). 
The tumour-node-metastasis (TNM) breast cancer staging system is a more 
complex categorisation system (Table). It takes into consideration the local 
extend and size of the tumour (T), the number and extent of affected regional 
lymph nodes (N) and the presence or absence of metastasis (M) (Singletary 
and Connolly, 2006).  
Table 1.1: Breast cancer according to the TMN stage system.  
(Singletary and Connolly, 2006; Cancer Research UK, 2014e) 
Tumour size (T) 
TX Cannot be assessed 
T0 No tumour detected 
T1 The tumour is ≤2 cm 
T2 The tumour is ≥2cm, but ≤ 5cm 
T3 The tumour is ≥5cm 
T4 a – The tumour has spread into the chest wall 
b – The tumour has spread into the skin and the breast may be swollen 
c – The tumour has spread to both the skin and the chest wall 
d – Inflammatory carcinoma – this is a cancer in which the overlying skin is 
red, swollen and painful to the touch 
Regional lymph nodes (N) 
NX Cannot be assessed 
N0 No regional lymph node metastasis 
N1 Movable ipsilateral axillary lymph nodes affected 
N2 a – cancer cells in the lymph nodes in the armpit, which are stuck to each other 
and to other structures 
b – cancer cells in the lymph nodes behind the breast bone (the internal 
mammary nodes), which have either been seen on a scan or felt by the doctor. 
There is no evidence of cancer in lymph nodes in the armpit 
N3 a – cancer cells in lymph nodes below the collarbone 
b – cancer cells in lymph nodes in the armpit and behind the breast bone 
c – cancer cells in lymph nodes above the collarbone 
Disease metastasis (M) 
MX Cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
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1.2.3.2. Molecular Breast Cancer Categories 
 
A number of well-established biomarkers exist which are routinely measured in 
breast cancer patients. These are oestrogen receptor (ER) and progesterone 
receptor (PR) as well as the human epidermal growth factor receptor 2 (HER2). 
They are overexpressed in different combinations in 85-90% of all breast 
tumours. A tumour is referred to as being receptor positive, if the receptor is 
strongly overexpressed. Most common is the overexpression of ER, in 75% of 
all breast tumours, of these 55% are also PR positive. Generally ER/PR+ 
tumours occur more in postmenopausal women and have the lowest incidence 
of general metastases, but the highest incidence of bone metastasis. Bone 
metastases may also develop upward of 10-20 years after initial diagnosis 
(Chikarmane et al., 2015). ER and/or PR+ tumours can further be grouped into 
two categories luminal A if HER2- and luminal B, if HER2 overexpressing. The 
2011 St. Gallen International Expert Consensus proposed a change to the 
classification system. There, luminal A tumours are ER+ and PR+ and HER2- 
with a low cellular proliferation index (Ki-67 <14%). Luminal B can be ER+/- 
PR+/- and HER2-/+ with a high proliferative index (Eroles et al., 2012).  
In total 20-30% of breast tumours are HER2 overexpressing (Slamon et al., 
1987; Slamon et al., 1989). 10-15% are hormone receptor negative and 
proliferation index high (Eroles et al., 2012). HER2 overexpressing tumours are 
more common in younger women. The metastases generally occur within 5 
years after initial diagnosis and are often found in the liver. Interestingly after 
the treatment with Trastuzumab, a HER2-targeting therapeutic agent, an 
increase in central nervous system metastasis can be observed (Chikarmane et 
al., 2015).  
Tumours that are negative for ER, PR and HER2 fall into three categories: 
basal-like or triple negative (ER-, PR- and HER2-, cytokeratine 5/6 and/or 
EGFR +, high proliferative index), Claudin-low (ER-, PR- and HER2-, 
cytokeratine 5/6 and/or EGFR +/-, high proliferative index) and normal breast 
like (ER-/+, HER2-, cytokeratine 5/6 and/or EGFR +/-, low proliferative index) 
(Eroles et al., 2012). 
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This categorisation is important in a clinical setting to devise the best possible 
treatment plan for each patient, especially with regards to the administration of 
ER-targeting therapy and HER2-targeting therapies.  
 
1.3. Oestrogen receptor 
 
The oestrogen receptor is an important breast cancer biomarker and 
therapeutic target. Oestrogen is involved in cell growth, reproduction, 
development and differentiation. In humans its most common form is 17β-
oestradiol, although oestrone and oestriol can also be found. 17β-oestradiol is 
synthesised by the ovaries in premenopausal women. In postmenopausal 
women and men 17β-oestradiol is converted from testosterone and 
androstenedione at different site of the body including breast and adipose tissue 
(Jia et al., 2015).  
 
Figure 1.3: Oestrogen receptor variants.  
Oestrogen receptor α has two well studied splice variants ER-α46 and 36. Common features 
between the ERs are the five domains. A/B: ligand-independent activation function (AF-1); C: 
DNA-binding domain (DBD); D: hinge domain (H) with a nuclear localisation signal; E: ligand-
binding domain (LBD) and ligand-dependent transactivation function (AF-2); F: 
agonist/antagonist regulator. 
 
Two highly homologous oestrogen receptors have been identified ER-α 
encoded by the oestrogen receptor 1 (ESR1) gene at position 6q25.1 and ER-β 
encoded by the oestrogen receptor 2 (ESR2) gene at position 14q23.2. Both 
receptors belong to the nuclear receptor superfamily of ligand-inducible 
transcription factors (Chan et al., 2015; Jia et al., 2015). The ER proteins are 
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made up of five main domains (Figure 1.3): The N-terminal A/B region contains 
a ligand-independent activation function (AF-1), a DNA-binding domain (DBD) 
in region C, a hinge domain (H) with a nuclear localisation signal in region D, a 
ligand-binding domain (LBD) and the ligand-dependent transactivation function 
(AF-2) in region E. Lastly region F with an agonist/antagonist regulator (Marino 
et al., 2006). In addition to wild type ER receptors both genes encode for a 
number of splice variants. Only the ER-α46 and 36 variants have been studied 
in more depths. Studies have suggested contradictory roles for the two ERs. 
ER-α is thought to promote growth and survival of breast epithelial cells, 
whereas ER-β is associated with growth inhibition (Chan et al., 2015).  
 
Figure 1.4: The oestrogen and oestrogen receptor (ER) signalling pathways. 
Oestrogen and ER can induce transcription of target genes through multiple pathways. In the 
classical model, oestrogen bound ER is translocated to the nucleus, where it recognises and 
binds oestrogen response elements in target genes (A) or acts as co-transcription factor (B), 
and thereby regulates transcription. C, Alternatively, ER can be phosphorylated through growth 
factor receptors or chemokine receptors and translocate to the nucleus, to regulate the 
transcription of target genes. D, In the non-genomic pathway, oestrogen activated ER can 
activate the PI3K/AKT and RAS/MAPK signalling pathways. These signalling pathways regulate 
transcription factors of target genes. Image has been derived from (Le Romancer et al., 2011). 
Oestrogen activates a complex signalling pathway. The classical model involves 
the high-affinity binding of oestrogen to ER, conformational changes and 
disassociation from heat shock proteins and immunophilin chaperones 
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(Gougelet et al., 2005). Following this, the ER dimers translocate into the 
nucleus, where ER recognises and binds to the oestrogen response element 
(ERE) within target genes (Figure 1.4). ER can indirectly affect transcription by 
causing the association or dissociation of components of coregulatory 
complexes, which regulate chromatin function and affect the transcription 
machinery (Kampa et al., 2013). The ER signalling pathway also includes non-
genomic activation (Figure 1.4). ER-α dimers localised in close proximity of the 
plasma membrane can be activated by oestrogen and in turn activate the 
phosphoinositide-3-kinase (PI3K)/AKT and rat sarcoma/mitogen-activated 
protein kinase (RAS/MAPK) signalling pathways. These pathways lead to cell 
proliferation, survival and control of cell cycle (Bjornstrom and Sjoberg, 2005; Le 
Romancer et al., 2011). The activity of ER can also be initiated independently of 
oestrogen. Growth factor and chemokine receptors can phosphorylate and 
activate ER through RAS/MAPK pathway members. The activated ER can then 
perform its transcription regulation function on the target genes (Kato et al., 
1995; Rhodes et al., 2011; Kampa et al., 2013). 
 
 
1.4. Progesterone receptor  
 
The steroid hormone progesterone is known for its essential function in normal 
female reproductive organs and the mammary gland, but it is also important in 
the normal function of the cardiovascular system, central nervous system and 
bones [reviewed in (Mulac-Jericevic and Conneely, 2004; Taraborrelli, 2015)]. 
Its main receptors are PR-A and B, but it can also act through other receptors 
such as the nuclear glucocorticoid receptor (Lei et al., 2012). PR is essential in 
the normal female reproductive organ and mammary gland development 
(Mulac-Jericevic and Conneely, 2004). It also plays an important role in the 
development of breast cancer and is therefore an important biomarker for 
breast cancer therapy.  
The two PR receptors, PR-A and PR-B are encoded by one gene from two 
alternative promoters (Kastner et al., 1990). They are members of the ligand 
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activated nuclear receptor superfamily of transcription factors. The PR-B protein 
contains two transactivation domain (AF-3, AF1) at the N terminus, followed by 
a DNA-binding domain, a ligand binding domain towards the C-terminus and 
another transactivation domain (AF2). PR-A differs from PR-B by lacking the 
AF3 domain, but containing an inhibitor domain at the N-terminus (Figure 1.5) 
(Leonhardt et al., 2003). Additional PR variants which are due to alternative 
splicing have been described, but more extensive investigation is necessary to 
understand their actual role (Cork et al., 2008). 
 
 
Figure 1.5: The domains of the progesterone receptor.  
The progesterone receptor gene encodes two proteins, PR-A and PR-B. The PR-B protein 
contains two transactivation domain (AF-3, AF1), followed by a DNA-binding domain (DBD), a 
ligand binding domain (LBD) and another transactivation domain (AF2). The PR-A differs from 
PR-B by lacking the AF3 domains, but containing an inhibitor domain at the N-terminus. 
 
Interesting to note is the fact that PR is an oestrogen responsive gene (Cork et 
al., 2008). Similar to ER, binding of the ligand, progesterone, induces a 
conformational change and dimerization of PR. Active and phosphorylated PR 
binds to progesterone-response-elements in the promoter of target genes. 
Activated PR can also, independently of progesterone-response elements, 
interact with co-activator/co-repressor proteins or general transcription factors to 
regulate transcription of target genes (Mulac-Jericevic and Conneely, 2004). 
Through the regulation of transcription, PR is involved in cell growth, apoptosis 
and protein and nucleic acid processing as well as metabolism (Richer et al., 
2002). The non-genomic action of PR can be mediated through its interaction 
with ER-α and initiation of the src/RAS/MAPK pathway which regulates cell 
proliferation and survival (Ballare et al., 2003). Again similarly to ER, PR can act 
in a ligand independent manner. For example in breast cancer with increased 
levels of casein-kinase 2 (ck2), PR-B can be activated by phosphorylation 
through ck2 and in turn initiate downstream pathways (Hagan et al., 2011).  
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1.5. Human epidermal growth factor receptor 2 
 
The human epidermal growth factor receptor 2 is a member of the 
erythoblastosis oncogene B family of receptor tyrosine kinases. It is also 
referred to as ErbB2 or NEU. Other members of this protein family are ErbB1 
(HER1) better known as EGFR, ErbB3 (HER3) and ErbB4 (HER4). The 
members of this family are known to interact by dimerization and regulate a 
large network of signalling pathways, most notably the PI3K/AKT and the 
RAS/MAPK pathways, which control cell proliferation, growth and survival, as 
well as angiogenesis and cellular metabolism (Roskoski, 2013; Dittrich et al., 
2014). In about ~20% of primary breast cancers HER2 is overexpressed, its 
ability to induce these cellular process makes it a driver of tumour development 
and persistence (Slamon et al., 1987; Slamon et al., 1989).  
1.5.1. The regulation of HER2 gene expression  
 
The HER2 gene is located on chromosome 17q12-21. Transcription of the gene 
is regulated by a number of transcription factors (Table 1.2). Some transcription 
factors such as activator protein-2 (AP-2) induce HER2 expression (Vernimmen 
et al., 2003a; Vernimmen et al., 2003b), others such as the Foxp3 are negative 
regulators (Zuo et al., 2007).  
In the past the HER2 gene has been shown to give rise to a complex set of 
mRNA transcripts. In Ensembl a number of HER2 transcripts have been 
collected. Most studies, including this research, considers ensembl transcript 
ERBB2-008 (ENST00000269571) the wild type transcript. It contains 27 exons 
and is 4.545 kb long.  
The high number of transcripts can be partially attributed to multiple promoters. 
The first promoter was shown to have up to three mRNA start sites at 178, 244 
and 257 nucleotides upstream of the translation initiation site in placenta tissue 
and the human HER2 positive breast carcinoma cell line SKBR-3. Additionally 
in the human breast cancer cell line MCF-7, which only expresses HER2 at a 
low level, two different mRNA start sites at 270 and 315 nucleotides upstream 
of the initiator ATG were found (Tal et al., 1987). The second promoter was 
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identified in conjunction with 4 additional exons upstream of the conventional 
exon 1, which is skipped if the upstream exons are used yielding a 5.2kb long 
mRNA transcript. They detected this transcript in the HER2-low MCF-7 cells, 
but not in HER2-positive SKBR-3 cells (Nezu et al., 1999). 
Table 1.2: Transcription factors and co-regulators of the HER2 gene.  
Adapted from (Dittrich et al., 2014). 
 
A number of proteins associate with mRNA transcripts to stabilise it, facilitate its 
export and translation. HDAC5 has a stabilising effect on HER2 mRNA in breast 
cancer cell lines (Scott et al., 2008). Translational inhibition and degradation of 
mRNA can be regulated by microRNAs (miRNAs). In the breast cancer cell line 
SKBR-3 the overexpression of miR-125a and miR-125b downregulates HER2 
mRNA levels. As a consequence anchorage dependent growth, migration and 
invasion was inhibited (Scott et al., 2007). This is supported by the observation 
that miR-125b is downregulated in some breast tumours (Ferracin et al., 2013). 
Furthermore, miRNAs have been identified that target the HER2 3’untranslated 
region: miR-2559, 548d-3p (Chen et al., 2009) and 331-3p (Epis et al., 2009). 
Recently, miR-155 was found to down-regulate HER2. The miRNA can target 
HDAC2, a transcription activator of HER2 and thereby downregulate the 
Name Co-regulators 
Type of 
regulation 
References 
HER2 Transcription 
Factor  
 Positive (Vernimmen et al., 2003a) 
Activator Protein 
Yin Yang 1; KU 
proteins 
Positive (Vernimmen et al., 2003b; 
Allouche et al., 2008; Nolens et 
al., 2009) 
PEA3 
c-June & p300 Positive (Vernimmen et al., 2003b; 
Matsui et al., 2006) 
EGR2/Krox20 CITED1 Positive (Dillon et al., 2007) 
Y-box Binding Protein-1  Positive (Kalra et al., 2010) 
Signal Transducer and 
Activator of 
Transcription 3  
 Positive (Qian et al., 2006) 
Myc Promoter-binding 
Protein-1 
Histone 
deacetylase 1 
Negative (Contino et al., 2013) 
ErbB3-Binding Protein 1  Negative (Ghosh et al., 2013) 
Foxp3  Negative (Zuo et al., 2007) 
PURA  Negative (Zhang et al., 2012) 
Nucleolin  Negative (Zhang et al., 2012) 
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expression of HER2. Additionally, miR-155 can directly target HER2 by binding 
in the coding region (He et al., 2016). 
1.5.2. HER2 transcript and protein variants 
 
In addition to wild type HER2, three functionally distinct alternative splice 
variants have been identified (Sasso et al., 2011; Jackson et al., 2013). These 
are membrane-bound Δ16HER2 and the secreted proteins Herstatin and p100 
(Doherty et al., 1999a; Aigner et al., 2001; Sasso et al., 2011). To date only a 
small number of studies have investigated the effect of HER2 splice variants on 
cell signalling and their role in breast cancer development and therapy. In 
breast cancer the secreted proteins have been associated with a good 
prognosis, especially Herstatin (Aigner et al., 2001; Hu et al., 2005). In contrast 
Δ16HER2 has been associated with more aggressive tumours and in vitro 
resistance to some forms of targeted therapy (Castiglioni et al., 2006; Mitra et 
al., 2009).  
 
 
 
 
 
 
 
 
 
Figure 1.6: HER2 protein variants.  
Protein variants of HER2 arise through different processes. Three are due to alternative 
splicing, these are Δ16HER2, p100 and Herstatin. Alternative translation initiation gives rise to 
687-CTF and 611-CTF. Additionally proteolytic cleavage can produce a truncated membrane 
bound 648-CTF.  
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Additional HER2 protein variants can arise from the HER2 transcript through 
alternative translation initiation, these are the cytoplasmic 687-C-terminal 
fragment (p95cyto) and the membrane bound 611-CTF (p110) (Pedersen et al., 
2009). Furthermore, post-transcriptional HER2 protein cleavage gives rise to 
membrane bound 648-CTF (p95m) (Sasso et al., 2011). Although these protein 
variants lack all or most of the extracellular domain, some studies have shown 
that they can induce downstream signalling and play a role in breast cancer 
outcome. Research showed 611-CTF to induce the transcription of metastasis 
associated genes and linked it to a poor prognosis (Pedersen et al., 2009; Ward 
et al., 2013). Similarly 648-CTF has also been linked to poor prognosis, through 
its constitutively active conformation and downstream signalling. It also lacks 
the epitope of the HER2 targeting therapeutic antibody Trastuzumab 
(Chandarlapaty et al., 2010; Tse et al., 2012). Recently, a HER2 protein with a 
short alternative N–terminus was identified, although the underlying 
mechanisms have not been studied (Kuyama et al., 2014). 
 
1.5.3. The protein structure of HER2 
 
The ErbB protein family shares a common general protein structure. Most 
studies concerning the ErbB protein structure have focused on EGFR, 
especially concerning the highly conserved intracellular domain. The structure 
and function of the tyrosine kinase domain is generally accepted to be common 
between the EGFR and HER2. The 185kDa sized HER2 protein consists of an 
N-terminal extracellular domain, followed by a transmembrane domain and the 
intracellular C-terminal domain.  
The extracellular domain 
The extracellular domain consists of two leucine-rich ligand-binding domains I/LI 
and III/LII that facilitate ligand binding as well as two cysteine-rich domains II/CI 
and IV/CII which facilitate the formation of disulphide bonds (Figure 1.7). 
Traditionally, HER2 is considered an “ligand” orphan receptor with an active 
“open structural” conformation, which allows the formations of dimers with other 
family members after ligand binding, followed by transactivation and 
Chapter 1: Introduction 
17 
 
downstream signalling via the intracellular tyrosine kinase domain (Roskoski, 
2013). Only very recently a ligand for HER2 was identified. A study reported 
that prolidase binds to pre-existing HER2 homodimers. Its binding disrupts the 
intracellular association of Src with HER2 and thereby inhibits downstream 
signalling in HER2 overexpressing cells. This study also found that in cells 
expressing HER2 at a low level, HER2 monomers are bound by prolidase 
initiating dimerisation and normal downstream signalling (Yang et al., 2014).  
  
Figure 1.7: Structure and interaction of HER2 proteins.  
The extracellular domain consists of two leucine-rich ligand-binding domains I and III that 
facilitate ligand binding, and two cysteine-rich domains II and IV which facilitate the formation of 
disulphide bonds. The domain II forms a β-hairpin dimerization loop which participates in the 
dimerisation. A short single-span α-helix transmembrane segment connects the extracellular 
with the intracellular domain. The intracellular domain consists of the juxtamembrane (JM), 
followed by the tyrosine kinase domain which is compromised of the N-terminal lobe (N-lobe) 
and the C-terminal lobe (C-lobe). The protein ends in a non-catalytic C-terminal tail. 
Dimerization and activation of the receptor frees the JM segment from the negatively charged 
membrane. The first 20 amino acids form an antiparallel coiled-coil structures between 
dimerising receptors (Jura et al., 2009; Roskoski, 2014). 
The domain II forms a β-hairpin dimerization loop which participates in the 
dimerisation (Burgess et al., 2003). HER2 primarily forms heterodimers with 
other members of its protein family, but in cells expressing high levels of HER2 
the close proximity increases the level of homodimerisation significantly (Di 
Fiore et al., 1987; Hudziak et al., 1987). 
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The transmembrane (TM) domain  
The extracellular domain is connected by a short single-span α-helix 
transmembrane segment with the intracellular domain. Solution NMR has 
shown that two ErbB protein TM domains associate in a right-handed α-helical 
bundle. This is thought to be mediated by the double GG4-like motif 
T648G649X2G
652A653 and the glycine zipper motif T652X3S
656X3G
660 (Escher et al., 
2009; Mineev et al., 2010; Arkhipov et al., 2013). Activating mutations in the TM 
domain can increase downstream signalling and thereby increase the risk to 
develop breast cancer, this under pins the importance of the TM domain 
(Segatto et al., 1988; Xie et al., 2000).  
 
The intracellular domain 
The intracellular domain consists of the juxtamembrane (JM) segment which 
can be subdivided into A and B. This is followed by the tyrosine kinase domain 
which is compromised of the N-terminal lobe (N-lobe) with the helix αC, αC-β4 
loop and the activation loop and the C-terminal lobe (C-lobe). The protein ends 
in a non-catalytic C-terminal tail.  
In recent years, the accepted receptor dimerization mechanism has gone from a 
symmetric activation to an asymmetric interaction of the intracellular domains. 
One receptor takes up the role of the donor/activator, its C-lobe interacting with 
the N-lobe of the acceptor/receiver (Figure 1.7) [reviewed in (Kovacs et al., 
2015)]. In the case of a HER2 – ErbB3 heterodimer, HER2 takes on the role of 
the acceptor and HER3 the donor (Collier et al., 2013). 
Intracellularly a 40 amino acid long JM segment follows the transmembrane 
domain (Jura et al., 2009; Roskoski, 2014). Dimerization and activation of the 
receptor frees the JM segment from the negatively charged membrane 
(Arkhipov et al., 2013; Matsushita et al., 2013). The first 20 amino acids make 
up the JM-A segments which forms an antiparallel coiled-coil structures 
between dimerising receptors. The N-terminal half of the JM-domain (JM-B) of 
the acceptor kinase interacts with the C-lobe of the donor kinase (Jura et al., 
2009; Roskoski, 2014). 
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Figure 1.8: Intracellular structure of ErbB proteins and their interaction.  
A, The tyrosine kinase domain is compromised of the N-terminal lobe (N-lobe) with the helix αC, 
αC-β4 loop and the activation loop and the C-terminal lobe (C-lobe). Its conformation changes 
dependent on activation. B, The dimerization of ErbB proteins is an asymmetric interaction of 
the intracellular domains. One receptor takes up the role of the donor/activator, its C-lobe 
interacting with the N-lobe of the acceptor/receiver. The JM segments interact and form an 
antiparallel coiled-coil structures between dimerising receptors. The C-lobe of the donor kinase 
interacts with the N-lobe of the acceptor kinase, this activates the acceptor kinase. The 
activated tyrosine kinase domain uses ATP to transphosphorylate the C-terminal tail. The 
phosphorylated C-terminal tail is essential for the recruitment of adaptor and effector proteins. 
Images adapted from (Collier et al., 2013). 
Fann et al. have suggested that HER2 has an autoinhibitory mechanism 
through the interaction of the αC-β4 loop in the N-lobe which forms a 
hydrophobic patch that interacts with the hydrophobic stripe of the activation 
loop, this keeps the helix αC and activation loop in an inactive conformation. 
Receptor dimerization and conformational changes cause the activation loop to 
be in an open confirmation to allow access to the kinase substrate-binding 
pocket and the helix αC to face the ATP-binding site (Fan et al., 2008).  
Controversial findings have been made concerning the importance of tyrosine 
phosphorylation of the activation loop in HER2, the study by Collier and 
colleagues suggest that this phosphorylation is not essential for tyrosine kinase 
activation (Collier et al., 2013). The C-lobe of the donor kinase interacts with the 
N-lobe of the acceptor kinase, which activates the acceptor kinase. As part of 
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the receptor dimerization and activation the tyrosine kinase domain uses ATP 
for the transphosphorylation of the C-terminal tail loop [reviewed in (Kovacs et 
al., 2015)]. The long C-terminal tail contains 6 tyrosine transphosphorylation 
sites, which are essential for the recruitment of adaptor (e.g. Grb2) and effector 
proteins (e.g. phospholipase C gamma – PLCγ) that contain src homology 
domain 2 (SH2) or phosphotyrosine binding (PTB) domains (Arteaga et al., 
1991; Dankort et al., 1997; Dankort et al., 2001; Hartman et al., 2013). These 
proteins are essential for the downstream signalling as will be discussed later 
[reviewed in (Dittrich et al., 2014)].  
 
1.5.4. HER2 signalling pathways  
 
The most prominent signalling pathways activated by HER2 are the PI3K/AKT 
and RAS/MAPK pathways (Figure 1.9), which mediate cell proliferation, growth 
and survival, as well as angiogenesis and cellular metabolism [reviewed in 
(Dittrich et al., 2014)]. In the last decade it was reported that the HER2 
signalling network extends to include crosstalk with other receptors such as ER 
(Creighton et al., 2006; Giuliano et al., 2013; Grabinski et al., 2014). 
Additionally, it was shown that HER2 can function as co-transcription factor of 
genes such as cyclooxygenase-2 (Cox-2) (Dillon et al., 2008) and cyclin D1 
(Beguelin et al., 2010; Diaz Flaque et al., 2013). These are only a few examples 
which show the complexity of the HER2 network and its ability to regulate cell 
proliferation, growth and survival, as well as angiogenesis and cellular 
metabolism via different pathways [reviewed in (Dittrich et al., 2014)]. It has to 
be noted that most studies only consider full length wild type HER2, not the 
other protein variants when studying the signalling pathways. The HER2 variant 
Δ16HER2 is an exception; work in cell lines and mouse models has elucidated 
a signalling pathway separate from wild type HER2 (Mitra et al., 2009; Marchini 
et al., 2011; Castagnoli et al., 2014). It has been described that Δ16HER2 
homodimerization induces the phosphorylation and translocation of the 
associated pSrc to the cell membrane (Mitra et al., 2009; Castagnoli et al., 
2014). The non-receptor cytoplasmic tyrosine kinase, Src is a key signalling 
molecule a complex signalling network which regulates cell survival, 
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mitogenesis and cell motility. In cancer it has been further implied to be 
important in EMT and metastasis (Guarino, 2010; Castagnoli et al., 2014).  
 
Figure 1.9: The main HER2 signaling pathways: Ras-MAPK and PI3K-AKT. 
Dimerisation and transphosphorylation of HER2 initiates the Ras-MAPK and PI3K-AKT 
pathways. Adaptor proteins bind to HER2 initiating a signaling cascade via Ras, Raf and MEK 
to ERK1/2. ERK induces transcription factors involved in cell growth, proliferation, survival, 
proteolytic activity and transcript-turnover. The PI3K-AKT pathway is also initiated by the 
transphosphorylation of HER2. The recruitment of p85 releases p110 to recruit PI3K 
heterodimer to its substrate PIP2, this is phosphorylated into PIP3. AKT becomes translocated 
to the plasma membrane by PIP3. AKT regulates proteins involved in a number of cellular 
processes; cell survival, cell cycle, proliferation, protein stability, epithelial to mesenchymal 
transition and invasion. Additionally, a number of negative feedback loops regulate the 
pathways. Image derived from (Dittrich et al., 2014). 
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1.5.4.1. Co-receptors of HER2 
 
HER2 is traditionally considered to be an orphan receptor which has to dimerise 
with a ligand-binding, activated co-receptor to induce downstream signalling. 
Dimerisation primarily occurs with other members of the ErbB family - EGFR, 
HER3 and HER4 [reviewed in (Hurvitz et al., 2013)]. They can bind a number of 
different ligands. Some ligands are receptor specific (Epithelial Growth Factor to 
EGFR) and others bind multiple receptors (Heregulin) [reviewed in (Barros et 
al., 2010)]. In tumours overexpressing HER2, homodimerisation can also occur. 
EGFR and ErbB4 are able to bind ligands and induce downstream signalling 
through functional tyrosine kinase domains. In contrast ErbB3 is able to bind its 
ligands, but has a truncated tyrosine kinase domain [reviewed in (Barros et al., 
2010)].  
Some studies have found HER2 to also interact with two receptors that are not 
part of the ErbB protein family. One is Ob-R, the receptor of the fat cell-derived 
peptide hormone leptin. Eisenberg et al. first showed that HER2 can be 
indirectly phosphorylated through Ob-R via JAK2 and initiate the RAS/MAPK 
pathway in human embryonic kidney HEK 293T cells (Eisenberg et al., 2004). 
Similar findings were observed in the breast cancer cell line SKBR3 (Soma et 
al., 2008). Only one study has shown a direct association between Ob-R and 
HER2, through co-immunoprecipitation (Fiorio et al., 2008). If, and how, Ob-R 
acts as co-receptor of HER2 remains unclear. 
The second unrelated co-receptor is Mucin 1 (MUC1), a protein heterodimer 
formed by an N-terminal extracellular and a C-terminal membrane bound 
subunit. The C-terminal subunit can interact with HER2 and other receptor 
tyrosine kinases [reviewed in (Kufe, 2013)]. It has been shown that Heregulin 
can induce a complex formation between MUC1 and HER2, which leads to the 
translocation of the C-terminal subunit of MUC1 together with γ-catenin to the 
nucleus (Li et al., 2003). Nuclear localisation of C-terminal MUC1 is thought to 
be involved in the regulation of cell proliferation, differentiation and epithelial to 
mesenchymal transition through the co-regulation of WNT target genes (Huang 
et al., 2003; Micalizzi et al., 2010; Gangopadhyay et al., 2013). The 
overexpression of MUC1 in breast and other cancers indicates that this 
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interaction with HER2 can have an important role in cancer cells 
(Mukhopadhyay et al., 2011; Torres et al., 2012). 
 
1.5.4.2. The RAS/MAPK signalling pathway 
 
One of the two main signalling pathways induced by the dimerisation of HER2 
and subsequent phosphorylation of the C-terminal tyrosines is the RAS-MAPK 
pathway. Major cellular functions are governed by this pathway, these include 
cell growth, survival, proliferation and migration [reviewed in (Castaneda et al., 
2010; Fruman and Rommel, 2014)]. 
The phosphorylated HER2 C-terminus acts as the docking site for proteins such 
as growth factor receptor-bound protein 2 (GRB2). GRB2 binding to the adaptor 
protein son of sevenless (SOS) activates it which in turn allows SOS to cause 
the exchange of guanosine diphosphate (GDP) to guanosine triphosphate 
(GTP) on RAS. The activation of RAS initiates the activation of a kinase 
cascade, at its end stands the phosphorylation and activation of extracellular 
signal-regulated kinases (ERK) 1 and 2 [reviewed in (Aksamitiene et al., 2012; 
De Luca et al., 2012)].  
Activated ERK regulates a number of transcription factors through 
phosphorylation. These include the erythroblastosis virus E26 oncogene 
homolog 1 like gene 1 (Elk-1) (Yordy and Muise-Helmericks, 2000), p90 
ribosomal S6 kinase (RSK) (Chen et al., 1992), c-Fos and c-Jun (Sistonen et 
al., 1989), as well as MAPK-interacting serine/threonine kinase (MNK) 
(Chrestensen et al., 2007). The RAS-MAPK pathway regulates the expression 
of genes involved in cell growth, differentiation, proliferation, survival, migration 
as well as transcript turnover and proteolytic activity through these transcription 
factors [reviewed in (Aksamitiene et al., 2012; De Luca et al., 2012; Romeo et 
al., 2012; Kasza, 2013)]. 
The ERK proteins can initiate a negative feedback loop by inhibiting the 
interaction of SOS with GRB2. This leads to a decreased activation of RAS. The 
subsequent inhibition of RAF negatively regulates the activation of MEK (Ueki et 
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al., 1994; Lemmon and Schlessinger, 2010). The RAS signalling activates a 
complex of cyclins and cyclin dependent kinases (CDKs) which can release the 
well-known tumour suppressor retinoblastoma (Rb) (Leone et al., 1997; Dimova 
and Dyson, 2005). Through the feedback loop this is inhibited.  
1.5.4.3. The PI3K-AKT signalling pathway 
 
The other main signalling pathway of HER2 is the PI3K-AKT pathway. Similar to 
the RAS-MAPK pathway it regulates a number of important cellular functions, 
such as cell growth, survival, proliferation as well as protein synthesis, invasive 
properties and drug resistance [reviewed in (Burris, 2013; Fruman and Rommel, 
2014)]. As with the RAS-MAPK pathway the phosphorylation of the HER2 C-
terminus recruits proteins, in this case p85. The recruitment of p85 
disassociates it from p110. p110 is now free to recruits the PI3K heterodimer to 
its substrate phosphotidylinositol-4,5-bisphosphate (PIP2) at the cell membrane 
(Carpenter et al., 1993). PIP2 in turn is phosphorylated by the PI3K heterodimer 
into phosphotidylinositol-3,4,5-triphosphate (PIP3) [reviewed in (Castaneda et 
al., 2010; De Luca et al., 2012)]. This process is negatively regulated by the 
phosphatase and tensin homolog (PTEN) [reviewed in (Hopkins et al., 2014)] 
and inositol polyphosphate 4-phosphatase type II (INPP4B) which 
dephosphorylate PIP3 [reviewed in (Burris, 2013)]. PIP3 next causes the 
translocation of AKT, a central protein of this signalling pathway, to the plasma 
membrane and where it is phosphorylated by 3-phosphoinositide-dependent 
kinase 1 (PDK1) and mammalian target of rapamycin (mTOR) complex 2 
(mTORC2) [reviewed in  (Castaneda et al., 2010)]. 
It is interesting to note that a study showed that of the three AKT isoforms, 
AKT1 and 3 levels seem to be increased in HER2 positive cells, but not AKT2. 
Knockdown of AKT 1 and 3 in these cells leads to reduced proliferation. 
Additionally, this study also suggested that the AKT isoform levels can affect the 
phosphorylation of HER2 and HER3. Depletion of AKT1 and 2 causing an 
increase of HER2 and HER3 phosphorylation, whereas the depletion of AKT3 
has the opposite effect downregulating protein expression at a 
posttranscriptional level and decreasing tyrosine phosphorylation (Grabinski et 
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al., 2014). This study suggests AKT3 as a more specific marker of HER2 
specific initiation of the PI3K/AKT pathway.  
Cell Survival 
This signalling pathway regulates cell survival through multiple channels. This 
includes the inhibition of pro-apoptotic proteins like B cell leukemia 2 antagonist 
of cell death (Bad) (Datta et al., 1997) or of the transcription factors of pro-
apoptotic proteins e.g. forkhead box O3a (FOXO3a) (Brunet et al., 1999). AKT 
can phosphorylate and activate the antagonist of the tumour suppressor p53, 
mouse double minute 2 (Mdm2). This inhibits the p53 mediated pro-apoptotic 
pathway, cell-cycle arrest and senescence pathways as well as its modulation 
of autophagy (Mayo and Donner, 2001). Further, the NF-kB survival pathway 
can be activated through the phosphorylation of its positive regulator IkB kinase 
(IKK) (Fresno Vara et al., 2004). Finally, survivin levels can be upregulated and 
the protein stabilised through the HER2-PI3K-AKT pathway (Wu et al., 2010; 
Wu et al., 2012; Chakrabarty et al., 2013; Ju et al., 2013; Lazrek et al., 2013). 
Cell Cycle Progression and Proliferation 
Another important cellular process regulated by the PI3K/AKT pathway is cell 
cycle progression and proliferation. AKT is able to regulate mTORC1 through 
tuberous scelerosis 2 (TSC2) and thereby the phosphorylation of eIF4E binding 
protein 1 (4E-BP1) and p70 ribosomal protein S6 kinase 1 and 2 (S6K1,2) (Inoki 
et al., 2002). S6K1 plays a role in the initiation and control of mRNA translation 
as well as cell growth and proliferation [reviewed in (Proud, 2009)]. S6K2 has 
been shown to be essential in cell survival (Sridharan and Basu, 2011). 
Phosphorylation of 4E-BP1 releases the eukaryotic translation initiation factor 
4E (eIF4E), which is incorporated into the translational machinery [reviewed in 
(Proud, 2009)]. 
Further, targets of AKT like FOXO1 inhibit p27 and increase cyclin D1 levels, 
this has been shown to cause an increased proliferation in breast cancer cell 
lines (Wu et al., 2010).  
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The other central player: Heat-Shock Factor 1 (HSF1) 
The HER2/PI3K/AKT pathway has been linked to invasion and epithelial to 
mesenchymal transition (EMT), both central mechanisms in cancer 
development and progression, through the activation of HSF1 (Fresno Vara et 
al., 2004; Yilmaz and Christofori, 2009; Carpenter et al., 2014; Schulz et al., 
2014). HSF1 is considered a positive “master regulator” of a number of adaptor 
proteins and heat-shock chaperones including HSP90α, HSP70 and HSP27. In 
cancer HSP chaperons are essential in stabilising oncogenes and other cellular 
proteins, as tumour cells generally suffer higher levels of stress due to aberrant 
cellular processes and the tumour microenvironment [reviewed in (Ciocca et al., 
2013)].  
The role of HSF1 in EMT can be explained by its role as a transcription factor of 
Slug, which in turn is a transcriptional repressor of E-cadherin (Carpenter et al., 
2014). The downregulation of E-cadherin causes changes in the adhesive 
properties of cells, which increases the invasive and metastatic potential of 
tumour cells [reviewed in (Yilmaz and Christofori, 2009; Tania et al., 2014)]. 
In addition, it has been indicated that HSF1 influence the expression of genes 
involved in the cell cycle regulation, metabolism, adhesion and translation 
(Mendillo et al., 2012). 
 
1.5.5. The crosstalk between HER2 and the hormone receptors 
 
Oestrogen receptor (ER) 
Studies have found that different hormone receptors ‘crosstalk’, which is 
especially important in breast tumours in which hormone receptors are often 
overexpressed and drive tumorigenesis. A small percentage of breast cancer 
cases show expression of both HER2 and ER (Arpino et al., 2008).  
The two oestrogen receptors have been implied to have antagonistic functions 
with ERα inducing proliferation and survival of breast cancer cells (Giuliano et 
al., 2013), and ERβ antagonising these functions (Omoto et al., 2003; Lattrich et 
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al., 2013). HER2 signalling has been linked to ER through both the RAS/MAPK 
and PI3K/AKT pathways. HER2 downregulates the expression of ERα through 
the RAS/MAPK pathway (Oh et al., 2001; Creighton et al., 2006) and the 
phosphorylation of p38MAPK inhibits ERβ and thereby its function as TF (St-
Laurent et al., 2005). The HER2/PI3K/AKT pathway causes phosphorylation 
and inactivation of FoxO3a through AKT and thereby also prevents or reduces 
ERα expression. This is supported by the finding that AKT3 depletion induces 
the protein expression of ERα. HER2 dependent signalling has been shown to 
be mainly mediated by AKT3, not AKT1 or 2 (Grabinski et al., 2014). 
These links between HER2 and ER might indicate a mechanism underlying 
mono-therapy resistance of cells that switch from HER2+/ER- to HER-/ER+ 
(Giuliano et al., 2013). 
Androgen receptor (AR) 
Less well understood is the link between HER2 and the androgen receptor 
(AR). The cross-regulation of steroid-response genes has been observed in a 
subgroup of HER2 positive molecular apocrine (ER-/AR+) breast cancer cell 
lines. The ligand heregulin is expected to induce target genes of HER2, 3 and 4, 
but a study found that it also induced AR target genes. The same cells when 
treated with testosterone, ligand of AR, showed the induction of HER2 target 
genes (Naderi and Hughes-Davies, 2008). Both signalling pathways act through 
phosphorylation of ERK (Naderi and Hughes-Davies, 2008). ERK and CREB1 
are linked back to AR via a positive feedback loop. It has also been shown that 
AR can act as a transcription inducer of HER2 (Chia et al., 2011). In the context 
of breast cancer it is interesting to note that a study has indicated that breast 
cancer patients which lack AR and ER, but overexpress HER2, have a poorer 
prognosis than patients that are also positive for AR and ER (Lin Fde et al., 
2012). 
Insulin-like growth factor-I receptor (IGF-IR) 
Recently, studies have described crosstalk between HER2 and IGF-IR, which 
has been linked to drug resistance. Both HER2 and IGF-IR activate the 
PI3K/AKT pathway and thereby induce cell proliferation (Baxi et al., 2012). 
There are likely to be multiple forms of interaction. It was found that targeting 
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either receptor can induce activation of the other receptor (Haluska et al., 2008). 
In some Trastuzumab resistant breast cancer cell lines both a hetero-
dimerisation of IGF-IR with HER2 (Nahta et al., 2005) as well as a complex 
formation of IGF-IR with both HER2 and HER3 has been observed (Huang et 
al., 2010). A study has also shown that HER2 can induce the IGF-IR pathway 
through the downregulation of IGF binding protein-3, which increases the 
secretion of the IGF-IR ligand IGF-1 (Worthington et al., 2010). 
 
1.5.6. Function of nuclear HER2 
 
Until now, HER2 has been described as a membrane bound receptor protein, 
but in the last ten years ErbB family proteins have been identified in the nucleus 
and been shown to affect transcription directly [reviewed in (Mills, 2012)]. 
Nuclear HER2 has been found in cell lines and primary tissues [reviewed in 
(Wang et al., 2004)]. Interestingly, a study correlated dual nuclear and high 
membrane HER2 staining with a worse outcome for breast cancer patients 
(Schillaci et al., 2012).  
For the translocation into the nucleus an active tyrosine kinase domain is 
necessary. A short amino acid sequence (676-KRRQQKIRKYTMRR-689) 
located at the beginning of the intracellular domain has been suggested to act 
as a nuclear localisation signal (Wang et al., 2004). 
Target genes of nuclear HER2 are COX-2, PRPK, MMP-16 and DDX-10 (Wang 
et al., 2004; Dillon et al., 2008). Of these target genes only COX-2 has been 
further studied. Its expression has been correlated to HER2 expression, but is 
not exclusively dependent on the HER2 induced RAS/MAPK pathway 
(Subbaramaiah et al., 2002; Wang et al., 2004). It has been observed that the 
correlation between HER2 and COX-2 is stronger in metastatic tumours and 
with a poorer prognosis (Wang et al., 2004; Dillon et al., 2008). 
HER2 has also been found to act as a co-transcription factor of PR in MCF-7 
cells (Beguelin et al., 2010). PR can regulate a number of cellular proteins 
lacking the progesterone response element (PRE).  For these proteins PR 
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forms a complex with other transcription factors (Beguelin et al., 2010). A well-
studied case is the cyclin D1 gene. It has been found that the synthetic 
progestin medroxyprogesterone acetate (MPA) via ERK1/2 causes the 
translocation of c-Fos and c-Jun to the nucleus. PR co-localises with c-Fos and 
c-Jun, as the AP-1 complex on the cyclin D1 promoter (Diaz Flaque et al., 
2013). Furthermore, MPA cause the phosphorylation of STAT3 and HER2. 
These can then be found in a transcription complex on the STAT3 binding site 
of the cyclin D1 promoter (Beguelin et al., 2010). These two transcription 
complexes assemble at the same time. The HER2 STAT2 complex only forms 
in the presence of c-Jun and c-Fos on the promoter. The treatment with MPA 
also induces chromatin structure favourable to gene transcription. It has been 
suggested that both AP-1 and nuclear HER2 are essential for progestin 
dependent growth (Beguelin et al., 2010; Diaz Flaque et al., 2013).  
 
1.6. Breast cancer therapy 
 
The treatment of breast cancer is designed on a case-to-case basis depending 
not only the patient’s age, health, medical history, the characteristics of the 
tumour and the patient’s preferences, but also on resources and practice in 
different hospitals. In most cases a combination therapy is used.  
Typically, a surgical intervention is performed to remove the tumour mass and 
some of the surrounding normal tissue. Practise has mostly moved away from 
whole breast removal (mastectomy) to surgeries that remove the tumour but 
keep as much as possible of the normal breast intact. During surgery sentinel 
lymph node biopsy might be performed, to remove potentially abnormal lymph 
nodes. Before surgery, following ultrasound, fine needle aspiration or biopsy 
might be performed on potentially abnormal axillary lymph nodes to determine 
spread of the tumour. The excised tumour tissues and lymph nodes are used to 
determine follow up treatment (NICE, 2009; Cancer Research UK, 2014d). In 
patients above 70 with health problems a surgery might not be possible and 
hormone therapy will be recommended (primary endocrine therapy) (Cancer 
Research UK, 2014c). 
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If cancer cells have spread to the axillary lymph nodes the remaining axillary 
lymph nodes will most probably be removed too. Depending on the risk and 
extent of the cancer, radiotherapy might be applied to lymph nodes (Cancer 
Research UK, 2014d). Recently it has become possible to perform a rapid test, 
RD-100i OSNA, during surgery to determine whether cancer cells have spread 
to lymph nodes (NICR, 2013; Cancer Research UK, 2014d).  
Radiotherapy generally follows breast conserving surgeries, but can also be 
necessary after mastectomy to remove any remaining cancer cells (NICR, 
2013; Cancer Research UK, 2014d). It has been shown that radiation 
decreases the likelihood of recurrence of cancer in the treated breast tissue and 
surrounding lymph nodes (Early Breast Cancer Trialists' Collaborative et al., 
2011). In addition chemotherapy and hormone therapy might be performed 
before or following surgery. Treatment before surgery whether it is 
chemotherapy or hormone therapy is referred to as neo-adjuvant therapy. Neo-
adjuvant therapy is mostly performed in locally metastatic breast cancer or large 
tumours, to reduce the size of the tumour before surgery (Cancer Research UK, 
2014a). Adjuvant therapy follows after surgery and is performed to reduce the 
risk of recurrence. The treatment options will depend on the age and health of 
the patients and the category of tumour. In cases of small localised tumours 
adjuvant therapy might not be necessary (Cancer Research UK, 2014a). 
Targeted therapies 
Current national guidelines recommend that early oestrogen positive tumours 
should be treated with hormone/endocrine therapy following surgery. In younger 
ER positive patients hormone therapy is often combined with chemotherapy. As 
mentioned before ER is often found to be overexpressed in breast tumours and 
to act as a driver of the tumour, therefore in premenopausal women treatments 
that stop oestrogen production might be suggested (Cancer Research UK, 
2014c). Tamoxifen is the most common ant-ER drug, it binds to the AF-2 
domain of ER and blocks interaction with ER as well as its co-activator complex. 
Toremifene, drooxifene, idoxifene, TAT-59 and GW5638 are similar to 
Tamoxifen in regard to their chemical structure and function. Raloxifene 
although similar in function belongs to a different SERM family (Osborne et al., 
2000). Fulvestrant is another common anti-ER drug, which blocks the 
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interaction with ER and causes its degradation (Osborne et al., 2000; Dahlman-
Wright et al., 2006). In patients with metastasis or in post-menopausal patients 
with tamoxifen resistance other types of drugs might be used, such as 
aromatase inhibitors, which stop the synthesis of oestrogen (Ali and Coombes, 
2002). However, despite the several endocrine treatments which have been 
developed, more than 50% of patients with metastatic disease do not respond 
to endocrine therapy (Giuliano et al., 2013). 
As discussed earlier a subset of tumours is characterised through the 
overexpression of HER2. These patients will be given HER2 targeting agents 
such as the monoclonal antibody Trastuzumab (Herceptin). In more advanced 
cancers tyrosine kinase inhibitors such as Lapatinib will also be considered 
(Cancer Research UK, 2014b). 
Chemotherapies 
Chemotherapeutic agents are cytotoxic drugs that target all growing and 
proliferating cells. The main problem with these agents is that they do not 
differentiate between normal dividing cells and tumour cells. The impaired self-
repair mechanisms in cancer cells, increase the efficiency of these drugs in 
cancer cells. In addition to adjuvant and neoadjuvant settings, chemotherapy is 
also used on metastatic cancer. In many cases they are administrated in 
combination. The main drugs used are: Cyclophosphamide, Epirubicin, 
Fluorouracil (5FU), Methotrexate, Mitomycin, Mitozantrone, Doxorubicin, 
Docetaxel and Gemcitabine (Cancer Research UK, 2014a). 
 
1.6.1. HER2 targeting therapy 
 
Through the development of HER2 targeting drugs, the prognosis of HER2 
positive patients has strongly improved (Hurvitz et al., 2013). At present time 
four anti-HER2 drugs for breast cancer have been approved by either the U.S. 
Food and Drug Administration (FDA) or National Health Service (NHS) or both; 
these are trastuzumab, trastuzumab emtansine, pertuzumab and lapatinib. 
 
Chapter 1: Introduction 
32 
 
Trastuzumab 
Both trastuzumab and pertuzumab are humanized monoclonal antibodies 
targeting the extracellular domain of HER2. Trastuzumab has been approved by 
FDA and NHS for adjuvant therapy of both lymph node positive and negative, 
HER2-positive breast cancer (NICE, 2002; NICE, 2009; NIH, 2013). The FDA 
has also approved trastuzumab in combination with pertuzumab and docetaxel 
for use in neoadjuvant inflammatory or early stage breast cancer (Amiri-
Kordestani et al., 2014). It is to be used in combination with one or multiple 
chemotherapeutic drugs, such as cyclophosphamide, doxorubicin, paclitaxel, 
docetaxel and carboplatin. It can also be applied as a single agent following 
multi-modality anthracycline based therapy. In metastatic HER2-overexpressing 
breast cancer it is indicated for first line treatment in combination with paclitaxel 
or as single agent after previous chemotherapy for metastatic disease (NICE, 
2002; NICE, 2009; NIH, 2013). By targeting the extracellular domain of HER2, 
trastuzumab blocks the dimerization of HER2 with other ErbB family members 
and thereby down-regulates HER2 signalling. The antibody has also been 
shown to induce apoptosis by mediating antibody-dependent cellular 
cytotoxicity (ADCC), as well as complement mediated cytotoxicity in breast 
cancer cells (Tai et al., 2010; Bianchini and Gianni, 2014). In humans the main 
effect of trastuzumab is through the engagement of the immunsystem. In clinical 
studies it has been observed that in patients responding to trastuzumab 
containing therapies the levels of lymphocytes are increased (Bianchini and 
Gianni, 2014). 
Recently an antibody drug conjugate of trastuzumab, ado-trastuzumab 
emtansine (T-DM1) has been approved by the FDA as single agent treatment of 
HER2-overexpressing, metastatic breast cancer, which had previously been 
treated with trastuzumab and taxane (U.S. Food and Drug Administration, 
2013). Due to low cost-effectiveness it is not recommended in the UK (National 
Institute for health and Care Excellence, 2015). The maytansinoid anti-
microtubule agent DMT1 is bound to trastuzumab and thereby directly delivered 
to HER2 overexpressing cells (Zardavas et al., 2013). The HER2-T-DM1 
complex is internalized after binding and the drug is released in the cytoplasm. 
Once there DM1 can cause the degradation of microtubules. In addition, the 
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abilities of Trastuzumab to block the HER2 signalling and mediate ADCC are 
retained (Lewis Phillips et al., 2008). 
Pertuzumab 
The second monoclonal antibody which has been approved for breast cancer 
treatment is pertuzumab. Similarly to trastuzumab the antibody binds an 
extracellular domain of HER2 by which it inhibits dimerization with its co-
receptors and down regulates HER2 signalling. Pertuzumab also mediates 
ADCC. It has to be noted that the binding domain of pertuzumab does not 
overlap with the epitope of trastuzumab. The antibody is indicated for use with 
trastuzumab and docetaxel for therapy of patients with HER-2 overexpressing 
metastatic breast cancer, which have not received previous anti-HER2 
treatment or chemotherapy for metastatic cancer (U.S. Food and Drug 
Administration, 2012; National Health Service, 2013). In 2014 this therapy was 
also approved for the neo-adjuvant use in patients with locally advanced, 
inflammatory or early stage breast cancer (Amiri-Kordestani et al., 2014). 
Lapatinib 
A different class of targeted therapeutics are tyrosine kinase inhibitors. At the 
moment only lapatinib is approved for the treatment of advanced or metastatic 
HER2-positive breast cancer (U.S. Food and Drug Administration, 2007; Dillon, 
2012; Hurvitz et al., 2013). Lapatinib is given after prior therapy with 
anthracycline, taxane and trastuzumab. In patients with advanced or metastatic 
HER2-positive breast cancer lapatinib is used in combination with capecitabine 
and in postmenopausal women with ER+/HER2+ metastatic breast cancer it is 
applied in combination with letrozol (U.S. Food and Drug Administration, 2007; 
Dillon, 2012). This tyrosine kinase inhibitor interrupts the signalling of both 
EGFR and HER2. Lapatinib binds reversibly to the ATP-binding domain of the 
receptor inhibiting the tyrosine phosphorylation (Tai et al., 2010). Studies 
showed that lapatinib is able to interrupt the signalling of HER2 and EGFR, 
inhibit growth and IGF-1R signalling as well as inducing apoptosis (Konecny et 
al., 2006; Tai et al., 2010). 
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Pre-approval anti-HER2 drugs  
Research for new HER2 targeting therapies is on-going. A number of molecules 
downstream of the HER2 receptor are being targeted. Further, monoclonal 
antibodies that target the dimerization site of HER2 are under investigation. One 
example is ertumaxomab, a trifunctional bispecific monoclonal antibody 
targeting HER2 and the T–cell specific CD3 antigen. Its epitope does not 
overlap with trastuzumabs and pertuzumabs. It has been shown to induce 
ADCC and antibody-dependent cellular phagocytosis (Diermeier-Daucher et al., 
2012). Novel tyrosine inhibitors are also under investigation. Neratinib and 
afatinib bind irreversibly to HER1, HER2 and HER4 as well as mutated HER2 
(Zardavas et al., 2013). Additionally, tumour vaccines against HER2 are being 
investigated (Hurvitz et al., 2013; Zardavas et al., 2013). The E75 HER2/neu 
peptide based vaccine was designed based on an epitope other than the one 
trastuzumab and pertuzumab bind to. It induces an immune system response of 
antibodies, helper T-cells and cytotoxic T-cells, which recognise cells 
expressing the immunogenic peptide on their surface and induce their lysis 
(Mittendorf et al., 2008).  
Although these and other new therapeutic agents have shown promising 
results, more research is required and clinical data has to be collected to 
determine their efficiency in the clinic. 
 
1.7. Eukaryotic mRNA processing 
 
The complex mechanism of transcription and mRNA regulation is essential for 
the translation of fixed genetic information in a flexible, circumstance- and cell-
specific manner into cellular proteins. 
The process of mRNA transcription begins with changes in chromatin that allow 
the assembly of a transcription complex, containing RNA polymerase II 
[reviewed in (Hahn, 2004)]. A number of genes poses multiple promoters, 
through context specific DNA binding proteins and the chromatin structure, one 
will be selected for transcription initiation [review in (de Klerk and t Hoen, 
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2015)]. The different mRNA synthesis and processing steps e.g. transcription 
initiation and elongation, 5’ capping, splicing, transcription termination and 
polyadenylation are tightly interwoven [reviewed in (Cramer et al., 2001)].  
As the mRNA is being synthesised, the 5’-end of the transcript is modified, 
capped, by a methylated GTP linked through a 5’ to 5’ triphosphate bridge to 
the pre-mRNA. Termination of transcription is followed by polyadenylation at the 
3’ end of the transcript. The typical recognition sequence for polyadenylation is 
AAUAAA, 11-30 nucleotides downstream an endonuclease cuts the mRNA and 
the polyA polymerase adds several hundred adenines [reviewed in (Cramer et 
al., 2001)].  
Genes encode exonic (exons) and intronic sequences (introns), both sequences 
are transcribed into pre-mRNA, but introns are generally removed from the 
sequence; spliced out. Leaving exons as the protein coding sequences. This 
was first described by Gilbert in 1978 (Gilbert, 1978). In humans, exons are 
generally between 50 and 300 nt (Berget, 1995). Introns can range in size from 
a few dozen nucleotides to over a megabase, with a median size of 1520 bases 
in coding genes (Hube and Francastel, 2015). Most eukaryotic pre-mRNAs 
contain short exons and long introns [reviewed in (Matera and Wang, 2014)].  
 
1.7.1. The importance of pre-mRNA splicing 
 
Alternative splicing was first described approximately 40 years ago (Berget et 
al., 1977; Chow et al., 1977). It is an essential cellular process in most 
organisms. In recent years studies have indicated that over 95%, possible up to 
100% of human transcripts are alternatively spliced, giving rise to a vastly 
increased proteome [reviewed in (Lee and Rio, 2015)]. Changes in the pattern 
of alternative splicing, can be observed for example in the development of an 
organism or in response to the environment [reviewed in (Zhang et al., 2007; 
Pagliarini et al., 2015)].  
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Figure 1.10: Canonical alternative splicing events.  
A, Cassette exon. B, Mutually exclusive exons. C, Intron retention. D, Alternative 5’/3’ splice 
sites. E, Alternative promoter. F, Alternative polyadenylation site. 
Splicing and alternative splicing occurs mostly while the pre-mRNA is still being 
transcribed, but can also occur in the nucleus post-transcriptionally. The basic 
principle of splicing lies in the recognition of specific nucleotide sequences 
within the pre-mRNA which are recognised as introns (intergenic regions) and 
excised, whereas the exons (expressed regions) are assembled together 
(Sharp, 2005). Introns are mostly degraded in the nucleus and the mature 
mRNA is exported to the cytoplasm. Alternative splicing is the deviation from 
this basic pattern of exon inclusion and intron exclusion.  
Different forms of alternative splicing can be observed, as illustrated in figure 
1.10. These are the exclusion of an exon or the use of mutually exclusive 
exons, as well as the retention of introns. Further, alternative 5’ or 3’ splice sites 
(ss) within an exon as well as alternative promoters or polyadenylation sites can 
be used in mRNA processing [reviewed in (Tazi et al., 2009)].  
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1.7.2. Basic mechanisms of splicing 
 
The boundaries of exons and introns are highly conserved. The donor or 5’ ss is 
the boundary between an exon ending on AG and an intron generally starting 
with “GURAGU”, where the R indicates a purine. The acceptor or 3’ ss is 
defined by an intron/exon junction of YAG/G, Y being a pyrimidine. Additional 
conserved sequence motifs are the branch point (BP), which is an adenine as 
part of a “YNYURAY” sequence, which is located 18 to 40 nucleotides upstream 
of the 3’ splice site. The polypyrimidine tract (PPT), which consists of 15 to 20 
consecutive uracils and cytosins between 5-40 nucleotides upstream of the 3’ 
splice site and downstream of the BP [reviewed in (Burge et al., 1999; Cartegni 
et al., 2002)]. These sequences are of high importance in the recognition by and 
assembly of the spliceosome (Figure 1.11). The spliceosome is the catalytic unit 
that mediates the two-step trans-esterification that underlies splicing [reviewed 
in (Jurica and Moore, 2003; Will and Luhrmann, 2011)].  
In the first step the phosphodiester bond between the last nucleotide of the 
exon and the first intronic nucleotide, at the 5’ ss (AG\GU) is broken. The now 
freed phosphate group of the guanosine interacts with the adenosine of the 
branch point (YNYURAY). As a consequence the lariat, an intron loop is 
formed. The 3’-hydroxyl (OH) group of the last nucleotide of the exon interacts 
with the phosphate group of the first nucleotide of the following exon, at the 3’ss 
(YAG/G). The second trans-esterification step joins the two exons and releases 
the lariat [reviewed in (Moore and Sharp, 1993; Sharp, 1994)]. 
 
Figure 1.11: Conserved exon and intron sequences.  
The 5’ splice site is the boundary between an exon “AG” and an intron “GURAGU”, where the R 
indicates a purine. The 3’ splice site is defined by an intron/exon junction of YAG/G, Y being a 
pyrimidine. The branch point is an adenine as part of a “YNYURAY” sequence, which is located 
18 to 40 nucleotides upstream of the 3’ splice site; and the polypyrimidine tract, which consists 
of 15 to 20 consecutive uracils and cytosines between 5-40 nucleotides upstream of the 3’ 
splice site and downstream of the BP. 
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1.7.3. Assembly and function of the spliceosome 
 
The spliceosome is the catalytic macromolecular complex that undertakes the 
above described splicing process. Throughout the splicing process it undergoes 
changes in its composition, structure and function (Figure 1.11). The 
spliceosome can consist of more than 170 proteins and 5 small nuclear 
ribonucleoproteins (snRNPs) [reviewed in (Jurica and Moore, 2003; Will and 
Luhrmann, 2011)]. The snRNPs consist of small nuclear RNAs and proteins that 
recognise the before discussed conserved signal sequences in the pre-mRNAs 
(Figure 1.11) [reviewed in (Matera and Wang, 2014)]. 
Splicing has been most extensively studied in yeast, but the processes are very 
well conserved in humans. A main difference lies in the length of human introns. 
Where in yeast introns tend to be short, in humans they are usually long with 
shorter exons (Fox-Walsh et al., 2005). The first step for the splicing of shorter 
introns, is intron definition (Berget, 1995). The first weak complex is ATP-
independent and has to be stabilised by the cap-binding complex and trans-
elements, proteins bound to specific sequences on the pre-mRNA. The early 
complex (complex E) is formed through base pairing of U1snRNP with the 5’ss 
of the intron, this is aided by the C-terminal domain of the polymerase in co-
transcriptional splicing. Following this splicing factor 1 (SF1), also known as 
BBP (branch point bound protein) binds to the BPS and interacts with the 
U2snRNP which recognises and binds the 3’ss of the intron (Berglund et al., 
1997). U2snRNP is associated with the U2 auxiliary factor (U2AF) heterodimer. 
U2AF binds to both the PPT with its 65kDa subunit and to the 3’ss of the intron 
with its 35kDa subunit (Merendino et al., 1999; Wu et al., 1999; Zorio and 
Blumenthal, 1999). In the next step which is an ATP-dependent reaction 
DExD/H helicases pre-mRNA-processing 5 (Prp5) and Sub2 catalyse the 
recognition of the BP by U2snRNP. Prp5 has been suggested to have a BPS 
proofreading and stabilising function (Liang and Cheng, 2015). SF1 is removed 
and U2snRNP interacts with U1snRNP to form the complex A [reviewed in 
(Matera and Wang, 2014)].  
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Figure 1.12: The splicing process. 
A rough depiction of the essential steps in the splicing process. Complex E is formed through 
base pairing of U1snRNP with the 5’ss and U2snRNP with the 3’ss of the intron. Prp5 and Sub2 
interact with the mRNA and cause a re-arrangement whereby U1 and U2snRNP interact. Prp28 
catalysis the addition of U4/U6.U5 tri-snRNP complex to form Complex B. Extensive 
remodelling produces the active complex B*. In complex C the lariat is formed and the exons 
joined together. The lariat is then degraded and the snRNPs recycled. 
 
In the case of long introns, typical for mammals, the initial steps are less well 
understood. The exons become recognised through the exon definition 
complex, a pairwise interaction of U1 and U2snRNPs across the exon 
(Robberson et al., 1990). The subsequent rearrangement yields an intron 
definition complex, which is considered to be equivalent to the complex A 
(Sharma et al., 2008). 
The spliceosomal B complex is formed by the recruitment of the preformed 
U4/U6.U5 tri-snRNP complex. This is catalysed by Prp28 (Sun and Manley, 
1995; Matera and Wang, 2014). A number of helicases and snRNP components 
are necessary for the extensive remodelling of complex B into the catalytically 
active Complex B*. As a result U1 and U4 snRNPs disassociate (Raghunathan 
and Guthrie, 1998). 
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On addition of ATP and Prp2 to the B* complex, the 2’-OH of the branch point 
adenosine attacks the phosphodiester bond at the 5’ss to produce a free 5’ 
exon and a lariat structure connected to 3’ exon within the spliceosomal C 
complex. The lariat is removed and the two exons joined through another ATP-
dependent reaction. This reaction is dependent on Prp8, Prp16 and synthetic 
lethal with U5 snRNP 7 (Slu7). The remaining snRNPs are released by RNA 
helicases in an ATP-dependent manner and recycled (Fourmann et al., 2013) 
[reviewed in (Matera and Wang, 2014)]. 
 
1.7.4. Regulators of alternative splicing 
 
The efficiency of splicing and the occurrence of alternative splicing is dependent 
on a number of factors. As discussed before the important signalling sequences 
in the definition of an intron are well conserved. The splice site and correct 
splicing might be inhibited, depending on the extent of divergence from the 
consensus of these sequences (Kelemen et al., 2013). The total length of exons 
and introns can also influence the efficiency of splicing. In exons that are 
shorter than 50nt the splice sites and splicing factor binding sites come into 
close proximity and thereby can sterically inhibit each other. On the other hand 
exons larger than 300nt are less likely to be recognised in an exon definition 
complex, and might therefore be spliced out (Fox-Walsh et al., 2005). Just as 
important is the length of the introns for the recognition of exons and proper 
splicing. Long introns, especially upstream introns impair exon recognition (Fox-
Walsh et al., 2005; Wang et al., 2014). 
The secondary structures of the pre-mRNA itself can mask recognition 
sequences such as splice sites and inhibit splicing factor binding and 
spliceosome assembly. The opposite can also be observed, where secondary 
structures promote the recognition of a splice site and the correct splicing of an 
exon (Graveley, 2005; Kralovicova et al., 2015). It has been suggested that a 
high GC content around the splice sites stimulates the formation of stabilising 
secondary structures that promote correct splicing (Zhang et al., 2011). 
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Cis- and trans-acting elements 
The most well studied factors regulating pre-mRNA splicing are referred to as 
cis- and trans-acting elements. Cis-elements are sequences encoded into the 
pre-mRNA sequence that are recognition sites for trans-acting elements. 
Depending on localisation and effect, recognition sequences can be described 
as exonic splicing enhancers (ESE) and exonic splicing silencers (ESS) as well 
as intronic splicing enhancer (ISE) and intronic splicing silencers (ISS) 
(Fairbrother and Chasin, 2000; Faustino and Cooper, 2003; Srebrow and 
Kornblihtt, 2006). 
Trans-acting elements, splicing factors, can help recognition of a splice site by 
the spliceosome, stabilise it and promote splicing or they can mask a splice site 
and inhibit splicing. Some of these trans-elements will remain on the pre- and 
mature mRNA to regulate further processes such as the transport into the 
cytoplasm, translation and mRNA decay (David and Manley, 2010; Twyffels et 
al., 2011). Traditionally arginine and serine rich (SR) proteins have been 
considered to enhance exon recognition (Cartegni et al., 2002). They have two 
main motifs. One is a RS domain which contains repetitions of arginine-serine in 
the C-terminus and mediates protein-protein interactions. The second is one or 
more RNA recognition motifs (RRM) in the N-terminus contains (Twyffels et al., 
2011). Opposed to SR proteins heterogeneous nuclear ribonucleoproteins 
(hnRNPs) have been thought to inhibit exon recognition, although shown 
opposing functions have also been observed (Venables et al., 2008). Similarly 
to SR proteins hnRNPs contain one or more RNA binding domains and a 
protein-protein interaction domain (Dreyfuss et al., 1993; Geuens et al., 2016). 
Diverse mechanisms by which hnRNPs inhibit exon recognition have been 
proposed. The first mechanism is by hnRNPs competing with SR proteins for 
binding sites on the pre-mRNA, and thereby inhibiting recognition and assembly 
of the spliceosome. The second mechanism is through hnRNPs interacting with 
each other and altering the structure of the pre-mRNA and thereby masking 
some regions of the pre-mRNA (Cartegni et al., 2002; Venables et al., 2008; 
Geuens et al., 2016). The pre-mRNAs are generally occupied by a large 
number of splicing regulating proteins (splicing factors) which affect each 
Chapter 1: Introduction 
42 
 
other’s function, antagonizing or enhancing. This can occur locally, but also 
over a larger distance (Cartegni et al., 2002).  
 
Alternative splicing is linked to chromatin structure and transcription 
 
As splicing mostly occurs co-transcriptionally, chromatin structure and 
transcription is strongly linked with alternative splicing. Two models have been 
described to explain the effect of chromatin on splicing. The kinetic model links 
the transcription elongation rate to alternative splicing. Fast transcription 
elongation is likely to inhibit the recognition of alternative exons with weak splice 
sites by the spliceosome in favour of stronger downstream exons. Decreased 
velocity of transcription increases the likelihood of inclusion of a weak exon into 
the mature mRNA (de la Mata et al., 2003; Fong et al., 2014). Additionally, it 
has been suggested that an optimal velocity is necessary for correct splicing 
and change of elongation rate in either direction can lead to the same patterns 
of incorrect splicing (Fong et al., 2014).  
Transcription elongation rate dependent splicing has also been linked to 
nucleosome assembly. Exons of highly expressed genes are associated with an 
increased number of nucleosomes. Transcription by RNA polymerase II is 
slowed down by the nucleosome, this promotes exon inclusion (Naftelberg et 
al., 2015). It has been shown that gene regions encoding exons tend to be more 
highly DNA methylated than introns. It was shown that about 22% of studied 
alternative exons are regulated by DNA methylation. Again this has been linked 
to the transcription elongation rate, but also to a recruitment of splicing factors 
by heterochromatin protein 1 [reviewed in (Lev Maor et al., 2015)]. This is also 
referred to as the recruitment model (Naftelberg et al., 2015). Lastly, changes to 
the transcription termination also influence the splicing of the last intron of the 
pre-mRNA (Niwa and Berget, 1991). 
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1.8. Alternative splicing and cancer 
 
Given the importance of alternative splicing in the normal homeostasis of cells 
and organisms, it is not surprising that changes to alternative splicing patterns 
are also important factors in the development and maintenance of cancer. 
There are multiple ways in which aberrant splicing can occur in cancer. 
Epigenetic changes can affect transcription linked to the previously discussed 
kinetic and recruitment model. An example is the skipping of exon 8 in the 
tumour suppressor gene CDH1 in gastric cancer that is linked to the methylation 
pattern of the exon encoding gene region (Li et al., 2015b). The changes can 
affect the normal equilibrium of splice variants of one gene or cause the 
production of splice variants that are not normally expressed in the cell type or 
which are altogether novel [reviewed in (Pal et al., 2012)].  
In cancer common targets of aberrant alternative splicing are genes that are 
important in signalling pathways such as cell survival and growth or metastasis 
[reviewed in (Siegfried et al., 2013)]. One example is the tumour suppressor 
BRCA1, which main role is in DNA repair, not only plays an important role in 
developing hereditary cancer when mutated, but is also a target of alternative 
splicing [reviewed in (Orban and Olah, 2003)]. One splicing factor involved in its 
aberrant splicing is SRSF1. It is the most extensively studied splicing factors in 
breast cancer and has been considered a proto-oncogene 2 [reviewed in (Silipo 
et al., 2015)]. Deregulated SRSF1 causes changes to the alternative splicing 
pattern of a number of important genes such as cell cycle protein cyclin D1, 
vascular endothelial growth factor (VEGF) a promoter of angiogenesis and 
apoptosis regulator Bcl-2 [reviewed in (Silipo et al., 2015)]. Another study 
showed how members of the hnRNP family cause changes in the alternative 
splicing pattern of apoptotic genes promoting breast cancer development 
(Venables et al., 2008). 
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1.9. HER2 splice variants and their role in cancer 
 
As mentioned previously, three functionally distinct alternative splice variants of 
HER2 have been identified; the membrane bound Δ16HER2 and the two 
secreted proteins Herstatin and p100 (Doherty et al., 1999a; Aigner et al., 2001; 
Sasso et al., 2011). These three HER2 protein variants have been studied to 
different extents in the context of cancer and much of their function is still not 
understood. 
P100 
In 1993 Scot and colleagues identified a short HER2 transcript. This transcript 
encodes the first 2.1 kb of the otherwise 4.6 kb long wild type HER2 transcript. 
The transcript is compromised of the first 15 exons and a part of the following 
intron (Scott et al., 1993). This causes the use of an in-frame stop codon and an 
early alternative poly(A) site within intron 15 (Scott et al., 1993; Aigner et al., 
2001). The partial intron 15 inclusion gives rise to a novel 20 amino acid long C-
terminal tail. Once translated this transcript produces a 633 amino acid long and 
100 kDa sized glycosylated protein that only contains the extracellular domain 
of HER2 and can be found both in cells and as a secreted protein. Due to its 
size it was termed p100 (Scott et al., 1993). 
First identified in breast cancer cell lines, this transcript was also found to be 
expressed in other HER2 overexpressing gastric and ovarian cell lines (Scott et 
al., 1993; Aigner et al., 2001). This HER2 variant was later also found to be 
expressed at varying levels in breast cancer tissue and metastasis samples 
(Gebhardt et al., 1998) as well as gastric cancer (Aigner et al., 2001).  
Studies into its role in cancer have given rise to controversial results. Initially it 
was shown that if cells overexpressed p100, the effect of HER2 targeting 
growth-inhibiting antibodies was decreased. Presumably, because the antibody 
binds p100 instead of wild type HER2, and as p100 is not able to induce 
signalling the antibody losses its effect (Scott et al., 1993). A later study showed 
that the overexpression of p100 causes a decrease of cell proliferation in the 
breast cancer cell line MCF-7. It was also shown that p100 overexpression 
reduces heregulin dependent HER4 activation and thereby inhibits the induction 
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of the important cellular MAPK pathway. Additionally, it reduced the colony 
forming ability on soft agar of the gastric cancer cells MKN7. These observation 
were supported by an inverse association of p100 expression with advanced 
gastric cancer (Aigner et al., 2001). Most studies do not distinguish between 
different secreted extracellular domain (ECD) HER2 proteins. Although, some 
studies have found ECD HER2 expression to be a good prognostic factor for 
patients treated with trastuzumab, others have associated it with a bad 
prognosis. A meta-analysis has not been able to show any clear associations 
(Lennon et al., 2009). Interestingly, a recent study has shown that patients with 
an elevated ECD HER2 level benefit from lapatinib treatment (Lee et al., 2016). 
Herstatin 
Herstatin is the second secreted HER2 isoform arising from alternative splicing. 
It was first described by Doherty and colleagues in 1999 in an ovarian 
carcinoma cell line. The Herstatin mRNA transcript differs from WT HER2 
through the inclusion of intron 8. From the 274bp of the intron 237bp are 
translated and the translation is terminated by an alternative stop codon in the 
intron. The arising protein is 68 kDa and consists of the extracellular domain of 
HER2 and a novel 79 amino acid long C-terminus. The novel C-terminal domain 
has been termed ECDIIIa. Herstatin is a minor HER2 protein variant (<5% of all 
HER2) in breast and ovarian cell lines as well as fetal tissue. Anti-sera was 
raised against Herstatin and endogenous Herstatin could be detected both in 
cell lysate and supernatant from the embryonic kidney cell line HEK-293 
(Doherty et al., 1999a). Herstatin inhibits WT HER2 signalling by binding to 
HER2 and disrupting dimer formation with EGFR, HER3 and HER4, this inhibits 
tyrosine phosphorylation and consequently anchorage-independent growth 
(Doherty et al., 1999a; Azios et al., 2001; Justman and Clinton, 2002; Shamieh 
et al., 2004) and proliferation in general (Jhabvala-Romero et al., 2003). It has 
also been shown that HER2 and Herstatin can be found co-localised in the 
endoplasmic reticulum and cytoplasm, and this complex formation seems to 
prevent HER2 from transitioning to the cell surface (Hu et al., 2006). 
Herstatin has been found both in cancerous and adjacent normal tissue both at 
mRNA and protein level. Interestingly, in 75% of the cancer tissue samples the 
mRNA levels did not predict the protein levels. Relative ratio between Herstatin 
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and HER2 were similar in cell lines and tissue, but generally lower in tissue. The 
same study also shows that about 20% of the HER2+ tumours studied also 
expressed relatively high Herstatin levels. In the surrounding normal tissue only 
relative low levels of Herstatin could be detected. This subgroup of tumours was 
further characterised by a high level of cytoplasmic phospho-AKT/p21 proteins. 
Such high cytoplasmic phospho-AKT/p21 levels in combination with HER2 
overexpression have also been associated with an adverse prognosis in breast 
cancer and poor therapy outcome (Koletsa et al., 2008). Although the 
mechanisms in Herstatin high breast cancer are still not well understood, 
Herstatin is generally considered to act as an autoinhibitor of HER2 and 
function as a tumour suppressor in cancer.  
Δ16HER2 
The third HER2 splice variant, Δ16HER2, was first described by Kwong and 
Huang in 1998 as well as Siegel and colleagues in 1999. It is produced by the 
in-frame deletion of the 48 bp long cassette exon 16. This exon encodes 16 
amino acids that are part of the extracellular domain (IV) directly preceding the 
transmembrane domain (Kwong and Hung, 1998; Siegel et al., 1999). Earlier 
research had identified a deletion mutant of the HER2 orthologue Neu in mice 
to cause a loss of the same amino acids (Guy et al., 1992; Siegel et al., 1994; 
Siegel and Muller, 1996). The loss of cysteine residues in this region of the 
extracellular domain causes a conformational change, which gives rise to a 
continuously active conformation and promotes homo-dimerization by 
intermolecular disulphide bonds as well as strong association with HER3 
(Siegel et al., 1999). Depending on the study Δ16HER2 mRNA has been found 
to make up 5% to 9% of the total HER2 mRNA transcripts (Siegel et al., 1999; 
Castiglioni et al., 2006). Δ16HER2 has been found expressed in both cancerous 
and non-cancerous breast tissue, but it has been found at increased levels in 
cancerous breast (Siegel et al., 1999; Castiglioni et al., 2006). Another study 
found that 89% of local lymph node-positive and HER2-positive breast cancer 
patients expressed Δ16HER2 (Mitra et al., 2009). It has been suggested that 
the gene amplification of HER2 in breast cancer may cause the elevation of 
Δ16HER2 expression over a threshold, where the splice variant contributes to 
the progression of the tumour (Siegel et al., 1999; Castiglioni et al., 2006). 
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Already in initial studies exogenous Δ16HER2 was shown to have a six-fold 
stronger downstream signalling ability than exogenous WT HER2 when 
transiently transfected into cell lines. Furthermore, Δ16HER2 has been shown 
to have an increased transforming capability compared to wild type HER2 
(Kwong and Hung, 1998; Siegel et al., 1999; Mitra et al., 2009; Sasso et al., 
2011). This transforming capability has been shown in 3D cell culture models 
using the normal-like mammary cell line MCF-10A that only formed invasive 
structures when Δ16HER2 was overexpressed, but not with WT HER2 
overexpression (Alajati et al., 2013) and in mice models (Castiglioni et al., 2006; 
Marchini et al., 2011; Alajati et al., 2013). In mice models injected with WT 
HER2 transfected human cells no tumour growth could be observed. When the 
same experiments were performed with cells transfected with Δ16HER2, 
tumour growth and lung metastasis could be observed (Castiglioni et al., 2006; 
Marchini et al., 2011; Alajati et al., 2013). This ability to induce tumour formation 
has been suggested to be due to the ability of Δ16HER2 to induced the 
expression of genes that mediate the endothelial to mesenchymal transition 
(Alajati et al., 2013). Similar to previous studies Castagnoli et al., showed that 
Δ16HER2-positive mice develop tumours faster and at a higher rate than WT 
HER2-positive mice. Interestingly, they observed changes in FISH analysis of 
the mice tumour tissues. They found WT HER2 mice tissues to have a near-
tetraploid karyotype, but Δ16HER2 mice tissue to retain a diploid karyotype. 
Furthermore, they found WT HER2 tumours to be histologically very 
homogeneous, whereas Δ16HER2 tumours seemed to have three different 
zones with morphological differences in the cells (Castagnoli et al., 2014).  
Different studies have indicated that Δ16HER2 induces, at least partially, a 
different signalling pathway than WT HER2. Microarray expression profiling 
showed an expression profile that is typical for ER-negative, high-grade 
metastatic primary tumours, not HER2 positive tumours (Alajati et al., 2013). 
Δ16HER2 has been shown to directly interact with the proto-oncogene Src. 
Δ16HER2 induces the translocation of the associated Src to the cell membrane, 
Src induces AKT, MAPK and cell motility regulating focal adhesion tyrosine 
kinase (FAK) pathways. Inhibition of Src caused destabilization of Δ16HER2 
and decreased tumorigenicity (Mitra et al., 2009). This was supported by a 
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study that found a direct correlation between Src phosphorylation and 
Δ16HER2 expression in a panel of breast tumours (Castagnoli et al., 2014). 
First studies in human cell lines indicated that Δ16HER2 might play a role in 
resistance to trastuzumab therapy (Castiglioni et al., 2006; Mitra et al., 2009). It 
was shown that although the therapeutic antibody trastuzumab could bind 
Δ16HER2 and cause its downregulation, the downstream signalling was not 
affected. Opposed to the WT HER2 model the tumour suppressor PTEN was 
also not induced in the Δ16HER2 model in response to trastuzumab (Mitra et 
al., 2009). However, in the last seven years research has moved to study 
Δ16HER2 in vivo. Some studies injected mice with Δ16HER2/WT HER2 human 
cancer cells (Alajati et al., 2013) and in other studies transgenic mouse models 
were used (Marchini et al., 2011; Castagnoli et al., 2014). In the in vivo study by 
Castagnoli et al. Δ16HER2 positive tumours were shown to be associated with 
an increased susceptibility to trastuzumab therapy (Castagnoli et al., 2014). 
Additionally, using a method to infer Δ16HER2 levels through the expression of 
its downstream targets (Δ16HER2 metagene) Castagnoli and colleagues 
studied therapy resistance and prognosis in Δ16HER2 positive patients. They 
observed a positive association between the Δ16HER2 metagene and 
susceptibility to trastuzumab treatment (Castagnoli et al., 2014). 
 
1.10. Anti-HER2 therapy resistance: Focus on HER2 splice variants 
 
As encouraging as HER2 targeting therapeutics are, resistance against them in 
HER2 positive tumours has been observed. It was shown that in cases of 
metastatic breast cancer up to 74% of the patients were resistant to treatment 
with trastuzumab (Vogel et al., 2002). Moreover, in 50% of the cases there was 
no response to combining trastuzumab with chemotherapy (Slamon et al., 1989; 
Hurvitz et al., 2013). The treatment with lapatinib alone yields similar 
percentages of resistant tumours. It has been suggested that an improved 
outcome could be attained when combining trastuzumab with lapatinib 
(Gampenrieder et al., 2013). Studies have indicated that a treatment of 
pertuzumab in combination with trastuzumab and chemotherapy yields a 
Chapter 1: Introduction 
49 
 
pathologic complete response rate of 60%, and up to 90% have at least a 
partial response (Schneeweiss et al., 2013). 
As can be deducted from the numbers above, patients with an intrinsic or 
acquired resistance are not uncommon. A number of different mechanisms 
have been implied to be responsible for this resistance. Studies showed that 
often the aberrant activation of the HER2 signalling pathway, downstream of the 
receptor is the cause of resistance against therapy both with antibodies and 
lapatinib (Garrett and Arteaga, 2011). An example for this is the gain of function 
mutation to the PI3K subunit p110alpha (Campbell et al., 2004). Another 
mechanism of resistance that has been suggested to be mediated by HER3, as 
trastuzumab seems to inhibit the heterodimerization of HER2 with EGFR, but 
not with HER3 (Junttila et al., 2009; Hurvitz et al., 2013). Additionally, targeting 
of HER2 seems to activate HER3 via an AKT-mediated feedback loop (Hurvitz 
et al., 2013). Furthermore, trastuzumab resistance has also been observed to 
be caused by the masking of HER2 by increased expression of the membrane-
associated mucin MUC4 (Nagy et al., 2005).  
Another potential reason for therapy resistance is the expression of a truncated 
version of HER2, p95HER2. This protein consists of the intracellular domain of 
HER2 and is mostly membrane bound. Trastuzumab has no effect on it as it 
lacks the extracellular domain which contains the epitope of trastuzumab 
(Aigner et al., 2001). The tyrosine kinase inhibitor lapatinib is effective as the 
intracellular domain is intact. Similarly, as the intracellular domain of Δ16HER2 
is also intact, it is also expected to be an effective target of lapatinib (Mitra et al., 
2009).  
The cross-talk between ER and HER2 pathways has also been shown to affect 
drug treatment (Hurvitz et al., 2013). The success of tamoxifen therapy, a 
competitive antagonist of oestrogen in ER-positive breast cancer, is strongly 
influenced by the co-expression of HER2. Studies showed that half of ER-
positive breast cancer patients also express HER2 and up to 70% of these are 
resistant to tamoxifen therapy. This can be linked to the ability of HER2 and ER 
positive tumours to acquire oestrogen-independence. A study found that in up 
to 30% of the ER-positive breast tumours Δ16HER2 is expressed, and that 
Δ16HER2, not WT HER2 is responsible for increased oestrogen independent 
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growth and resistance against tamoxifen. The following mechanism has been 
described. In response to tamoxifen, resistant cells upregulate the expression of 
the ant-apoptotic protein B-cell lymphoma-2 (BCL-2). This has been shown to 
be due to Δ16HER2 mediated downregulation of miRNAs 15a and 16, which 
normally target BCL-2 and cause its degradation (Cittelly et al., 2010a; Cittelly 
et al., 2010b).  
Although it has been speculated that the binding of trastuzumab to Δ16HER2 
could be inhibited by the epitope of the antibody lying in close proximity of the 
deleted region, it has been shown that trastuzumab is still able to bind 
Δ16HER2. Until recently studies indicated that Δ16HER2 was associated with 
trastuzumab resistance probably mediated by Src signalling (Mitra et al., 2009), 
but recently a study showed Δ16HER2 expressing mice tumours to be 
increasingly susceptible to trastuzumab compared to WT HER2 expressing 
tumours (Castagnoli et al., 2014).  
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1.11. Rationale, hypotheses and aims 
 
1.11.1. Study rationale 
 
When breast cancer is diagnosed the hormone receptor and HER2 status is 
assessed to determine the best possible treatment. HER2-positive breast 
cancers can be treated with HER2-targeting therapies (Hurvitz et al., 2013). 
However their efficiency has been shown to be impacted by the presence of 
HER2 protein variants (Scott et al., 1993; Aigner et al., 2001; Mitra et al., 2009; 
Lee et al., 2016). Clinically the presence of HER2 protein variants is not 
assessed. Additionally, the mechanisms regulating the production of important 
HER2 splice variants has not been sufficiently studied. 
Furthermore, although a number of HER2 protein variants have been identified, 
findings of our research group indicate the presence of additional HER2 protein 
variants. It has been shown by western blot and transient knockdown of HER2 
that there are additional HER2 protein bands that cannot be attributed to known 
HER2 protein variants (Gautrey et al., 2015).  
 
1.11.2. Hypotheses 
 
We hypothesize that: 
 The production of HER2 splice variant Δ16HER2 is primarily regulated 
through specific cis-and trans-acting elements. 
 The presence of HER2 protein variants affects the HER2 status 
assessment and the subsequent therapy.  
 Novel HER2 protein variants exist as a result of alternative splicing. 
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1.11.3. Aims 
 
The aims of this project were to: 
 Investigate the mechanisms regulating the Δ16HER2 splicing event 
 Identify RNA-binding proteins that bind to the Δ16HER2 splicing region 
and regulate its splicing, and the RNA sequences they bind to 
 Investigate a potential feedback loop between HER2 and its splicing 
regulators 
 Study the effect of progesterone on HER2 expression and splicing 
 
 Characterise a cohort of breast tumours for HER2 protein expression 
and localisation as well as the HER2-gene copy number 
 Characterise breast tumours with discordant HER2 status results  
 Study the HER2 splice variant levels in discrepant breast tumour 
samples 
 
 To identify any potential novel HER2 splice variants 
 To characterise any novel HER2 splice variant and their expression in 
normal and cancerous human tissues 
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Chapter 2: General materials and methods 
 
2.1. Cell lines 
 
Three breast cancer cell lines were used in this study, these were MCF-7 
(ATCC® HTB-22™), MDA-MD-231 (ATCC® HTB-26™) and SKBR3 (ATCC® 
HTB-30™). The cell lines were acquired from the American Type Culture 
Collection (ATCC) and LGC Standards, Europe. All cell lines are adherent.  
MCF-7 
This cell line is an epithelial cell line derived from the metastatic site of a breast 
adenocarcinoma of a Caucasian 69 year old female. It is considered to be a 
model for early stage, non-invasive breast cancer (Soule et al., 1973). MCF-7 is 
ER/PR positive and HER2 negative (Subik et al., 2010). 
MDA-MB-231 
The MDA-MB-231 cell line is an epithelial cell line derived from the metastatic 
site of a breast adenocarcinoma of a Caucasian 51 year old female. The cell 
line is considered to be an invasive (Cailleau et al., 1974) triple negative cell line 
(ER/PR/HER2 negative) (Subik et al., 2010). 
SKBR3 
This cell line is an epithelial cell line derived from the metastatic site of a breast 
adenocarcinoma of a Caucasian 43 year old female (Trempe, 1976). This non-
invasive cell line is ER/PR negative, but HER2 positive (Subik et al., 2010). 
 
2.2. Cell culture  
 
Cell culture techniques were performed under aseptic conditions in a Class II 
laminar flow microbiological safety cabinet. All cell lines were routinely cultured 
in 75 cm2 or 25 cm2 tissue culture flasks (Greiner) in a humidified atmosphere 
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containing 5% CO2 at 37°C. The MCF-7 and MDA-MB-231 cells were cultured 
in phenol-red free Dulbecco’s Modified Eagles medium (DMEM) (Sigma-
Aldrich), supplemented with 10% foetal bovine serum (FBS) (Sigma-Aldrich), 2 
mM L-Glutamine (Sigma-Aldrich) and 100 units/ml penicillin and 0.1mg/ml 
streptomycin (Sigma-Aldrich). SKBR3 cells were grown in McCoy’s 5A 
(modified) medium + GlutaMAXTM (Life Technologies) supplemented with 10% 
FBS (Sigma-Aldrich) and 100 units/ml penicillin and 0.1mg/ml streptomycin 
(Sigma-Aldrich). 
 
2.2.1. Cell line maintenance  
 
The cells were grown to 70-80% confluency, passaged every 3 to 5 days. For 
cell passaging the medium was removed and the cells rinsed with Dulbecco’s 
phosphate buffered saline (PBS) (Sigma-Aldrich) and incubated with 2mM 
trypsin-EDTA (Sigma-Aldrich) for 5 minutes at 37C. To neutralise the trypsin 
complete growth medium was added and the cells were centrifuged at 200 x g 
for 5 min. The supernatant was discarded and the cells re-suspended in 
complete growth medium and passage at a ratio of 1:3-1:4. 
 
2.2.2. Mycoplasma testing 
 
To ensure that the cells used in the experiments were not contaminated with 
Mycoplasma. Mycoplasma testing was routinely carried out using the 
MycoAlertTM PLUS Mycoplasma Detection kit (Lonza). Briefly, supernatants 
were collected from cells after a minimum of 48h of growth. The reagents were 
re-constituted and kept at RT for 20 min before use. The supernatants were 
centrifuged for 2.5 min at 2000 x g. The MycoAlertTM PLUS Reagent was added 
to the samples and incubated for 20 min. The absorbance was measured on a 
TD-20/20 Luminometer DLReady (Turner Designs), set for 1 sec (integrated). 
The first measurement ‘A’ was taken. Then MycoAlertTM PLUS Substrate was 
added to the samples and incubated for 30 min. The second reading ‘B’ was 
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taken. The ratio of ‘B’/’A’ was calculated. It was considered negative at < 1, 
borderline between 1 and 1.2, and contaminated at >1.2. 
 
2.2.3. Cryopreservation of cells 
 
Cells were frozen at passages 10-20 for a continuous stock of cells. Cells were 
collected during routine cell passaging as described before (see section 2.2.1). 
The cell pellet was resuspended in 1 ml of undiluted FBS with 10% dimethyl 
sulphoxide (DMSO) (Sigma-Aldrich). The re-suspended cells were transferred 
to a cryo-vial (Gibco) and frozen down to -80C in a Mr. FrostyTM Freezing 
Container, after which they were transferred to liquid nitrogen. 
When needed, cells were brought up from liquid nitrogen and thawed at 37C in 
a water bath. The cells were pelleted with the addition of complete growth 
medium at 200 x g for 5 min. The DMSO containing supernatant was removed 
and the cells re-suspended in complete growth medium and plated into tissue 
culture flasks.  
 
2.2.4. Cell counting 
 
The cells were counted to plate the appropriate number of cells. An improved 
Neubauer chamber haemocytometer (Hawksley) was used to count cells. For 
this 10 µL of completely re-suspended cells in complete growth media were 
applied to the haemocytometer. The number of cells were counted for the four 
large squares (16 small squares) of the grid using a 10 x magnification on an 
inverted microscope (Leica). The average of four large squares was calculated. 
To calculate the number of cells per mL, the counted average was multiplied by 
104. The appropriate amount of cells depending on the experiment was then 
plated. 
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2.2.5. Transient gene knockdown by siRNA transfection 
 
For transient gene knockdown experiments Silencer® Select siRNAs from Life 
Technologies were used (Table 2.2). The INTERFERinTM siRNA Transfection 
Reagent (Polyplus-Transfection) was used to transfect the siRNAs into the 
cells. The protocol was based on the manufacturers’ instruction, with minor 
changes. Volumes used are indicated in table 2.1. For experiments where 
proteins were to be isolation 24 well plates were used and for RNA isolation 12 
or 6 well plates were used. Cells were seeded 24 h before transfection. For the 
untreated control only Opti-MEM® medium (Life Technologies) was added to the 
cells. The target specific siRNAs or scrambled negative control siRNA were 
added to Opti-MEM® medium. INTERFERinTM was added and immediately 
vortexed for 10 sec. After 10 minutes incubation at RT the transfection mix was 
added to the cells. Beforehand, the complete medium was removed and 
antibiotic-free complete medium was added. The medium was exchanged for 
complete medium 24h later. To measure the effect of the gene knockdown on 
the mRNA level RNA was isolated 48 h post-transfection. For the protein level 
effect, the proteins were collected 72 h post-transfection. Additionally, to 
measure the effect on downstream targets of the knocked down gene, RNA was 
collected 72 h post-transfection. 
Table 2.1: Transient knockdown with INTERFERin
TM
. 
 24 well plate 12 well plate 6 well plate 
Number of cells 3.5 x 104 7 x 104 1.75 x 104 
Opti-MEM® medium 100 µL 150 µL 200 µL 
siRNA (2nM) 1.25 µL 2.5 µL 6.25 µL 
Interferin 2 µL 4 µL 10 µL 
Antibiotic-free 
complete medium 
0.4 mL 0.85 mL 1.8 mL 
 
Table 2.2: List of Silencer® Select siRNAs used. 
Name siRNA ID Custom designed siRNA sequences 
GAPDH AM4622  
HER2 (a) s611  
HER2 (b) s613  
hnRNP A1 ASO20R9L Sense: CUUUGGUGGUGGUCGUGGAgg 
Antisense: UCCACGACCACCACCAAAGtt 
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hnRNP A/B s6716  
hnRNP A2B1 s6713  
hnRNP D s6722  
hnRNP F (1) s6727  
hnRNP F (2) s6725  
hnRNP FH ADVI3QW Sense: GGAAGAAAUUGUUCAGUUCtt 
Antisense: GAACUGAACAAUUUCUUCCtt 
hnRNP H1 (1) s6728  
hnRNP H1 (2) s6729  
hnRNP K (1) s6737  
hnRNP K (2) s6739  
Negative Control #1 4390843  
SRSF3 (1) s12733  
SRSF3 (2) s12731  
 
2.3. Human breast tissue  
 
Breast tumour tissue samples were obtained by an award from the Breast 
Cancer Now Tissue Bank. The samples were collected with full patient consent 
and ethical approval was taken from the Breast Cancer Now Tissue Bank 
(reference: TR000027). The samples are from primary invasive ductal 
carcinoma breast tumours, grade 3. 
RNA was isolated by research technician Amy Keelty and cDNA generated with 
the Superscript III Reverse Transcriptase (Life Technologies). The cDNA was 
stored at -20C. 
 
2.4. Normal human tissue cDNA 
 
Normal human tissue cDNA from cerebellum, testis, heart, muscle and lung was 
kindly provided by Dr Julian Venables. RNA was originally procured from 
Clontech and each sample was pooled from 5 individuals. The cDNA was 
generated by Dr Venables group using Superscript III Reverse Transcriptase 
and stored at -20C. 
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2.5. RNA isolation techniques 
 
2.5.1. Total RNA isolation  
 
Total RNA was isolated from cells with the RNeasy Mini kit (Qiagen) for the 
PCR based mapping of HER2 (chapter 5.3.2) and the transient knockdown 
experiments in SKBR3 cells (chapter 3.3.4). For other experiments the 
ReliaPrepTM RNA Cell Miniprep (Promega) was used. This change was 
performed as the Promega kit was shown to produce comparable quality RNA 
and was more cost effective. Especially at small sample sizes the ReliaPrepTM 
RNA Cell Miniprep was superior to the RNeasy Mini kit. 
Both kits follow the same technical principals. They were used according to the 
manufacturer’s protocol.  
The RNeasy Mini kit, direct lysis of the adherent cells was performed on plates 
after the medium was removed. Lysis buffer was added and the cells lysed by 
mixing. The lysate was collected into 1.5 mL tube and homogenized using a 20-
gauge needle (BD Microlance). One volume of 70% ethanol was added and 
mixed. This was applied to the RNeasy spin columns. Centrifugation steps were 
performed at ≥ 8000 x g. The spin columns were centrifuged for 15 sec. The 
columns were washed with Buffer RW1 and centrifuged for 15 sec. The RNAs 
were treated with DNase I (Qiagen) to remove genomic DNA for 15 min at RT. 
This was followed by a wash with Buffer RW1 and then Buffer RPE. The 
columns were washed again with Buffer RPE and centrifuged for 2 min. The 
columns were placed into new tubes and spun down for 1 min. The columns 
were then placed into collection tubes and 25-35 µL of nuclease-free water was 
added. After one minute incubation the columns were centrifuged for 1 min. The 
RNAs were stored at -80C. 
The ReliaPrepTM RNA Cell Miniprep, direct lysis of cells was performed. 
Medium was removed and cells washed twice with PBS. The BL + TG lysis 
Buffer was added and the cells lysed by mixing. The lysate was collected into 
1.5 mL tube and homogenized using a 20-gauge needle in case of 6 well plate 
derived samples or vortexed for smaller sample sizes. 100% isopropanol was 
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added according to sample size (see manufacturers protocol) and mixed by 
vortexing. This was applied to the Minicolumns and centrifuged for 30 sec. 
Centrifugation steps were performed at 13000 x g. The columns were washed 
with RNA Wash Solution and centrifuged. A 15 min DNase I treatment was 
performed to remove genomic DNA, followed by a wash with Column Wash 
Solution and then RNA Wash Solution. The columns were placed into new 
tubes, washed again with RNA Wash Solution and centrifuged for 2 min. The 
columns were then placed into collection tubes and 25-30 µL of nuclease free 
water was added. After one minute incubation the columns were centrifuged for 
1 min. The RNA samples were stored at -80C. 
 
2.5.2. mRNA isolation 
 
To isolate an RNA fraction strongly enriched for polyadenylated mRNA the 
GenElute Direct mRNA Miniprep kit (Sigma-Aldrich) was used. The RNA was 
isolated according to the manufacturer’s guidelines. 
An 80% confluent 75 cm2 flask of cells was used on two columns. All 
centrifugation steps were performed at 16000 x g. Cells were pelleted and 
treated with the Proteinase K containing lysis solution. After vortexing, the cell 
lysates were applied to filtration columns and spun down. The columns were 
incubated for 10 min at 65C to eliminate RNase. 5 M NaCl and oligo (dT) 
beads were added to the samples according to the manufacturers protocol and 
vortexed. The mix was incubated for 10 min at RT, then the beads were 
pelleted. The supernatants were removed carefully. To concentrate the mRNA 
the beads were re-suspended in lysis-buffer and 5 M NaCl. This was followed 
by a 5 min incubation step at 65C and then 5 min at RT. The beads were 
pelleted for 2 minutes and the supernatant carefully removed. The beads were 
then re-suspended in wash solution and transferred to a spin column. The 
column was spun down for 2 min and the flow-through was discarded. The 
wash step was repeated with a low salt wash solution. The column was placed 
into a new collection tube. Pre-warmed elution solution was added and the 
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samples incubated at 65C for 5 min. The enriched mRNA was collected by 
centrifuging for 2 min. The elution was repeated. 
An ethanol precipitation step was performed to concentrate the mRNA. For this 
20 µg of glycogen (Fermentas), 0.1 volume of 3M sodium acetate buffer pH 5.2 
(Sigma-Aldrich) and 3 volumes of ice cold absolute ethanol were added. The 
mRNA was precipitated overnight at -20C. The mRNA was centrifuged at 
maximum speed for 15 min at 4C. The supernatant was carefully removed and 
the pellet air dried. The mRNA was resuspended in 20µL nuclease-free water. 
The mRNA was stored at -80C until use. 
 
2.5.3. Isolation of Cytoplasmic and Nuclear RNA Fraction 
 
Nuclear and cytoplasmic RNA fractions were isolated using the Cytoplasmic 
and Nuclear RNA Purification kit (NORGEN BIOTEK Corp.). For the RNA 
isolation the manufacturer’s instructions were followed. 
Cells were detached from plates with trypsin, collected, counted and RNA was 
isolated from 1 x 106 cells. The cells were pelleted at 200 x g for 10 min and 
lysed using the Lysis Buffer J. The pellet was homogenized by vortexing. The 
lysate was centrifuged at maximum speed for 3 minutes. The supernatant, the 
cytoplasmic RNA, was collected in a new tube. Buffer SK was added to the 
cytoplasmic RNA and vortexed for 10 sec. Then 100% ethanol was added and 
again mixed by vortexing. This mix was applied to the column and spun down at 
3500 x g for 1 min. The same was performed for the pellet, the nuclear RNA 
fraction. 
DNase [concentration: 2.73 Kunits/µL] (Qiagen) was used to treat the RNA 
fractions. For each column 100 µL 0.25 Kunits/µL was prepared in DNase 
Buffer. After addition of the Wash solution, the columns are centrifuged at 
14000 x g for 2 min. Then the DNase mix was added to the columns and 
centrifuged for 1 min at 14000 x g. The flow-through was applied back onto the 
columns and incubated for 15 min at RT. Then the columns were washed with 
Wash solution and spun down for 2 min at 14000 x g. The columns were placed 
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into fresh tubes and 25 µL elution buffer E added. The columns were 
centrifuged at 200 x g for 2 min and 1 min at maximum speed. The RNA 
samples were stored at -80C. 
 
2.6. Polymerase chain reaction (PCR) based techniques 
2.6.1. Reverse transcription  
 
RNA quantity and quality was assessed using the NanoDrop1000 
(ThermoScientific). Reverse transcription was performed using the SuperScript 
III Reverse Transcriptase kit (Invitrogen). For each sample a reaction containing 
all reagents except the SuperScript III reverse transcriptase was performed as a 
negative (-ve) control to check for genomic contamination. Additionally a control 
containing all reagents but no template was used as an RT- control. 
Table 2.3: Reverse transcription reaction mix. 
 
 
 
 
 
 
For each reaction (0.2 to) 1 µg of RNA was used, the amount was kept 
consistent in each set of experiments. The reagents, except the reverse 
transcription enzyme, were pipetted together with the RNA and made up to a 
total volume of 49 µL (Table 2.4). Lastly the reverse transcription enzyme was 
added. The sample was then incubated in a BioRad or G-storm thermocycler for 
59 min at 50C and 15 min at 70C. Synthesised cDNA was stored at -20C.  
 
 
Reaction mix components For a 50 µL reaction 
5x First Strand buffer 10 µL 
Oligo (dT) primers (0.5 µg/µL) 1 µL 
dNTP mix (25 mM each) 0.8 µL 
DTT (0.1 M) 1 µL 
RNaseOUT (40 unts/µL) 1 µL 
SuperScript III reverse 
transcriptase 
1 µL 
RNA  (0.2 to ) 1 µg  
Nuclease free water Make up to 50 µL 
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2.6.2. Conventional PCR 
 
For conventional PCR the 2 x PCR Master Mix (Promega) was used. The 
reaction mix was prepared according to the manufacturer’s instructions (Table 
2.4). Only for Intron 25 detection the primer amount used was decreased to 0.2 
µL each and the annealing temperature set for 60C. The full list of primers is 
shown in table 2.8. The PCRs were undertaken using either a BioRad or a G-
storm thermocycler, the cycle number of the basic programs was adjusted 
according to the gene to be amplified and cDNA source (Table 2.5). 
Orange G loading dye [50% Glycerol, 60mM EDTA, 10mM Tris-HCl, 0.15% 
Orange G (Sigma-Aldrich)] was added to the PCR products which were then 
separated on 2% agarose (Bioline) gels with 0.04 µL/mL ethidium bromide in 
0.5 x crystal TBE running buffer (Bioline). The voltage used was dependent on 
the size of tank and gel used. It was visualised under UV light on a 
Biospectrum®500 Imaging system (UVP) with the VisionWorks LS software 
(UVP). 
Basic PCR Program 
95C  2 min 
95C   30 sec 
55C   30 sec                           x cycles 
72C   30 sec - 1.5 min 
72C   5 min 
12C     ∞ 
 
Table 2.4: PCR reaction mix. 
 For a 25 µL reaction 
2x Master Mix 12.5 µL 
(0.5 µg/µL) Forward/Reverse Primer 0.25 µL 
Nuclease-free water 11 µL 
cDNA 1 µL 
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Table 2.5: Number of PCR cycles used. 
 SKBR3 
cDNA 
MCF-7 / 
MDA-MD-231 
cDNA 
Human 
Tissue 
cDNA 
Breast 
Tumour 
cDNA 
Δ16HER2 27 30 N/A 35 
Β-actin N/A N/A 25 25 
GAPDH 20 20 20 N/A 
Herstatin N/A N/A N/A 35 
hnRNP A1 35 N/A N/A N/A 
hnRNP A2B1 25 N/A N/A N/A 
hnRNP F 26 N/A N/A N/A 
hnRNP H 28 N/A N/A N/A 
hnRNP K 25 N/A N/A N/A 
I12HER2 30 N/A N/A N/A 
I25HER2 30 32 32 35 
P100 N/A N/A N/A 35 
SRSF3 24 N/A N/A N/A 
Wild type HER2 23 25 32 32 
 
Table 2.6: List of PCR primers used. 
Name Sequence 
Novel exon 1 Forward CGAGGCGATAGGGTTAAGGG 
Novel exon 6 Forward ATTCCAGAAGATATGCCCCG 
Exon 1 Forward TCCTCCTCGCCCTCTTGC 
Exon 2 Forward CCAGCCTGTCCTTCCTGC 
Exon 3 Forward CGCTGAACAATACCACCCCT 
Exon 3 Reverse AGGGGTGGTATTGTTCAGCG 
Exon 5 Forward CTCCGATGTGTAAGGGCTCC 
Exon 6 Forward CCACTGACTGCTGCCATGAG 
Exon 9 Reverse TGCCAGGCTCCCAAAGATC 
Exon 10 Forward GAGACTCTGGAAGAGATCAC 
Exon 12 Forward GGCCAGAGGACGAGTGTG 
Intron 12 Forward CCCTTCCTCCTCACTGCAG 
Exon 14 Forward AGTGACCTGTTTTGGACCG 
Exon 16 Exclusion Reverse CGTCAGAGGGGAGTGGGT 
Exon 16 Inclusion Reverse GGACCTGGATGACAAGGG 
Exon 16 Inclusion Forward (3Fa) GTGTGGACCTGGATGACAAGGG 
Exon 16 Exclusion Forward (3Fb) CACCCACTCCCCTCTGAC 
Exon 16 Reverse (3R) GCTCCACCAGCTCCGTTTCCTG 
Exon 17 Forward (F1) CATTCTGCTGGTCGTGGTCT 
Exon 18 Reverse (R1) CCGTCTCTTTCAGGATCCGC 
Exon 19 Reverse (R2) TGGCTTTGGGGGATGTGTTT 
Exon 20 Reverse (R3) AGAGGCAGCCATAGGGCATA 
Exon 20 Forward (F2) GGTGACACAGCTTATGCCCT 
Exon 21 Reverse (R4) GCACATCCTCCAGGTAGCTC 
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Exon 22 Reverse (R5) CCACACATCACTCTGGTGGG 
Exon 23 Reverse (R6) AGGTTTGGCCCCAAAAGTCA 
Exon 23 Forward (F3) GGCCAAACCTTACGATGGGA 
Exon 24 Reverse (R7) GCGGGAGAATTCAGACACCA 
Exon 25 Reverse (R8) TGGGCCCAAGTCCTCATT 
Exon 25 Forward (F4) CACCGCAGCTCATCTACCAG 
Exon 26 Reverse (R9) CCCATTCCCAGGTCACCATC 
Exon 27 Reverse (R10) CCTTTCCAGAGTGGCACCAG 
HER2_ n3UTR_R CAGAAGTCAGGCCTTCCCTG 
HER2_3UTRv1_R GAAGATTCCCAGCCACTCCC 
HER2_3UTRv2_R GGACAGCTGGTGTTCTCCAA 
HER2_Intron 24_F GAGGGTGGGAAGGAGAGATGAG 
HER2_Intron 24_R GCCTGGCATACTGGACTCAT 
New Herstatin Forward CCTGTCCTATCCTTCCTCAGAC 
Intron 25 qPCR Forward GCTCATCTACCAGGGTCAGT 
Intron 25 qPCR Reverse TGGGGTTTCCTTGAGAGGTG 
hnRNP A1 Forward CCAGAGAAGATTCTCAAAGACC 
hnRNP A1 Reverse CTTCAGTGTCTTCTTTAATGCC 
hnRNP A2B1 Forward TTTGATGACCATGATCCTGT 
hnRNP A2B1 Reverse CTCTGAACTTCTTGCATTTC 
hnRNP F Forward GAGGGAGGTGAAGGCTTTGT 
hnRNP F Reverse CGGCCCCATCATGAATCGT 
hnRNP H Forward TCCTGACACGGCCAATGATC 
hnRNP H Reverse TTGGCACGATTTCCAACCCT 
hnRNP K Forward GTGCACAGCCTTATGATCCC 
hnRNP K Reverse ACCAGGAGGCATTCTGTCAA 
P100 Forward TGGACCGGAGGCTGACCAG 
P100 Reverse AGACCGTTGGACTCACGAGTGG 
GAPDH Forward (conv. PCR) CTGCCGTCTAGAAAAACC 
GAPDH Reverse (conv. PCR) CCAAATTCGTTGTCATACC 
GAPDH (2) Forward (qPCR) CCACCCATGGCAAATTCC 
GAPDH (2) Reverse (qPCR) GATGGGATTTCCATTGATGACA 
 
2.6.3. Real-Time PCR: SYBR Green 
 
For HER2 splice variant expression studies, the cDNA samples derived from 
SKBR-3 cells were diluted 1:10 because of the high HER2 expression level and 
from the MCF-7 cells the cDNA samples were diluted 1:2 due to low HER2 
expression levels. The QuantiFAST SYBR Green PCR Master mix was used. 
The primers for wild type HER2 (3Fa, 3R), Δ16HER2 (3Fb, 3R) and p100 are 
listed in table 2.6. For normalisation the housekeeping gene GAPDH was used. 
The reaction mix was prepared as detailed in table 2.7. Triplicates were applied 
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to MicroAmp Optical 96-Well Reaction Plates (Applied Biosystems®). Negative 
control reactions were included for each primer pair. The sealed plates were 
spun down for 5 min at 500 x g, to remove any air bubbles. A fast comparative 
CT (ΔΔCT) program with a melting curve was run on a StepOnePlusTM Real-
Time PCR System. 
The real-time PCR program;  
95C  5 min 
95C  10 sec  
60C  30 sec 
Melting curve was set to have a 0.5C ramp rate. 
 
Table 2.7: PCR reaction mix with QuantiFAST SYBR Green PCR Master Mix. 
 For a total volume of 25 µL 
2x QuantiFast SYBR Green 
PCR Master Mix 
12.5 µL 
10 µM Forward/Reverse Primer 2.5 µL 
cDNA (1 to 100 ng) 1 µL 
Nuclease-free water 6.5 µL 
 
2.6.4. Real-Time PCR:  TaqManTM Assays 
 
Where available real-time PCR with TaqManTM assay (Life Technologies) was 
performed. The TaqManTM assays used are listed in table 2.9. For TaqManTM 
real-time PCR reactions 1:10 diluted SKBR3 cDNA samples were used. The 
reaction mix was prepared following the manufacturers protocol (Table 2.10).   
Table 2.8: TaqMan
TM
 Assays. 
 TaqMan
TM
 Assay ID 
GAPDH Hs0258991_g1 
hnRNP H1 HS01033855_g1 
hnRNP F Hs01855422_s1 
hnRNP K Hs03989611_gH 
SRSF3 Hs00751507_s1 
 
40 cycles 
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Four replicates were plated onto MicroAmp Optical 96-Well Reaction Plates and 
negative controls for each TaqManTM assay were included. The sealed plates 
were spun down for 1-2 min at 500 x g, to remove any air bubbles. The 
standard program for a standard comparative CT (ΔΔCT) program on the 
StepOnePlusTM Real-Time PCR System was used. 
Table 2.9: TaqMan
TM
 Real-Time PCR reaction mix. 
 
 
 
 
2.7. Protein based techniques 
2.7.1. Protein isolation  
 
Protein lysate was prepared following transient knockdown using 2 x SDS 
lysis/loading buffer [30% Urea, 2.5% SDS, 35µl/ml Mercaptoethanol, 0.1% 
Bromophenol Blue in 0.5M Tris pH 6.8 (Sigma Aldrich)]. After direct lysis of cell 
with SDS lysis buffer, the protein extract was denatured by incubation at 10min 
at 95C. 
After lapatinib treatment cells grown in 12 well plates were collected in 
radioimmunoprecipitation assay (RIPA) buffer. After removing the medium and 
washing with 1 x PBS, 200μL of RIPA buffer (25mM Tris-HCL, 150mM NaCl, 
5mM EDTA, 1% NP-40 substitute, 1% sodium deoxycholate, 0.1% sodium 
dodecyl sulfate [Sigma Aldrich]) supplemented just before use with 2% protease 
inhibitor (Sigma Aldrich) and 1% phosphatase inhibitor cocktail III (Sigma 
Aldrich) was added. The cells are lysed and scraped in the buffer. The cell 
lysate is collected and centrifuged for 15 min at 14000 x g. The supernatant was 
collected, frozen in liquid nitrogen and transferred to a -80C freezer. For 
western blot 30 μg samples were prepared. To the appropriate amount of 
protein sample 10 μL of 2 x SDS lysis/loading buffer was added and the protein 
sample denatured through a 10 min incubation at 95C. 
 For 10 µL total volume 
20x TaqMan Gene Expression Assay 0.5 μL 
2x TaqMan Gene Expression Master Mix 5 μL 
cDNA template (1 to 100 ng) 2 μL 
RNase-free water 2.5 μL 
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2.7.2. Protein quantification 
 
To quantify proteins the colourimetric DC Protein Assay (Bio-rad) was used. For 
this a protein standard was prepared from bovine serum albumin (BSA) in the 
same buffer as the proteins were isolated into. The protein quantification was 
performed according to the manufacturer’s protocol. The absorbance was read 
at 750nm on a SpectraMax 190 microplate reader (Molcular Devices) using the 
parameters set for the Lowry assay on the SoftMax Pro software (Molecular 
Devices). The standard curve was plotted and the equation of the linear trend 
line used to calculate the protein concentrations of the samples. 
2.7.3. SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
To size separate proteins SDS-PAGE was performed. The samples were 
denatured and prepared with SDS-lysis buffer as loading dye and applied to a 
polyacrylamide gel (Table 2.8). If not otherwise indicated, reagents were bought 
from Sigma-Aldrich. The SDS-PAGE was performed in a Mini-PROTEAN III 
system (Bio-Rad) with a 1 x electrophoresis buffer (25 mM Tis-HCl pH 8.3, 190 
mM glycine, 0.1% SDS). A PageRulerTM Prestained protein ladder or a 
PageRulerTM Plus Prestained protein ladder (Thermo Scientific) was used as a 
reference molecular weight marker. Electrophoresis was performed at 175V for 
1h, or as necessary using a PowerPAC 3000 system (Bio-Rad). The gel was 
immediately used for protein transfer. 
Table 2.10: Components of polyacrylamide resolving and stacking gels. 
For a volume of 20 mL 7.5% 10% 12% 4% stacking gel 
40% Acrylamide/Bis 
solution (Bio-Rad) 
3.76 mL 5 mL 6 mL 500 µL 
H2O  10.94 mL 9.7 mL 8.7 mL 3.2 mL 
1.5 M Tris HCl pH 8.8 5 mL 5 mL 5 mL N/A 
SDS 200 µL 200 µL 200 µL 50 µL 
TEMED 10 µL 10 µL 10 µL 5 µL 
10% Ammonium 
persulphate 
100 µL 100 µL 100 µL 25 µL 
0.5 M Tris HCl pH 6.8  NA NA NA 1.26 mL 
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2.7.4. Western blot 
 
A wet transfer was performed to transfer the proteins from the SDS-gels o to 
Immun-Blot® PDVF membranes (Thermo Scientific). The transfer was 
performed in 1 x transfer buffer (25 mM Tris-HCl pH 8.3, 150 mM glycine, 10% 
methanol) at 90 V for 90 min in the case of small to medium sized proteins and 
for 2 h for large proteins using the PowerPAC 200 system (BioRad). The run 
was performed under constant cooling.  
The membrane was blocked with 10% not-fat milk powder (Marvel) in 1 x PBS 
(Sigma Aldrich) for 1 h. This was followed by overnight incubation with the 
primary antibody at 4C. The antibody was prepared in the recommended or 
optimised concentration in 1% milk powder (Table 2.9). Following incubation the 
antibody was recovered and the membrane washed three times for 10 min in 1 
x PBS. The appropriate horseradish peroxidase (HRP) conjugated secondary 
antibody (Dako) (Table 2.9) was diluted 1:3000 in 1 x PBS and applied to the 
membrane for 1h at RT under agitation. The membrane was then washed three 
times with 1 x PBS for 10 min. To detect the proteins through 
chemiluminescence an ECL detection was used. With normal abundant proteins 
Pierce ECL Western Blotting Substrate (Thermo Scientific) was used and for 
increased sensitivity AmershamTM ECL SelectTM Western Blotting detection 
reagent (GE Healthcare) was used. X-ray films (Kodak) were exposed to the 
membranes and developed.  
Alternatively, if phosphorylated proteins were to be detected the membranes 
were blocked with 5% Albumin, serum bovine (BSA) (Sigma-Aldrich) in 1x TBS. 
The primary antibodies were prepared in 5% BSA, 1 x TBS with 0.1% 
Tween®20 (Sigma-Aldrich) and the secondary antibody in 1 x TBS. The washes 
before the secondary antibody were alternatively performed with 1x TBS or 1 x 
TBS-Tween®20. After the secondary antibody the washes were performed with 
1 x TBS and once with 1 x PBS. 
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Table 2.11: Details to the antibodies used in western blotting. 
Antibody Company Western Blot  
antibody ratio 
2nd Antibody 
GAPDH (FL335) Santa Cruz 1:1000 rabbit 
HER2/ErbB2 (c-terminal) Cell Signaling 1:1000 rabbit 
HER2/ErbB2 (D8F12) XPTM Cell Signaling 1:1000 rabbit 
Phospho-HER2/ErbB2 
(Tyr1221/1222) (6B12) 
Cell Signaling 1:1000 rabbit 
hnRNP 1 GeneTex 1:3000 rabbit 
hnRNP A1 GeneTex 1:3000 mouse 
hnRNP A/B GeneTex 1:3000 rabbit 
hnRNP A2B1 GeneTex 1:10000 rabbit 
hnRNP D / AUF1 GeneTex 1:3000 rabbit 
hnRNP H GeneTex 1:3000 rabbit 
hnRNP K GeneTex 1:3000 rabbit 
SRp40/p55/p75 (H-180) Santa Cruz 1:1000 mouse 
SRSF3 Zymed 1:1000 mouse 
Akt (pan) (C67E7) Cell Signaling 1:1000 rabbit 
phospho-Akt (Ser473) 
(D9E) XP® 
Cell Signaling 1:2000 rabbit 
Anti-MAP kinase 1/2 
(Erk1/2) 
Merck Millipore 1:1000 rabbit 
phospho-p44/42 MAPK 
(Erk1/2) (Thr202/Tyr204) 
(D13.14.4E) XP® 
Cell Signaling 1:2000 rabbit 
 
 
2.8. Cloning and transformation in Escherichia coli (E.coli)  
 
To verify the identity of PCR amplified sequences, the PCR products were 
excised from gels after size separation, purified and cloned into the pCRTM4-
TOPO® vector, which contains an Ampicillin resistance gene for selection. E.coli 
were transfected with plasmids and a colony picked for plasmid isolation. To 
verify the sequences plasmids were sent for sequencing. The detailed steps are 
described in the next subsections. 
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2.8.1. PCR product isolation from agarose gel 
 
To recover PCR products after size separation from a 1% agarose gel, the 
GeneJET Gel Extraction and DNA Cleanup Micro Kit (Thermo Scientific) was 
used. The recovery was performed as recommended by the manufacturer. 
Briefly, under UV light the PCR band was excised from the gel and placed into a 
1.5 mL tube. Maximum 200 mg of gel was used on one column. Next Extraction 
Buffer was added and mixed by pipetting. The gel was dissolved over 10 min at 
50-58°C with inversions to homogenise the solution. Then ethanol (96-100%) 
was added and mixed. The solution was added onto DNA Purification Micro 
Columns and centrifuged for 1 min at 14000 x g. The flow-through was 
discarded and the column was washed with prewash Buffer and centrifuged 
again. This was repeated twice with Wash Buffer. The column was dried by 
centrifuging for 1 min at 14000 x g. The column was placed into a new tube and 
the DNA eluted in 10 µL H20 by centrifuging for 1 min at 14000 x g. The DNA 
was used immediately for the best results. The concentration was determined 
using a NanoDrop1000. 
 
2.8.2. Ligation into pCRTM4 TOPO® and transformation into E.coli 
 
The previously purified PCR product was cloned into the pCRTM4 TOPO® 
vector. The TOPO TA Cloning® Kit for Sequencing (Life Technologies) was 
used for this. To 4 µl of PCR product 1 µl of Salt Solution and 1 µl of the 
pCRTM4 TOPO® vector were added. This was incubated for 30 min at RT. Then 
4 µL of the mix was added to 25 µL of One Shot® Chemically Competent E.coli 
thawed on ice. After a 30 min incubation on ice the E.coli were heat shocked for 
30 sec at 42°C and placed back onto ice. To the E.coli 250 µL of S.O.C. 
medium (Life Technologies) was added and they were grown at 37C in an 
orbital shaker at 7 x g for 1 h. LB agar plates were prepared with 100 mg/mL of 
Ampicillin and pre-warmed before the E.coli were plated. From the transformed 
E.coli 50-150 µL were plated and grown for 14 h. Colonies were picked and 
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grown in 3 mL sterilised lysogeny broth (LB)  [1% peptone, 0.5% yeast extract, 
1% NaCl, pH 7.5 (Sigma-Aldrich)] for 12-16 h. 
 
2.8.3. Plasmid DNA isolation from E.coli 
 
Before plasmids were isolated 500 µL of transformed E.coli were frozen away 
as stocks. For this 500µL of 50% Glycerol (Sigma-Aldrich) were added to the 
E.coli and vortexed. They were then stored at -80C. 
The plasmid DNAs were extracted using the PureYieldTM Plasmid Miniprep 
System (Promega). The plasmid isolation was performed according to the 
manufacturer’s guideline. Briefly, for all centrifugation steps 16900 x g was 
used. The E.coli were pelleted into 1.5 mL tubes in two parts for 30 sec each. 
The pellet was dissolved in 600 µL of nuclease-free water. Then the cell Lysis 
Buffer was added and the tubes inverted six times. Then the ice cold 
Neutralizing Solution was added and mixed by inverting. The cell lysate was 
centrifuged for 3 min. The supernatant was carefully transferred onto the 
PureYieldTM Minicolumn and centrifuged for 1 min. The flow-through was 
discarded and the column was washed with the Endotoxin Removal Wash 
(ERB) and centrifuged for 15 sec, and then washed with Column Wash Solution 
(CWC) and centrifuged for 30 sec. After discarding the flow-through the column 
was shortly spun down to remove any remaining liquid. To elute the plasmid 26 
µL of nuclease-free water was added and the column incubated at RT for one 
minute. To elute the plasmids the column was placed into a new tube and 
centrifuged for 30 sec. The DNA concentration was measured using the 
NanoDrop1000. 
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2.8.4. Restriction digest 
 
To verify that the insert was in the isolated plasmids a restriction digest was 
performed using the EcoR1 restriction enzyme (Promega) and buffer H 
(Promega). The reaction mix was prepared (Table 2.12) and digested for 2 h at 
37°C. The mix was size separated on a 1% agarose gel to verify the excision of 
the insert. 
Table 2.12: EcoR1 restriction digest reaction mix. 
 For a 10 µL reaction mix 
EcoRI 0.5 µL 
10 x Buffer H 1 µL 
Nuclease-free water 6 µL 
Plasmid DNA 2.5 µL 
 
2.9. Sanger sequencing 
 
The plasmids were send for DNA sequencing to Source BioScience 
Lifesciences Services. As by requirement of the company the samples were 
diluted to 100ng/µL and were sequenced with primers supplied by the company 
(Table 2.13). 
Table 2.13: Primers used for sequencing. 
 
 
 
 
2.10. In-silico prediction of RNA secondary structure 
 
Online predictive tools were used to predict the secondary structure folding of 
HER2, I25HER2 and Δ16HER2 mRNA sequences. The RNAfold web server 
(http://rna.tbi.univie.ac.at/) from the University of Vienna was used for the 
 Primer 
pCRTM4 TOPO® 
vector 
M13 Forward 
M13 Reverse 
pcDNA™3.1(–) 
vector 
T7 Forward 
BGH Reverse 
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prediction (Lorenz et al., 2011). The full length mRNA sequences were used 
excluding the polyA-tail, as the length of it is unknown. Two models were used 
for prediction the standard minimum free energy (MFE) and the newer centroid 
prediction model. A stable RNA secondary structure with the lowest energy 
state is predicted by the MFE model (Zuker and Stiegler, 1981; Lorenz et al., 
2011). The algorithm for the centroid model calculates the statistically most 
likely Boltzmann weighted ensemble of predicted secondary structures. This is 
informed by structures of comparative sequence analysis (Ding et al., 2005).
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Chapter 3: Investigating the regulation of the Δ16HER2 splicing 
event 
3.1. Introduction 
 
HER2 is an important growth factor receptor that induces signalling of the 
PI3K/AKT and the RAS/MAPK pathways, which control cell proliferation, growth 
and survival as well as cellular metabolism (Roskoski, 2013; Dittrich et al., 
2014). HER2 is overexpressed in about ~20% of primary breast cancers, where 
due to its ability to induce these cellular process it acts as a driver of tumour 
development and persistence (Slamon et al., 1987; Slamon et al., 1989). The 
HER2 gene encodes for a number of alternative splice variants (Jackson et al., 
2013). In this chapter the HER2 splice variant Δ16HER2 was investigated. It 
arises when 48 bp long cassette exon 16 is not recognised during pre-mRNA 
processing and is spliced out. At the protein level this translates to a HER2 
protein variant (Δ16HER2) which lacks 16 amino acids of the extracellular 
domain (IV) directly preceding the transmembrane domain (Kwong and Hung, 
1998; Siegel et al., 1999). Δ16HER2 can be expressed in both normal and 
cancerous tissues. The relative expression ratio compared to wild type HER2 
varies, but generally Δ16HER2 mRNA is a minor transcript making up 2 to 10% 
of all HER2 transcripts (Siegel et al., 1999; Castiglioni et al., 2006; Turpin et al., 
2016). Despite it being a minor transcript, studies have shown Δ16HER2 to be a 
driver of tumour formation (Mitra et al., 2009; Alajati et al., 2013; Turpin et al., 
2016). It has been hypothesized that as a consequence of gene amplification 
events in breast cancer Δ16HER2 expression might be elevated above a 
threshold, whereby the splice variant contributes to the progression of the 
disease (Siegel et al., 1999; Castiglioni et al., 2006). Δ16HER2 has been shown 
to have a continuously active conformation which promotes homo-dimerization 
and downstream signalling (Siegel et al., 1999). It has been reported to induce 
signalling pathways separate from normal wild type HER2 (Alajati et al., 2013). 
Strong evidence exists that suggests that Δ16HER2 as opposed to wild type 
HER2 induces tumour formation (Kwong and Hung, 1998; Siegel et al., 1999; 
Mitra et al., 2009; Sasso et al., 2011). Contradictory results exist on the 
Chapter 3: Investigating the regulation of the Δ16HER2 splicing event 
75 
 
importance of Δ16HER2 in the resistance of breast cancer cells to the 
therapeutic antibody trastuzumab (Mitra et al., 2009; Castagnoli et al., 2014). 
Initially, in vitro studies had shown Δ16HER2 to be resistant to trastuzumab 
(Mitra et al., 2009), however in in vivo studies, in mouse models, Δ16HER2 
overexpressing tumours showed an increased susceptibility to trastuzumab 
therapy (Castagnoli et al., 2014). Using a method to infer Δ16HER2 levels 
through the expression of its downstream targets (metagene) has been used to 
study therapy resistance and prognosis in Δ16HER2 positive patients. Through 
this it was observed that patients with the Δ16HER2 metagene were more likely 
to respond to trastuzumab treatment (Castagnoli et al., 2014). This effect is 
likely mediated by trastuzumab causing an immune response against the 
tumour cells (Bianchini and Gianni, 2014; Triulzi et al., 2016). Research, to 
date, has focused on defining the role of the oncogenic Δ16HER2 protein in 
breast cancer progression and drug resistance (Kwong and Hung, 1998; Siegel 
et al., 1999; Mitra et al., 2009; Sasso et al., 2011; Castagnoli et al., 2014), 
however the mechanisms that regulate production of Δ16HER2 mRNA and 
protein have not been investigated. 
 
Link between hormones and alternative splicing 
It is well established that breast cancer is a disease that is influenced by the 
female sex hormones oestrogen and progesterone (Breast Cancer, A Lobular 
Disease, 2011). Recently, progesterone and PR came back into focus in breast 
cancer research, because PR was shown to regulate the function of ER-α in 
favour of a tumour inhibiting signalling pathway (Mohammed et al., 2015). This 
highlighted the need for further investigations into the role of progesterone and 
PR in breast cancer biology. Previous studies have reported crosstalk between 
wild type HER2 and both ER and PR (Beguelin et al., 2010; Diaz Flaque et al., 
2013; Giuliano et al., 2013). It has also been shown that oestrogen can affect 
alternate splicing in breast cancer cell lines, specifically the splicing of the type 
1 corticotropin-releasing hormone receptor (Lal et al., 2013). Previous research 
in our group suggests that oestrogen does not affect HER2 mRNA expression 
in breast cancer cell lines (unpublished data). In light of the role that hormones 
can play in alternative splicing, and the new findings on the roles of 
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progesterone and PR in breast cancer, we wished to investigate whether 
progesterone affects HER2 expression and alternative splicing. 
 
3.2. Aims  
 
The aims of this chapter are to: 
 Investigate the mechanisms regulating the Δ16HER2 splicing event 
 Identify RNA-binding proteins that bind to the Δ16HER2 splicing region 
and regulate its splicing 
 Identify the regulating RNA sequences of the Δ16HER2 splicing event 
 Design and construct a Δ16HER2-minigene 
 Investigate a potential feedback loop between HER2 and its splicing 
regulators 
 Study the effect of progesterone on HER2 expression and splicing 
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3.3. Methodology  
 
3.3.1. In-silico prediction of the splicing factor binding 
 
Freely available online in-silico tools were used to determine RNA-binding 
proteins that could potentially bind the splicing region of Δ16HER2. The 
programs that were used are shown in table 3.1. The in-silico predictions were 
performed on the pre-mRNA sequences that were subsequently studied by 
experimental in-vitro approaches (Table 3.2). The sequences studied reached 
from the last 75 bp of intron 15, over exon 16 to the first 74 bp of intron 16. The 
software predicted the binding of RNA-binding proteins to protein specific RNA-
binding motifs present in the query sequence.  
 
Table 3.1: In-silico prediction tools for splicing factor binding. 
 
 
 
 
 
Table 3.2: The synthesised RNA oligonucleotides.  
Name Region covered Synthesised RNA oligonucleotide sequence  
(exon 16 in red) 
H1 Intron 15 (21 bp) –
Exon 16 (48 bp) –
Intron 16 (14 bp) 
AUGAGACUGUUUCUCCUGCAGCUGUGUGGACCUGGA
UGACAAGGGCUGCCCCGCCGAGCAGAGAGCCAGGUU
GGCCUGGACCC 
H2 Intron 15 (75 bp) –
Exon 16 (8 bp) 
GUUGUUGUGAGGCUGGAAAGGUGGUCCCAAGAGGGU
GGUUCCCAGAAUUGUUGAUGAGACUGUUUCUCCUGCA
GCUGUGUGG 
H3 Exon 16 (9 bp) –
Intron 16 (74 bp) 
GAGAGCCAGGUUGGCCUGGACCCCAGGAUGUACCCU
UCAUUGCCCUUCACUCCCCCACUGGAUGCUGGGUGG
UCACUGCUGUA 
 
 
 
Name Website 
SpliceAid http://www.introni.it/splicing.html 
Human Splice Finder http://www.umd.be/HSF3/HSF.html 
SFmap http://sfmap.technion.ac.il/ 
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3.3.2. RNA chromatography assay 
 
To identify RNA-binding proteins that bind the sequence of interest a RNA 
chromatography assay (RNA-assisted protein pull-down) was performed 
[adopted from (Michlewski and Caceres, 2010)]. Briefly, single stranded RNA 
was synthesised that covers the region of interest. This was incubated with 
nuclear proteins. Stringent washing removed unbound proteins. The RNAs are 
digested and the previously RNA bound proteins collected (Figure 3.1). These 
were separated out on a SDS-PAGE from which protein bands of interest were 
cut out and sent for mass spectrometry. In addition these protein extracts were 
applied in a western blot experiment to validate the identity of the RNA-binding 
proteins. 
 
 
 
Figure 3.1: The schematic depiction of the 
RNA chromatography assay.  
Agarose beads coated with single stranded 
RNAs were incubated with a nuclear protein 
extract. This is followed by stringent washing. 
The RNA is digested and the previously RNA 
bound proteins can be collected separately 
from proteins that bound the agarose beads. 
 
Nuclear protein extract 
Nuclear proteins were extracted from SKBR3 breast cancer cells as a protein 
source for the RNA chromatography assay. These cells were used as they 
express all known HER2 splice variants. The nuclear protein extract is also a 
highly enriched source of nuclear RNA-binding proteins. 
Three 75 cm2 flasks of SKBR3 cells near confluency were used. The cells were 
washed with ice cold PBS and then collected by scraping into PBS. The cell 
suspension was centrifuged at 173 x g for 5 min at 4°C. The cell pellet was re-
suspended in 500 μL of Buffer A (10 mM HEPES pH 7.9, 1.5 mM MgCl2, 10 mM 
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KCl, 0.5 mM DTT, 5 μL/mL protease inhibitor cocktail in H2O) and incubated for 
15 min on ice. NP-40 substitute was added to the cell lysate to give a final 
concentration of 0.5% and then vortexed for 10 sec. The cell lysate was 
centrifuged at 4487 x g for 1 min. This centrifuged the nuclei into a pellet. The 
supernatant could be recovered as cytoplasmic cell lysate fraction and stored at 
-80°C. The nuclear pellet was re-suspended in 150 μL of Buffer C (20 mM 
HEPES pH 7.9, 1.5 mM MgCl2, 420 mM NaCl, 0.2 mM EDTA, 25% (V/V) 
Glycerol, 5 μL/mL protease inhibitor cocktail in H2O) and incubated for 30 min at 
4°C under vigorous agitation. The nuclear lysate was centrifuged at 15294 x g 
for 10 min at 4°C. The supernatant, the nuclear fraction, was recovered and 
stored at -80°C until use. 
 
RNA synthesis 
Three DNA templates were designed for the synthesis of RNA single strands 
that correspond to the splicing region of interest (Table 3.2). Table 3.3 shows 
the DNA templates with the T7 promoter sequence (indicated in bold). These 
were annealed to DNA oligonucleotides that contained the complementary 
sequence to the T7 promoter in a 2:1 ratio. The reaction was performed in an 
annealing buffer (10 mM Tris, pH 7.5 - 8.0, 50 mM NaCl, 1 mM EDTA). 
Annealing was undertaken by heating the reaction mix up to 95°C and slowly 
cooling down to room temperature. RNA was synthesised by overnight in-vitro 
transcription with T7 RNA polymerase (New England Biolabs). The 
manufacturer’s protocol was adapted; 3 µL of DNA template mix were added to 
the reaction mix (Table 3.4) and incubated overnight at 37°C. The template 
DNA was degraded by TURBOTM DNase (Ambion) for 30 min at 37C and the 
RNA was purified by phenol-chloroform extraction.  
Table 3.3: DNA oligonucleotide for RNA synthesis.  
Name DNA oligonucleotide for RNA synthesis  
H1 GGGTCCAGGCCAACCTGGCTCTCTGCTCGGCGGGGCAGCCCTTGTCATCC
AGGTCCACACAGCTGCAGGAGAAACAGTCTCATTATAGTGAGTCGTATTA 
H2 CCACACAGCTGCAGGAGAAACAGTCTCATCAACAATTCTGGGAACCACCCT
CTTGGGAACCACCTTTCCAGCCTCACAACAACTTATAGTGAGTCGTATTA 
H3 TACAGCAGTGACCACCCAGCATCCAGTGGGGGAGTGAAGGGCAATGAAGG
GTACATCCTGGGGTCCAGGCCAACCTGGCTCTTATAGTGAGTCGTATTA 
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Table 3.4: T7 RNA polymerase reaction mix (New England Biolabs). 
 Total volume of 40 µL 
DNA template mix 3 µL 
10 x T7 Polymerase Buffer (New England Biolabs) 4 µL 
25 mM NTP mix (Thermo Scientific) 0.8 µL 
RNaseOUT (Ambion) 2 µL 
T7 RNA Polymerase (New England Biolabs) 4 µL 
RNase-free water 26.2 µL 
 
Phenol-chloroform extraction 
To purify the RNA, 230 µL RNase-free water and 30 µL Ammonium Acetate 
Stop Solution (5 M Ammonium acetate, 100mM EDTA in RNase-free water) 
were added to the RNA and mixed. An equal volume of Phenol:Chloroform 5:1 
(Sigma Aldrich) was added and mixed by vortexing. The RNA mix was then 
centrifuged at 14000 x g for 5 min at 4°C. The upper aqueous phase was 
recovered and an equal volume of chloroform (Sigma Aldrich) was added. After 
vortexing, the mix was centrifuged at 14000 x g for 5 min at 4°C. The upper 
aqueous phase was recovered and one volume of 2-propanol (Sigma Aldrich) 
was added. After mixing, the 2-propanol-RNA mix was incubated for 30 min at -
20°C. This was followed by a 15 min 16900 x g centrifugation step at 4°C. The 
supernatant was removed and the pellet washed with 70% ice cold ethanol. 
This was followed by centrifugation at 16900 x g for 15 min at 4°C. The ethanol 
was removed and the pellet air dried for 15 min. The pellet was then 
resuspended in 11 µL of RNase-free water. 
 
RNA chromatography 
For the RNA chromatography 1 nmole of each synthesized RNA was used. The 
RNA was prepared by adding 360 µl 5 mM sodium-m-periodate solution (Sigma 
Aldrich) in 0.1 M sodium acetate (NaOAc) pH 5 to maximum of 40 µL of RNA. 
RNase-free water was added for a final volume of 400 µL. The mix was 
incubated for 1 h in the dark on a rotator. Next the RNA was ethanol 
precipitated. For this 1/10 volume 3M NaOAc (pH 5.2) and 2.5 volumes 100% 
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ethanol were added to the RNA. The RNA mix was the incubated at -80°C for 2 
h. Next the RNA mix was centrifuged at 16900 x g for 30 min at 4°C. The 
supernatant was removed and 1 mL of ethanol was added to the RNA pellet. 
The pellet was centrifuged at 16900 x g for 5 minutes at 4°C. Then the ethanol 
was removed and the pellet air dried for 15 min. At last the RNA was 
resuspended in 100 µL of 0.1 M NaOAc pH 5.  
Adipic dihydrazide agarose beads 50% (Sigma Aldrich) were prepared for 
incubation with the RNA. 100 µL of beads per RNA were washed four times with 
10 mL 0.1 M NaOAc pH5. Finally the beads were resuspended in 300 µL 0.1 M 
NaOAc pH 5. A RNA-free control was also included. The RNA or control were 
incubated with the beads overnight at 4C on a rotator. The following day the 
bead-RNA mix was washed three times with 2 M KCl by incubating on a rotator 
for 5 min and centrifuging at 3824 x g for 5 min. This was followed by four 
washes with Buffer D (20 mM Tris HCl (pH 8), 20% (V/V) Glycerol, 0.1 M KCl, 
0.2 mM EDTA, 0.5 mM DTT, 0.2 mM PMSF in H2O). Then 300 µL nuclear 
protein extract mix (40% nuclear proteins, 1.5 mM MgCl2, 5 mM ATP in RNase-
free water) was added and incubated for 30 min at 37C.  To remove any 
unbound proteins the mix was washed four times with Buffer D with added 1.5 
mM MgCl2. Additionally, the Bead-RNA mix was washed twice with nuclease-
free water. The beads were then incubated with an RNase reaction mix (10 mM 
0.1 Tris HCl (pH 7.2), 1 mM MgCl2, 40 mM NaCl, 8.33% A/T1 RNase (Ambion)) 
for 30 min at 37C and mixed to digest the RNA. The supernatant containing the 
now unbound proteins was collected and denatured with 30 µL of 2 x SDS lysis 
buffer/loading dye at 95C for 10 min. 
The collected proteins were separated on a 4-12% NuPage pre-cast poly-
acrylamide gel (Invitrogen, Life Technologies) alongside the PageRulerTM 
Prestained protein ladder and 10 µL of nuclear protein. SimplyBlue Safestain 
(Invitrogen, Life Technologies) was used to visualise the protein bands after 
size separation. Bands up to the size of ~ 100kDa were excised and sent for 
Mass spectrometry (Prof Gary Black and Andrew Porter at Northumbria 
University). The RNA chromatography was repeated and used for Western 
blotting as described previously.  
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3.3.3. Δ16HER2-minigene construction 
 
A minigene is a manipulable experimental system which can be used to study 
the regulation of splicing. A Δ16HER2-minigene was designed and constructed 
by cloning the splicing region of Δ16HER2 into the pcDNA3.1- expression 
plasmid. It was not possible to clone the whole region from intron 14 to exon 18 
into the vector, due to the size of intron 15 (2306 bp) and intron 16 (3484 bp). 
Therefore three fragments were generated and cloned into pcDNATM 3.1- 
(Figure 3.2).  
 
 
 
Figure 3.2: The design of 
Δ16HER2-minigene.  
The Δ16HER2 splicing region 
was cloned into the 
pcDNA3.1- vector in three 
parts. The large middle parts 
of the two introns are not 
included in the Δ16HER2-
minigene.  
The fragments were labelled MG15, MG16 and MG17. They contained the 
following regions: 
 MG15 contains 76 bp of intron 14, the whole exon 15 (161 bp) and 191 
bp of the beginning of intron 15.  
 MG16 contains 285 bp of the end of intron 15, exon 16 (48 bp) and 
263bp of the beginning of intron 16.  
 MG17 contains 272 bp of the end of intron 16, exon 17 (139 bp), intron 
17 (80 bp) and exon 18 (137 bp). 
 
Amplification and cloning of Δ16HER2-minigene fragments 
Genomic DNA (isolated by PhD student Marco Silipo) from SKBR3 cells was 
used in PCRs to amplify the above described regions. The primers used are 
listed in table 3.5.  
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Table 3.5: List of Δ16HER2-minigene primers. 
Primer name Restricti
on site 
Sequence 
AL_MG_F15 in intron 14 NheI GCTAGCCCCAACTAAGGGCCTGATCC 
AL_MG_R15 in intron 15 XbaI  TCTAGATTAACAGTGGGGATAGAACTGCT 
AL_MG_F16 in intron 15 XbaI  TCTAGAGAGGGAATAGTTGAGCTCCCG 
AL_MG_R16 in intron 16 XhoI  CTCGAGTGTGTCCCTCACAAGGCATC 
AL_MG_F17 in intron 16 XhoI  CTCGAGATTGTTGAAGCCCTAAGCCAGAG 
AL_MG_R17 in exon 18 HindIII AAGCTTGACCTGGCCCTGACCTTGTAG 
AL_MG_Plasmid_R  CTTCCAGGGTCAAGGAAGGC 
 
A Platinum Taq High Fidelity Polymerase (Invitrogen) was used to ensure 
amplification without mutations. The PCR was performed according to the 
manufacturer’s instructions on a BioRad thermocycler (Table 3.6). The product 
was run out on a 2% agarose gel with ethidium bromide for visualization. The 
bands were excised and a gel elution step was performed to recover the PCR 
product from the gel. The GeneJet gel extraction and DNA clean up Micro kit 
(Thermo Scientific) was used for PCR product recovery (see chapter 2.8.1). 
Table 3.6: Platinum Tag PCR Reaction for Minigene segments. 
Reaction mix components Volume for a 50 µL reaction 
10 x High Fidelity OCR Buffer 5 µL 
50 mM MgSO4 2 µL 
25 mM dNTP mix 0.4 µL 
Primer Frw./Rev. (10 µM) each 1µL 
Genomic DNA 500 ng  
Platinum Taq DNA polymerase High 
Fidelity 
0.2 µL 
Nuclease-free water Fill up to 50 µL 
 
PCR program: 
94C  1 min 
94C  15 sec 
55C  30 sec            35 cycles 
68C  30 sec 
12C  ∞ 
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The isolated PCR product was cloned into pCRTM4-TOPO® vector and 
transfected into competent E.coli as described before in section 2.8.1. 
Transformed E.coli were plated on agar plates with ampicillin, colonies were 
picked after ~12 h and grown in LB media with ampicillin (see section 2.8.2). 
The plasmids were isolated with the PureYieldTM Plasmid Miniprep System and 
100 ng/µl plasmid DNA was sent for sequencing to Source BioScience 
Lifesciences Services (see section 2.9). 
 
Assembly of the Δ16HER2-minigene 
The three Δ16HER2-minigene fragments were digested out of the pCRTM4-
TOPO® vector with the appropriate enzymes and buffers (Promega) at 37°C for 
2-3 h (Table 3.7). The digested Δ16HER2-minigene fragments were size 
separated on a 1% agarose gel and gel eluted (see section 2.8.1). At the same 
time the pcDNATM 3.1(-) vector was digested with the same restriction enzymes, 
so that the Δ16HER2-minigene fragment could be ligated in. The digested 
pcDNATM 3.1(-) was also size separated and the appropriate band of the double 
digested vector was gel eluted.  
As the restriction sites of MG15 NheI and XbaI produce compatible ends, they 
had to be treated with CIP (alkaline phosphatase, calf intestinal) (New England 
BioLabs) to prevent self-ligation of the vector. After digestion, the heat 
inactivation was performed at 65C for 20 min. To 20 µL of vector for the 
Δ16HER2-minigene fragment 1µL of CIP was added and incubated for 10 min 
at 37C. Again the product was size separated and gel eluted. 
 
Table 3.7: Restriction digestion for the Δ16HER2-minigene fragment. 
Δ16HER2-minigene 
fragment 
Restriction enzymes Restriction enzyme buffer 
MG15 NheI and XbaI 10 x CutSmart Buffer (NEB)  
MG16 XbaI and XhoI 10 x Buffer H 
MG17 XhoI and HindIII 10 x Buffer C 
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Ligation with T4 (5U) Ligase (Invitrogen) 
The reaction was performed according to the manufacturer’s guidelines. A 3:1 
vector to insert ratio was used. The reaction was performed at RT for 1-2 h. 5U 
of T4 ligase per 20 µL reaction was used. Of the ligation product 2 µL were 
used to transform 25 µL of E.coli. The transformed E.coli were plated on 
ampicillin containing agar plates, colonies were picked the next day and grown 
in LB media with ampicillin. The plasmids were isolated with the PureYieldTM 
Plasmid Miniprep System and sent for sequencing to Source BioScience 
Lifesciences Services. For details see sections 2.8.2, 2.8.3 and 2.9. 
Sequentially all Δ16HER2-minigene fragments were cloned into the same 
pcDNATM 3.1(-) backbone. The end product was sent for sequencing. The clone 
MG-3 was shown to contain all Δ16HER2-minigene fragments in the correct 
orientation. 
 
3.3.4. Site-directed mutagenesis v.1 on Δ16HER2-minigene  
 
Site-directed mutagenesis was performed on the Δ16HER2-minigene to identify 
the binding site of RNA-binding proteins. For this the Q5 site-directed 
mutagenesis kit (New England Biolabs) was used. Primers were designed using 
the base changer web tool (http://nebasechanger.neb.com/) as suggested by 
the kit manufacturer. The reactions were performed as suggested by the 
manufacturer. Three site directed mutations were performed (Table 3.8). Briefly, 
a PCR was performed using the Δ16HER2-minigene as DNA template (Table 
3.9) and the primers listed in table 3.6.  
 Table 3.8: Primers for site directed mutagenesis. 
 
 
 Forward Primer Reverse Primer T(An)
C  
MGMut-2 GGAGTATTTACGGTAAACTG TTGACGTCAATGGAAAGTC 59 
MGMut-4 CCAGGATGTAcgcttgATTGCCCTTCAC GGTCCAGGCCAACCTGGC 69 
MGMut-5 TGGTTCCCAAtagcGTGGTTCCCAG CCTTTCCAGCCTCACAAC 63 
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Table 3.9: Q5
®
 site-directed mutagenesis reaction. 
Reaction mix components Volume for a 25µL reaction 
Q5 Hot Start High-Fidelity 2x Master Mix 12.5µL 
10µM Forward/Reverse Primer 1.25µL each 
Template DNA - Δ16HER2-minigene (10ng/µl) 1µL 
Nuclease-free water 9µL 
 
PCR program: 
98C  30 sec 
98C  10 sec 
x C  30 sec   25 cycles 
72C  3.5 min 
72C  2 min 
10C  ∞ 
Following the PCR reaction 1 µL of the PCR product was used in a reaction 
which causes the linear mutated Δ16HER2-minigene to be ligated into a circular 
plasmid. It also causes the degradation of any remaining original DNA template. 
To the PCR product 5 µL 2x KLD Reaction Buffer, 1 µL 10x KLD Enzyme Mix 
and 3 µL nuclease-free water was added, mixed and incubated for 5 minutes at 
RT. A vial of NEB 5-alpha Competent E.coli cells was thawed on ice and half of 
the enzyme reaction was added to the cells. After 30 min incubation on ice the 
cells were heat shocked for 30 sec at 45C. After a further 5 min on ice 950 µL 
SOC medium was added to the cells and they were then incubated at 37C and 
220 rpm shaking for 1 h. 100-200 µL of the transformed E.coli were then plated 
on ampicillin containing agar plates. After overnight incubation colonies were 
picked and grown in ampicillin containing LB medium for 6-14 h. Plasmid 
isolation was performed using the PureYieldTM Plasmid Miniprep System. For 
details see sections 2.8.2, 2.8.3 and 2.9. 100 ng/µl plasmid DNA was send for 
sequencing to Source BioScience Lifesciences Services. Initially, T7 forward 
and BGH reverse primers were requested to be used for the sequencing of the 
mutated Δ16HER2-minigene. Recurrent issues with incomplete or failed 
sequencing reactions led us to use the dGTP chemistry in the sequencing 
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reactions for MGMut6. The dGTP chemistry produced improved sequencing 
results on samples that could not be sequenced using the conventional method. 
 
3.3.5. Site-directed mutagenesis v.2 on Δ16HER2-minigene  
 
As the site-directed mutagenesis v.1 had a high percentage rate of unspecific 
mutations an alternative approach was used for MGMut-6. Overlapping primers 
were designed with the desired mutation embedded in them. The MGMut-6 
forward primer was used in combination with the MG16 reverse primer, and the 
MG16 forward primer with the MGMut-6 reverse primer to amplify the MG16 
region of the Δ16HER2 minigene region while incorporating the point mutations. 
For the PCR the Pfu DNA Polymerase (Promega) was used (Table 3.10). 
Table 3.10: Pfu DNA polymerase site-directed mutagenesis reaction. 
Reaction mix components Volume for a 50 µL reaction 
Pfu DNA Polymerase 10x Buffer with MgSO4 5 µL 
25 mM dNTP mix 4 µL 
Forward/Reverse Primer (0.5 µg/µL) 0.25 µL 
DNA Template 200 ng 
Pfu DNA Polymerase 1.25 µL 
Nuclease-free water Fill up to 50 µL 
 
PCR program: 
95C  1.5 min 
95C  1 min 
55C  30 sec   35 cycles 
72C  1.50 min 
72C  5 min 
12C  ∞ 
 
The PCR products were run out on a 1% agarose gel and gel extracted (section 
2.8.1). To combine the two PCR products into the full MG16 fragment another 
PCR was performed. The PCR reaction was performed using the Pfu DNA 
Chapter 3: Investigating the regulation of the Δ16HER2 splicing event 
88 
 
Polymerase. The same reaction mix as described above was prepared, with 
375 ng of DNA from each PCR reaction. Initially no primers were added. The 
PCR program was run for 5 cycles with a 45 sec annealing period and 2 min 
elongation. Then 0.25 µL of the forward and reverse primer MG16 were added 
and the PCR run for an additional 15 cycles with a 30 sec annealing period.  
The PCR product was run out on a 1% gel and a gel extraction was performed. 
1 µg of the Δ16HER2-minigene was digested with the restriction enzymes XhoI 
and XbaI (see sections 2.8.4 and 3.3.3 for details). The digested Δ16HER2-
minigene was size separated on a 1% gel and gel extracted. The mutated 
fragment was inserted into the Δ16HER2-minigene by T4 ligation (see section 
3.3.3 Ligation with T4 (5U) Ligase for details).  
Competent E.coli were transfected with the ligation product and plated on 
ampicillin containing agar plates. After overnight incubation colonies were 
picked and grown in ampicillin containing LB medium. The plasmids were 
isolated with the PureYieldTM Plasmid Miniprep System. For details see sections 
2.8.2, 2.8.3 and 2.9. 100 ng/µl plasmid DNA was send for sequencing to Source 
BioScience Lifesciences Services. As the basic sequencing reaction using the 
T7 forward primer and BGH reverse primer have yielded a high number of 
incomplete or failed sequencing reactions, the MG16 forward primer was used. 
The Δ16HER2-minigene has been sequenced previously and the length of the 
mutated MG16 fragment was expected to be covered by a single sequencing 
reaction.  
PCR program: 
95C  1min 
95C  30 sec 
55C  45/30 sec  5/15 cycles 
72C  1.50 min 
72C  5 min 
12C  ∞ 
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3.3.6. Transfection of the Δ16HER2-minigene with and without 
transient splicing factor knockdown 
 
The Δ16HER2-minigene or mutants of it (described in 3.3.5) were transfected 
into breast cancer cells. For this 7 x 104 MCF-7 or SKBR3 cells/well were 
seeded onto 12 well plates. After 24 h they were transfected using FuGeneHD 
Transfection reagent (Promega). The transfection was performed according to 
the manufacturer’s guidelines. Briefly, the experiment was scaled up to 10 x 96 
well plate reaction size. 350 ng of plasmid DNA was added to Opti-MEM® 
medium and mixed. Then 1.5 µL of the transfection reagent was added and 
mixed. The total reaction volume was 20 µL. The mix was incubated for 10 min 
at RT and then added to the cells. The plates were swirled to promote even 
distribution of the transfection mix. The medium on the cells was not 
exchanged. The RNA was collected 24 h after transfection of the Δ16HER2-
minigene. 
To determine if the previously identified splicing factors affect the Δ16HER2-
minigene, the splicing factors were transiently knocked down by RNAi followed 
by Δ16HER2-minigene transfection. The knockdown was prepared as 
described previously (section 2.2.5.). On day 2 after the siRNA transfection the 
minigene was transfected (see above). RNA was isolated 24 h later (see 2.5.1). 
 
3.3.7. Treatment of SKBR3 cells with lapatinib 
 
To study the effects of HER2 signalling inhibition HER2 overexpressing SKBR3 
cells were treated with the HER2 tyrosine kinase inhibitor lapatinib. Lapatinib 
was dissolved in DMSO and diluted to a 1mM stock solution. On 12 well plates 
1.5 x 105 SKBR3 cells/well were seeded. After 24 h the treatment was 
performed. The cells were treated with 1 µM lapatinib, and control cells for each 
time point were treated with an equal volume of DMSO. Proteins were collected 
after 15 min, 6 h, 12 h and 24 h. For the 15 min time point a control of untreated 
cells was also collected. Three independent experiments were carried out. The 
proteins were used in western blot experiments to study the effect of the 
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treatment on protein levels and phosphorylation status (see section 2.7.4). To 
measure and compare the band intensities densitometry was performed on the 
western blots of all three experiments (time points 6 h - 24 h). The ImageJ 
program (National institute of Health) was used. GAPDH was used for 
normalisation and for each time point the DMSO control was set to one.  
3.3.8. Treatment of cells with progesterone  
 
For the treatment of cells with progesterone, 1.4 x 105 MCF-7 cells/well were 
seeded in 6 well cell culture plates and grown for ~ 26 h. The medium was 
exchanged for serum-free phenol-free DMEM medium 14 h before treatment. 
Complete DMEM medium as described previously supplemented with 10% 
charcoal stripped FCS (Life Technologies) instead of normal FCS was used in 
the next step. Normal FCS contains hormones that could mask the effect of the 
progesterone treatment. Therefore the charcoal stripped FCS was used. 
Progesterone (Sigma-Aldrich) was dissolved in 100% ethanol for stock 
concentrations of 1 µM, 10 µM and 100 µM. From these appropriate amounts 
were added to the culturing medium for final concentrations of 1 nM, 10 nM and 
100 nM. Control cells were treated with the vehicle ethanol alone. Three 
independent experiments were carried out. Cell lysate was collected after 3, 6, 
12 or 24 h depending on the experiment and RNA was isolated (see section 
2.5.1). Reverse transcription and qPCR was performed as previously described 
in section 2.6. 
3.3.9. Statistical analysis 
 
Different statistical analyses were used depending on experiments. GraphPad 
Prism 6 was used for all statistical analyses. For the transient knockdown 
experiments paired t-tests between specific gene knockdowns and the negative 
controls were performed. For the progesterone dose response experiment one 
way ANOVA with Dunnett’s multiple comparisons tests and for the time line 
experiment one way ANOVA with Sidak’s multiple comparisons tests were 
performed. The mean of 3 experiments with +/- standard deviation is indicated. 
Statistical significance is shown as, * ≤ 0.05, ** ≤ 0.01, *** ≤ 0.001. 
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3.4. Results  
 
3.4.1. Describing the Δ16HER2 mRNA transcript  
 
Δ16HER2 had first been described in the late 1990s (Kwong and Hung, 1998; 
Siegel et al., 1999) and has since been studied by a number of research groups 
in regards to its function in breast cancer (Castiglioni et al., 2006; Mitra et al., 
2009; Sasso et al., 2011; Alajati et al., 2013; Castagnoli et al., 2014). Little is 
known, however, about the processing of the Δ16HER2 mRNA. Searching 
genome browser (http://ucscbrowser.genap.ca), NCBI AceView 
(http://ncbi.nlm.nih.goc/IEB/Research/Acembly/index.html) and Ensembl 
(http://www.ensembl.org) one cannot find any mRNA transcripts corresponding 
to Δ16HER2. Only one transcript shows exon 16 skipping, but this consists of 
only 6 exons (Ensembl: Erbb2-018). We therefore wished to verify that exon 16 
skipping is part of a full length HER2 transcript.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: The exon 16 skipping event as part of a full length HER2 mRNA transcript.  
The gel images show the products from PCRs with primers specific for exon 16 skipping in 
combination with primers specific for up and downstream exons. Exon 27 being the last exon of 
the HER2. 
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To verify the exact exon usage for Δ16HER2 in SKBR3 cells, a PCR based 
approach was used. It could be observed, using primers specific for the exon 
skipping event in combination with forward and reverse primers in up- and 
down-stream exons, that exon 16 skipping is part of a transcript spanning 
conventional exon 3 to exon 27. Only a very faint line appears when amplifying 
from exon 1 to exon 16 skipping. A very faint additional band can be observed 
when amplifying from exons 5, 7 or 10 to exon 16 skipping (Figure 3.3). This is 
thought to be caused by intron 12 retention. An event that was observed by 
fellow PhD student Marco Silipo. 
It is difficult to predict the impact of the presence or absence of exon 16 on the 
processing of the HER2 mRNA transcript. In-vivo mRNAs are assembled into a 
complex with several hundred proteins.  This complex formation determines the 
processing of the mRNA. Predicting this is nearly impossible, without knowing 
the proteins involved. To gain some insight into how wild type HER2 and 
Δ16HER2 might be differentially processed an in-silico mRNA secondary 
structure prediction was performed using both the standard minimum free 
energy (MFE) and the newer centroid prediction model from Vienna RNA 
Package 2 (Lorenz et al., 2011).  
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Figure 3.4: In-silico predicted secondary structure of wild type HER2 and Δ16HER2 
mRNA. 
The predicted secondary structure is shown for the full length mRNA transcripts (lacking the 
poly A tail). Predictions from two methods are shown the minimum free energy (MFE) plain and 
the centroid plain. Images were generated by the RNAfold web server (Lorenz et al., 2011). 
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Figure 3.5: In-silico predicted secondary structure of wild type HER2 and Δ16HER2 
mRNA, focus on miRNA-155 binding site. 
Magnification of predicted secondary structures of wild type HER2 and Δ16HER2 are shown. 
The upper panels shows the minimum free energy (MFE) plain predictions and the lower panels 
the centroid plain predictions. The binding sequence of miRNA-155 on exon 17 is indicated by 
the arrows. The arrows show the first and last nucleotide of the binding sequence. Images were 
generated by the RNAfold web server (Lorenz et al., 2011). 
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The conventional MFE model is based on algorithms that calculate a stable 
RNA secondary structure with the lowest energy state (Zuker and Stiegler, 
1981; Lorenz et al., 2011). The centroid model is generated by an algorithm that 
produces the statistically most likely Boltzmann weighted ensemble of predicted 
secondary structures. Predictions are informed by structures determined from 
comparative sequence analysis. This method has shown under certain 
circumstances to have an increased probability to predict the correct secondary 
structure of a RNA with less errors (Ding et al., 2005). As it is not known how 
long the poly(A)-tail is, this could not be taken into consideration when 
performing the prediction. The predictions from both models showed that the 
presence/absence of exon 16 affects the overall secondary structure of HER2 
mRNA (Figure 3.4). The MFE model shows a higher number of branches and 
loops for Δ16HER2. The centroid model shows a lesser number of changes to 
the secondary structure, but not a less complex alteration.  
Recently a publication described the binding site of miRNA-155 within the 
coding region of the HER2 mRNA (He et al., 2016), this binding site is located in 
exon 17 of HER2, within few nucleotides of exon 16. Both models predicted the 
secondary structures of the binding site to be structurally different between wild 
type HER2 and Δ16HER2 (Figure 3.5). The centroid plain prediction for 
Δ16HER2 shows the binding site sequence to be located on a large loop, but 
broken up by number of pseudoknots and single nucleotide interactions. 
Additional loping of the different structures makes this predicted secondary 
structure very different and potentially hard to access (Figure 3.5).  
 
3.4.2. In-silico predictions for the regulation of Δ16HER2 splicing 
 
To study the binding of RNA-binding proteins to the Δ16HER2 splicing region 
in-silico predictions were performed. The predictions were performed on the 
three sequences that were subsequently used for the experimental identification 
of RNA-binding proteins that bind the Δ16HER2 splicing region (see 3.3.1 and 
figure 3.6).  
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Figure 3.6: The three sequences covering the Δ16HER2 splicing region: H1, H2, H3. 
 
Table 3.11 shows the initial predictions of RNA-binding proteins that were 
predicted to bind the region of Δ16HER2 splicing. Overall 30 proteins were 
predicted to bind this region. When comparing the predictions only few overlap 
at least partially, close to none overlap fully with all three programs. Figure 3.7 
shows a schematic depiction of the binding sites predicted by at least two 
programs. The splicing factors that were predicted by at least 2 programs 
number only ten: hnRNP A1, hnRNP F, hnRNP H, SF2/ASF, sc35, SRp40, 
SRp55, SRSF3, CUG-BP and 9G8. The highest number of binding sites were 
found in the region covering exon 16. 
 
Table 3.11: In-silico prediction of RNA-binding proteins binding to the three sequences 
covering the exon 16 splicing region. 
 H1 H2 H3 
Human 
Splice 
Finder 
9G8, hnRNP A1, SRp40, 
SRp55, sc35, SF2/ASF 
hnRNP A1, SRp40, 9G8, 
SRp55, Tra2beta, sc35, 
SF2/ASF 
hnRNP A1, SF2/ASF, 
9G8, sc35, SRp40,  
SFmap Tra2beta, SRp20, CUG-BP, 
hnRNP U, MBNL2, hnRNP 
F, FOX1, sc35, hnRNP 
A2B1 
CUG-BP, sc35, MBNL1, 
hnRNP A2B1, hnRNP F, 
hnRNP M, hnRNP U, 
SRp20, SF2/ASF, 
Tra2beta 
FOX1, sc35, MBNL, 
SRp20, hnRNP A2B1, 
hnRNP A1 
Splice 
Aid 
ETR-3, HuB, TIA-1, TIAL1, 
SRp40, CUG-BP, Nova-1, 
TDP43, SRp55, SRp30c, 
hnRNP H, MBNL1 
ETR-3, ZRANB2, RBM5, 
hnRNP F, hnRNP H, HuB, 
SF2/ASF, hnRNP A1, 
SRp40, hnRNP K, hnRNP 
P, TIA-1, TIAL1, Nova-1, 
TDP43, CUG-BP  
Sc30c, MBNL1, SRp40, 
RBM5, ZRANB2, KSRP, 
hnRNP P, hnRNP H, 
SRp30c, SF2/ASF, 
hnRNP K, Nova-1 
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Figure 3.7: Filtered prediction of splicing factors binding to three sequences covering the 
Δ16HER2 splicing region (H1, H2, H3). 
This figure shows schematically splicing factors predicted by at least two programs to bind the 
three Δ16HER2 splicing region covering sequences. The three programs used were Splice Aid, 
Human Splice Aid and SFmap. 
 
3.4.3. Identification of splicing factors that bind the Δ16HER2 
splicing region 
 
In the previous section an in-silico approach was used to determine binding 
sites of RNA-binding proteins to the Δ16HER2 splicing region. A high number of 
possible candidates were thereby identified. To narrow down the number of 
possible splicing regulators an experimental approach was used. An RNA 
chromatography assay was performed for the Δ16HER2 splicing region. This 
assay identifies proteins that bind to a RNA of interest. Synthetic RNAs covering 
exon 16 and the intron/exon boundaries were used to pull down proteins 
binding specifically to the RNA (Figure 3.7 A). Stringent washing steps were 
performed to reduce unspecific binding. At the end the RNAs were digested and 
the previously RNA bound proteins were size separated on an SDS-PAGE. In 
figure 3.8 B, the SimplyBlue Safestain stained protein bands from the RNA 
chromatography assay can be seen. It shows the different patterns of proteins 
for the three RNA strands. Protein bands were excised and send for 
identification by mass spectrometry. The proteins identified were: hnRNP 1 
(PTB), hnRNP A1, hnRNP A/B, hnRNP A2B1, hnRNP D, hnRNP K and YBX1. 
The RNA chromatography assay was repeated, followed by a western blot. In 
addition to antibodies specific for the proteins identified by mass spectrometry a 
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panel of antibodies against other splicing factors was also used. This also 
included a pan-SR-protein antibody. Of the seven previously identified proteins 
YBX1 could not be verified by western blot. The other splicing factors (hnRNP 
1, A1, A/B, A2B1, D and K) could be verified to bind one or more of the 
synthesised RNAs (Figure 3.8 C). Two additional splicing factors were identified 
to bind to the RNA strands, hnRNP H and SRSF3. SRSF3 was the only SR-
protein that could be identified to bind these synthesised RNAs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8: The RNA chromatography assay followed by mass spectrometry and western 
blot.  
A, The depiction of the Δ16HER2 splicing region indicates the regions covered by the synthetic 
RNAs (H1, H2, H3) used in the RNA chromatography assay. B, The proteins collected from the 
RNA chromatography were size separated in a SDS-PAGE. NE indicates nuclear protein extract 
alone and CT, indicates the no RNA bead control. The numbers indicate the proteins identified 
by mass spectrometry (Professor Gary Black, Northumbria University). C, Western blots were 
performed with proteins from the RNA chromatography. A panel of antibodies against splicing 
factors were used. 
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3.4.4. Verification by transient knockdown in HER+/- cell lines 
 
The RNA chromatography assay identified eight splicing factors that bind the 
Δ16HER2 splicing region represented by synthetic RNAs. To study if these 
splicing factors affect the HER2 splicing pattern transient knockdowns were 
performed. As a model of HER2-overexpressing breast cancer the SKBR3 cell 
line was used. These cells were transfected with siRNAs targeting the genes of 
interest. To observe successful knockdown of target genes the mRNA levels 
were measured 48 h and the protein levels 72 h post-transfection. This was 
done twice, one representative blot is shown here (Figure 3.9 and 3.10). A 
GAPDH targeting siRNA was included to verify successful knockdown. In the 
initial experiments untreated cells (UT) as well as controls for the vehicle (V) 
and a negative control (NC) siRNA were included. In the following experiments, 
that were performed to determine the effect of splicing factor knockdown on 
HER2 splicing patterns, the scrambled siRNA was used as the negative control, 
as it mimics the conditions of the specific gene knockdowns best. For initial 
screening one siRNA for each splicing factor was used. If an effect on the HER2 
splicing pattern was observed a second siRNA was used to verify the effect. 
The knockdowns were performed in collaboration with Dr Hannah Gautrey and 
fellow PhD student Marco Silipo (Tyson-Capper Laboratory, Newcastle 
University). The knockdown of hnRNP 1 was attempted by M. Silipo. The levels 
of hnRNP 1 were too low in SKBR3 cells as to successfully perform a transient 
knockdown (data not shown). The detection of hnRNP 1 in the RNA 
chromatography assay can be explained by strong enrichment of nuclear 
proteins for the assay. The two siRNAs against hnRNP H and SRSF3 were 
tested by Dr. H Gautrey, and showed to work effectively (Gautrey et al., 2015). 
HnRNP H and F are highly homologous, therefore hnRNP F was studied in 
addition to hnRNP H. Additionally, an siRNA targeting both hnRNPs F and H 
(F/H) was used. 
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Figure 3.9: Transient knockdown of splicing factors measured on the mRNA and protein 
level in SKBR3 cells.  
Transient knockdowns were performed in SKBR3 cells. RNA was collected 48 h post-
transfection. Controls included were untreated (UT), vehicle (V), negative control (NC) 
scrambled siRNA and GAPDH siRNA. As housekeeping gene GAPDH expression was 
measured. The experiments were performed twice, on example is shown. A, PCR products for 
the expression of specific genes after transient knockdown of hnRNP A1, K (2), F(2) and a 
double knockdown of hnRNPs F and H with and siRNA targeting both. B, images provided by 
M. Silipo. PCR product for the expression of specific genes after transient knockdown of 
hnRNPs A/B, A2/B1, D, F (1) and K(1). 
 
Figure 3.9 shows the effect of the transient knockdowns of hnRNPs A1, A/B, 
A2B1, K, F, F/H and D on the mRNA level. The experiments in panel B were 
primarily performed by M. Silipo. The vehicle control in this experiment did not 
work, probably due to bad quality of the RNA, however all other controls works 
as expected. The knockdowns of hnRNPs D, K(1, 2), F(1, 2) and F/H were 
successful. For hnRNP A1 only a partial knockdown at the mRNA level could be 
observed. Our research group has previously attempted to knockdown hnRNP 
A1 with no success. No obvious knockdown on the mRNA level could be 
observed for hnRNPs A/B and A2/B1. However on the protein level the 
Chapter 3: Investigating the regulation of the Δ16HER2 splicing event 
101 
 
knockdowns of hnRNPs A/B, A2/B1, D, F, F/H, K and the double knockdown of 
hnRNPs F and H was successful. For hnRNP A1 a partial knockdown could be 
observed. It should be noted that the antibody against hnRNP H (56 kDa) also 
binds to hnRNP F (53 kDa). Our research group previously observed that 
knockdown of hnRNP F or H, causes an increase in the level of hnRNP H or F, 
respectively (data unpublished). This is likely linked to the high level of 
homology and overlapping actions of hnRNPs F and H (Caputi and Zahler, 
2001; Wang et al., 2012a). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.10: Transient knockdown of splicing factors measured on the protein level in 
SKBR3 cells.  
Transient knockdowns were performed in SKBR3 cells. Proteins were collected 72 h post-
transfection. Controls included were untreated (UT), vehicle (V), negative control (NC) 
scrambled siRNA and GAPDH siRNA. The experiments were performed twice, on example is 
shown. Western blot probed with antibodies for the knocked down genes and GAPDH as 
endogenous control are shown. The antibody against hnRNP H also binds hnRNP F.  
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To measure the effect of splicing factor knockdown on the splicing pattern of 
HER2 RNA was collected 72 h post-transfection. The siRNA target splicing 
factors are estimated to be knocked down at the protein level after 48 h, 
therefore HER2, the target of the splicing factors, is expected to be affected 
after 72 h on the mRNA level. The relative expression of wild type HER2 (exon 
16 inclusion), Δ16HER2 (exon 16 skipping) and p100 (partial intron 15 
retention) was measured by SYBR green qPCR, normalized with GAPDH. p100 
was  measured as it arises from a splicing event located in close proximity to 
the Δ16HER2 splicing region. The average of three independent experiments is 
shown in figures 3.11 to 3.13. The knockdown of the splicing factors hnRNP A1, 
A/B, A2B1 and D did not significantly affect the splicing pattern of HER2. Only a 
slight, but not significant decrease in the expression of wild type HER2 and 
Δ16HER2 was observed in the knockdowns of hnRNP A/B, A2B1 and D (Figure 
3.11). 
Figure 3.11: The effect of the transient knockdown of splicing factors (hnRNP A1, A/B, 
A2/B1 and D) on HER2 splicing in SKBR3 cells.  
The knockdown of splicing factors was performed in SKBR3 cells and the RNA was collected 
72h post-transfection. The graphs show the relative mRNA expression of wild type HER2, 
Δ16HER2 and p100 after gene specific knockdowns compared to the negative control 
knockdown. The average of three biological replicates is shown. Paired t-test was performed. 
Knockdowns were performed for hnRNPs A/B, A2/B1 and D (A) and hnRNP A1 (B). 
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As mentioned previously the initial knockdown of hnRNP H was performed by 
Dr. H. Gautrey and was shown to cause an increase in Δ16HER2 expression 
with no effect on p100 expression (Gautrey et al., 2015). The here shown 
results for the second siRNA against hnRNP H were also published in this 
article (Gautrey et al., 2015). In the first lane of figure 3.12 A, the knockdown 
with siRNAs hnRNP H (2), hnRNP F (1) and the double knockdown with both 
siRNAs is shown. A slight, but not statistically significant increase in the 
Δ16HER2 level can be observed with hnRNP H (2) and hnRNP F (1) siRNAs. 
The double knockdown showed a borderline significant increase in the 
Δ16HER2 level. The hnRNP F (1) siRNA causes a small statistically significant 
decrease in the p100 level. However this stands in contrast with the trend for 
hnRNP H (2) and the double knockdown. The second line of figure 3.12 A, 
shows the effect of the second hnRNP F siRNA and the siRNA targeting both 
hnRNP F and H. Both siRNAs show a statistically significant increase to the 
Δ16HER2 level. Opposed to the result with the hnRNP F (1) siRNA, p100 is 
clearly upregulated in these knockdowns. The double knockdown of hnRNPs F 
and H has an additive effect on the p100 levels but a cumulative effect on the 
Δ16HER2 levels.  
Figure 3.12 B, shows the effect of hnRNP K knockdown with two siRNAs. Both 
siRNAs targeting hnRNP K caused a statistically significant downregulation of 
Δ16HER2 and p100 mRNA levels. Additionally, the first siRNA also causes a 
smaller but significant downregulation of wild type HER2 expression.  
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Figure 3.12: The effect of the transient knockdown of splicing factors (hnRNPs F, H and 
K) on HER2 splicing in SKBR3 cells. 
The knockdown of splicing factors was performed in SKBR3 cells and the RNA was collected 72 
h post siRNA transfection. The graphs show the relative mRNA expression of wild type HER2, 
Δ16HER2 and p100 after gene specific knockdowns compared to the negative control 
knockdown. The average of three biological replicates is shown. Paired t-test was performed, * 
≤ 0.05, ** ≤ 0.01, *** ≤ 0.001. A, One siRNA was used against hnRNP H, two against hnRNP F 
and for the double knockdown of hnRNPs F/H siRNAs hnRNP H (1) and hnRNP F (1) were 
used and a siRNA targeting both hnRNPs F/H (2). B, Two siRNAs were used against hnRNP K.  
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In previous work by a member of our research group, Dr H. Gautrey studied the 
effect of SRSF3 on HER2 splicing with a focus on Δ16HER2 and p100. It was 
shown that the knockdown of SRSF3 causes the downregulation of Δ16HER2 
and the upregulation of p100 expression. No significant effect on wild type 
HER2 expression was observed (Gautrey et al., 2015). Figure 3.13 shows one 
repetition of this experiment, it was performed in the HER2 positive cell line 
SKBR3. The same general trend was observed, but as this experiment was only 
performed once no statistical analysis was performed. It was purely to observe 
the reproducibility of the previous work.  
 
 
Figure 3.13: The effect of the 
transient knockdown of 
SRSF3 on HER2 splicing in 
SKBR3 cells.  
SRSF3 was transiently 
knocked down in SKBR3 cells, 
the RNA was collected 72 h 
post-transfection (n=1). The 
graph shows the relative 
mRNA expression of wild type 
HER2, Δ16HER2 and p100 
compared to the negative 
control knockdown.  
 
Leading on from this we wished to observe whether the effect hnRNP F/H, K 
and SRSF3 were restricted to the HER2 overexpressing cell line SKBR3 or if 
the same mechanisms could be observed in the HER2 low MCF-7 cell line. For 
this SRSF3 and hnRNP K were transiently knocked down in MCF-7 cells 
(Figure 3.14 A). In addition, a double knockdown of SRSF3 and hnRNP K was 
performed to study if the absence of SRSF3 and hnRNP K had a cumulative 
effect on the alternative splicing of HER2. Opposed to the observations in 
SKBR3 cells, in MCF-7 cells the level of wild type HER2 was significantly 
induced by the knockdown of SRSF3 and the double knockdown. The level of 
Δ16HER2 was not downregulated in the SRSF3 knockdown compared to the 
negative control, but the relative expression level compared to wild type HER2 
did decrease (Figure 3.14 B). The knockdown of hnRNP K showed the same 
downregulation of Δ16HER2 as observed in SKBR3 cells. No increased effect 
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was observed for the double knockdown. The knockdown of SRSF3 increased 
the level of p100 as observed in SKBR3 cells. The results are borderline 
significant. It has to be noted that p100 levels are very low in MCF-7 cells. Low 
copy numbers of target cDNAs in SYBR green qPCR can increase the 
variability between experiments.  
 
Figure 3.14: The effect of the transient knockdown of 
SRSF3 and hnRNP K on HER2 splicing in MCF-7 cells.  
The knockdown of splicing factors was performed in MCF-7 
cells and the RNA was collected 72 h post-transfection. In 
addition to the single knockdowns of SRSF3 and hnRNP K, a 
double knockdown of both was also performed. A, The graphs 
show the relative mRNA expression of wild type HER2, 
Δ16HER2 and p100 after gene specific knockdowns compared 
to the negative control knockdown. The average of three 
biological replicates is shown. Paired t-test was performed, * ≤ 
0.05, ** ≤ 0.01, *** ≤ 0.001. B, The relative mRNA expression 
ratio of Δ16HER2 to wild type HER2. Calculated for the average 
of three biological replicates. 
 
As part of a separate study in our laboratory knockdowns of hnRNP K and 
hnRNPs F/H were performed in MCF-7 cells. Dr. H. Gautrey kindly provided 
cDNA from these experiments. The knockdowns have been carried out to the 
same standard protocol as used in this study. The levels of Δ16HER2 and wild 
type HER2 compared to GAPDH was measured by conventional PCR in three 
independent experiments, one representative image is shown in figure 3.15. 
These knockdowns confirmed the observation from figure 3.14 that hnRNP K 
strongly decreases the expression of Δ16HER2. The effect of hnRNP F/H 
double knockdowns is very pronounced; it strongly upregulates the Δ16HER2 
B 
A 
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levels. The levels of wild type HER2 and GAPDH were not obviously affected by 
the knockdowns. 
Figure 3.15: Effect of the transient 
knockdown of hnRNPs F/H and hnRNP K on 
HER2 splicing in MCF-7 cells.  
The knockdowns were performed in MCF-7 
cells and the RNA was collected 72 h post 
siRNA transfection. Two siRNAs against 
hnRNP K were used, and for the double 
knockdown of hnRNPs F/H siRNAs hnRNP F 
(1) and hnRNP H (1) were transfected together 
and a siRNA targeting both hnRNP F and H 
was used (2). PCRs were performed with gene 
specific primers for Δ16HER2, wild type HER2 
and the housekeeping gene GAPDH. NC 
stands for the negative control scrambled 
siRNA. 
 
3.4.5. Efficiency of the Δ16HER2-minigene construct 
 
The Δ16HER2-minigene construct was designed to study the Δ16HER2 splicing 
event in more detail. The construct covers the region from exon 15 to exon 18. 
Due to size limitations the whole introns 15 and 16 could not be included into 
the Δ16HER2-minigene. The Δ16HER2-minigene was transfected into MCF-7 
cells, which are low in endogenous HER2. The PCR was performed with 
primers specific for the Δ16HER2-minigene and therefore no endogenous 
HER2 should be amplified. The PCR products were verified to be transcripts 
produced by the Δ16HER2-minigene through sequencing. In addition to the 
expected band corresponding to exon 16 inclusion (wild type-like HER2) there 
is also a band that corresponds to the retention of intron 17. A similar extra 
band due to the retention of intron 17 can be observed with the Δ16HER2 
minigene primers for the exon 16 exclusion product (Δ16HER2-like). No p100-
like minigene product is transcribed from this Δ16HER2-minigene, as it lacks 
the necessary upstream region (data not shown). 
To investigate whether the Δ16HER2-minigene contained the binding sites for 
the previously identified splicing factors (hnRNP F/H, K and SRSF3) which 
affect HER2 splicing, transient knockdowns were performed. Both the HER2-
overexpressing SKBR3 cells and HER2-low MCF-7 cells (n=3) were transfected 
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with the Δ16HER2-minigene following transient knockdown of the splicing 
factors (Figure 3.16). The experiments were performed three times in both cell 
lines. One experiment in the SKBR3 cell line did not yield results due to bad 
RNA quality. However the observed splicing pattern was consistent across the 
experiments. The knockdown of SRSF3 had no obvious effect on the 
expression pattern of the Δ16HER2-minigene product. However, the 
knockdown of hnRNP K caused an increased expression of the wild type HER2 
and a decrease of Δ16HER2-like minigene product. The strongest effect on the 
splicing of the Δ16HER2-minigene can be observed when hnRNP F/H is 
knocked down. After hnRNP F/H knockdown wild type-like HER2 expression is 
strongly decreased and an unspecific amplification of plasmid DNA can be 
observed in cDNA from MCF-7 cells. At the same time the Δ16HER2-like 
minigene product is expressed strongly. 
 
Figure 3.16: Expression of the Δ16HER2-minigene products and the effect of the splicing 
factors on it.  
Transient knockdown of SRSF3, hnRNP K and hnRNPs F/H was performed in MCF-7 and 
SKBR3 (n=3) cells. 48 h after siRNA transfection the Δ16HER2-minigene was transfected. RNA 
was isolated 24 h later. A negative control siRNA was also transfected in both cell lines with the 
Δ16HER2-minigene. PCR was performed with an exon 16 inclusion or exon 16 skipping 
(Δ16HER2) specific forward and minigene product specific reverse primer. 
 
 
Chapter 3: Investigating the regulation of the Δ16HER2 splicing event 
109 
 
3.4.6. Identification of regulatory sequences by site-directed 
mutagenesis 
 
To further study the mechanisms regulating the Δ16HER2 splicing event the 
binding sites of the identified splicing regulators was investigated. From the four 
splicing factors regulating the Δ16HER2 splicing event only hnRNP K and 
hnRNPs F/H were shown to affect the splicing of the Δ16HER2-minigene. In the 
RNA chromatography assay hnRNP K was found to bind all three synthesised 
RNAs. Strongest binding was seen on the exon 16 covering RNA (H1) and least 
to the intron 16 covering RNA (H3). HnRNP H only bound to the intron 15 and 
16 covering RNAs (H2 and H3). 
 
Table 3.12: Summarizing the binding of the splicing factors from the RNA 
chromatography assay. 
 
 
 
In-silico analysis suggested a number of binding sites for hnRNPs F/H and two 
for hnRNP K (Figure 3.17). Interestingly, no hnRNP K binding site on exon 16 
was predicted. Only one binding site for hnRNP H in intron 16 was predicted. A 
number of binding sites overlapping with the polypyrimidine tract and the branch 
point were also predicted. It has been shown that the binding of hnRNPs F/H in 
the 3’ intron could regulate exon recognition (Xiao et al., 2009; Wang et al., 
2012a). Therefore the hnRNP H binding site in intron 16 was first point mutated 
(mut 2).  
It was not possible to design a mutation for the cluster of hnRNPs F/H binding 
sites around the branch point that was not predicted to interfere with normal 
exon recognition. Instead the hnRNPs F/H binding site in intron 15 that is 
upstream of the branch point was mutated, this binding site also contains the 
more typical recognition motive of triple G (mut 5). In addition, the binding site 
 H1 (exon 16) H2 (intron 15) H3 (intron 16) 
HnRNP K + (stronger) + + (fainter) 
HnRNP H - + + (stronger) 
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was also predicted by two predictive programs. Subsequently both the intron 15 
and 16 hnRNP K binding sites (mut 4 and 6) were mutated. 
 
Figure 3.17: Depiction of splicing factor binding sites in the Δ16HER2 splicing region.  
In silico predictions for the binding of hnRNPs F/H and hnRNP K filtered for the binding region 
identified in the RNA chromatography assay are shown. The green underlining indicates RNA 
H2, the grey shaded sequences are covered by H1 and the yellow underlined is covered by H3. 
The red line indicates the boundary of exon 16. The sites at which site-directed mutagenesis 
was performed are indicated (Mut). 
 
The types of mutations carried out are shown in table 3.13. The mutated 
Δ16HER2-minigenes and the unchanged Δ16HER2-minigene were transfected 
into SKBR3 cells. Figure 3.18 shows the expression pattern of the HER2-like 
minigene product. Mut 4 showed an increase in wild type-like levels and a 
decrease in Δ16HER2-like levels. This reflects the downregulation of Δ16HER2 
by hnRNP K knockdown. The hnRNP F/H mutants showed no increase in the 
Δ16HER2-like transcript level, contrarily it showed a very small decrease in 
Δ16HER2-like transcript level. The second hnRNP K mutant 6, showed overall 
decrease levels of Δ16HER2-minigene transcripts. 
 
Table 3.13: Δ16HER2-minigenes splicing factor binding site mutants. 
 Mut 2 Mut 4 Mut 5 Mut 6 
Mutation 
Deletion 
TGGGT 
ACGCTTGA TAGCGTG TCGCA 
Binding site for hnRNP H hnRNP K hnRNP F/H hnRNP K 
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Figure 3.18: The Δ16HER2-minigene expression after mutation of splicing factor binding 
sites. 
The Δ16HER2-minigene and the splicing factor binding site mutants were transfected into 
SKBR3 cells (n=3). RNA was collected 24 h after transfection. The PCR was performed with an 
exon 16 inclusion or exon 16 skipping (Δ16HER2) specific forward and Δ16HER2-minigene 
product specific reverse primer. The red rectangle marks a change in expression ratio. 
 
3.4.7. Regulation of splicing factor expression through HER2 
 
In the previous section the regulation of HER2 splicing by RNA-binding factors 
was investigated. Often regulatory pathways show complex feedback-loops to 
auto-regulate themselves. Unpublished work by Dr Evrim Besray Unal (Charite, 
Berlin) indicated regulation of hnRNP family proteins through the ras-MAPK 
signalling pathways in the breast cancer cell line MCF-7. This finding made us 
interested in defining whether HER2 initiated ras-MAPK signalling to regulate 
the four splicing regulators (SRSF3, hnRNP H, hnRNP F, hnRNP K) of HER2. 
HnRNP K expression has previously been shown to be induced by growth 
factors/growth factor receptors (Mandal et al., 2001). Additionally, hnRNP K 
expression has been shown to be induced by AKT in prostate cancer cells 
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(Ciarlo et al., 2012). AKT is a part of the PI3K-AKT pathway, which is one of the 
main HER2 signalling pathways [reviewed in (Dittrich et al., 2014)]. 
To observe the effect of HER2 signalling on the mRNA expression of the 
splicing factors, HER2 was transiently knocked down with two specific siRNAs 
in SKBR3 cells. A partial knockdown of HER2 mRNA could be observed by 
conventional PCR even 72 h after transfection (Figure 3.19, A), when the effect 
on the splicing factor expression was measured. A strong down regulation of 
HER2 on the protein level has been shown for these siRNAs by MSc student S. 
Satam (data not shown). Changes in expression were measured by qPCR with 
gene specific TaqMan probes. No change in the expression level of SRSF3 
could be observed after transient knockdown of HER2. A statistically significant 
increase in the expression of hnRNPs H, F and K was observed, but the 
increase is small (Figure 3.19, A). 
 
 
 
 
 
 
 
Figure 3.19: The effect of HER2 transient knockdown on splicing factor gene expression. 
Two siRNAs targeting HER2 were transfected into SKBR3 cells. RNA was collected 72h post-
transfection. A, PCRs were performed for the housekeeping gene GAPDH and HER2 to confirm 
the partial knockdown of HER2 expression. B, The graphs show the relative mRNA expression 
of the splicing factors SRSF3, hnRNP, hnRNP F and hnRNP K after HER2 knockdown 
compared to the negative control knockdown. The average of three biological replicates is 
shown. Paired t-test was performed, * ≤ 0.05, *** ≤ 0.001. 
A 
B
V 
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Both the work by Dr Unal and in the two studies on hnRNP K (Mandal et al., 
2001; Ciarlo et al., 2012) detected an effect on the protein level of the splicing 
factors. To study a possible effect of HER2 signalling on the protein level of the 
splicing factors, the HER2 overexpressing SKBR3 cells were treated with the 
HER2 tyrosine kinase inhibitor lapatinib. Using lapatinib it was possible to 
measure the splicing factor protein levels at specific time points after inhibition 
of signalling. Three independent experiments were carried out, from which one 
representative experiment is shown in figure 3.20. Literature suggests 
treatments should be performed with a 1 µM concentration of lapatinib (O'Neill 
et al., 2013; Venturutti et al., 2016). To verify that lapatinib inhibits HER2 
signalling, proteins were collected after 15 min lapatinib treatment. For this time 
point an untreated and DMSO vehicle control was also taken. The treatment of 
SKBR3 cells with lapatinib showed no changes to the total protein levels of 
HER2 nor its downstream effectors AKT and ERK1/2. However, lapatinib 
treatment inhibited the phosphorylation of AKT (Ser473) and ERK 
(Thr202/Tyr204) (Figure 3.20). 
After confirming for each experiment that the HER2 signaling pathway was 
inhibited, the protein levels of the previously studied splicing factors SRSF3, 
hnRNP K and hnRNP H/F were measure (Figure 3.20). The time points used 
were 6, 12 and 24 h post lapatinib treatment. A DMSO vehicle control was 
included. GAPDH levels are shown for normalisation. Densitometry was 
performed to compare the three experiements (Tables 3.14). The protein levels 
of the splicing factors fluctuate slightly experiments and time points. The results 
for the 24 h treatment were the most consistent, with a slight trend towards 
downregulation of the splicing factors.  
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Figure 3.20: The effect of HER2 signalling inhibition by lapatinib on splicing factor 
protein expression.  
SKBR3 cells were treated with 1 µM lapatinib for 15 min, 6, 12 and 24 h. After 15 min the 
protein levels of HER2, phospho-AKT (Ser473), AKT, phospho-ERK (Thr202/Tyr204), ERK 
and GAPDH were determined by western blot. Untreated, DMSO vehicle control and lapatinib 
treatment are shown. DMSO vehicle control and lapatinib treatments are shown for the other 
time points. Protein levels of hnRNP K, hnRNPs F and H as well as SRSF3 and the 
housekeeping gene GAPDH is shown. The experiment was performed 3 times, one 
representative experiment is shown.   
 
Table 3.14: Effect of HER2 signalling inhibition on splicing factor protein levels: 
densitometry of western blots. 
HnRNP K 
6 h 12 h 24 h 
DMSO Lapatinib DMSO Lapatinib DMSO Lapatinib 
Experiment 1 1 0.47 1 1.37 1 0.77 
Experiment 2 1 1.18 1 0.91 1 0.83 
Experiment 3 1 0.71 1 0.55 1 0.71 
Average 1 0.79± 0.36 1 0.94± 0.41 1 0.77± 0.06 
 
hnRNP F/H 
6 h 12 h 24 h 
DMSO Lapatinib DMSO Lapatinib DMSO Lapatinib 
Experiment 1 1 4.08 1 2.1 1 0.81 
Experiment 2 1 0.87 1 1.33 1 0.49 
Experiment 3 1 1.27 1 1.03 1 0.80 
Average 1 2.07± 1.75 1 1.49± 0.54 1 0.70± 0.18 
 
SRSF3 
6 h 12 h 24 h 
DMSO Lapatinib DMSO Lapatinib DMSO Lapatinib 
Experiment 1 1 1 1 1.36 1 0.75 
Experiment 2 1 0.74 1 0.5 1 0.8 
Experiment 3 1 0.54 1 0.93 1 0.49 
Average 1 0.76± 0.23 1 0.93± 0.43 1 0.68± 0.17 
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3.4.8. Progesterone induces HER2 expression 
 
As mentioned in the introduction of this chapter hormones have been shown to 
be able to regulate the splicing of receptor proteins (Lal et al., 2013). Previous 
work of our research group showed that oestrogen does not affect the 
expression or splicing of HER2 (unpublished). The other main hormone studied 
in the context of breast cancer is progesterone. Here the effect of progesterone 
on HER2 splicing was studied. The HER2 negative but ER and PR positive 
breast cancer cell line MCF-7 was used for this part of the study. The cells were 
treated for 24 h with a range of progesterone concentrations (1 nM, 10 nM, 100 
nM) to determine the effect of progesterone on the expression of wild type 
HER2 and Δ16HER2. RNA was collected and following reverse transcription 
SYBR Green qPCR was performed to measure HER2 and Δ16HER2 
expression. Figure 3.21 A and B show the relative mRNA expression compared 
to the vehicle. Both wild type HER2 and Δ16HER2 expression increases with 
progesterone treatment. At 1 nM of progesterone the deviation of expression 
levels between three experiments was large. A reproducible and statistically 
significant increased expression could only be measured at 100nM treatment, 
both for wild type HER2 and Δ16HER2. No significant difference in wild type 
HER2 and Δ16HER2 mRNA expression could be observed. The hereby 
determined optimal progesterone dose of 100 nM was used to treat the cells for 
3, 6, 12 and 24 hours. This was undertaken to determine the optimal time point 
at which progesterone starts to affect the expression and when the expression 
peaks. The average relative wild type HER2 and Δ16HER2 mRNA expression 
compared to time paired vehicle controls is shown in figure 3.21 C and D. The 
expression increases steadily, peaking roughly at 12 h, followed by a slight 
decrease at 24 h. Only 6 h and 24 h post-treatment could a statistically 
significantly increased expression of wild type HER2 be observed. The standard 
deviation between the three independent experiments for the 12 h treatment is 
increased, and no statistical significance is reached, although the average 
expression is peaked here. The highest level of Δ16HER2 expression and only 
statistically significant time point is reached at 12 h. No significant change in the 
expression of ratio between Δ16HER2 and wild type HER2 could be observed 
(Figure 3.21 E). 
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Figure 3.21: Effect of progesterone on HER2 
expression and splicing in MCF-7 cells.  
Cells were treated with progesterone at different 
concentrations after serum starvation (A, B) and 
with 100nM for different time durations (C, D, E). A, 
Dose dependent wild type HER2 expression 
measured after 24h treatment compared to vehicle. 
B, Dose dependent Δ16HER2 expression 
measured after 24h treatment compared to vehicle. 
C, Time dependent wild type HER2 expression 
measured after 3, 6, 12 and 24h treatment. Shown 
compared to paired vehicle control. D, Time 
dependent Δ16HER2 expression measured after 3, 
6, 12 and 24h treatment. Shown compared to 
paired vehicle control. E, Cells were treated with 
100nM progesterone for 3, 6, 12 and 24h. Paired 
vehicle control was taken for each time point. The 
relative mRNA expression ratio between Δ16HER2 
and wildtype HER2 is shown. N=3 for all 
experiments, standard deviation is indicated. One-
way anova with multiple comparison by – was used 
for A and B. Paired t-test was used for C, D and E. 
Statistical significance is indicated, * ≤ 0.05. 
A B 
C D 
E 
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3.5. Discussion  
 
Δ16HER2 is one of the three very well-studied HER2 splice variants. It has 
been extensively studied with regards to its ability to induce tumour formation 
(Mitra et al., 2009; Alajati et al., 2013; Turpin et al., 2016), its distinct signalling 
pathway and the types of breast tumours formed (Alajati et al., 2013; Castagnoli 
et al., 2014). However little is known about the mechanisms involved in its 
production and regulation. Here the mechanisms regulating the alternative 
splicing mechanism that produces Δ16HER2 were investigated. Although 
Δ16HER2 is accepted to be a full length mRNA variant which only lacks exon 
16, there is no supporting mRNA sequence logged with any of the publicly 
available databases. Here it was confirmed by conventional PCR, that exon 16 
skipping is part of a transcript that reaches at least from exon 3 to the last exon 
27. The variations of amplification strengths of the various PCR products can be 
explained by differences of primer efficiencies and the length of the transcripts.  
Using two RNA secondary structure prediction tools wild type HER2 and 
Δ16HER2 were compared. The absence of exon 16 is predicted to affect the 
secondary structure. Both models showed changes to the structure. The MFE 
model showed a higher number of branches and loops for Δ16HER2, whereas 
the centroid model showed a lesser number of changes to the secondary 
structure, but not a less complex alteration. Changes to the secondary structure 
are especially interesting when considering a recent publication. He and 
colleagues described a miRNA-155 binding site within the coding region of the 
HER2 mRNA (He et al., 2016). This binding site was found to be located in 
exon 17, within few nucleotides of exon 16. Both models predicted the 
secondary structures of the binding site to be different between wild type HER2 
and Δ16HER2. The most severe change was predicted by the centroid plain 
model, which predicted the binding site sequence in Δ16HER2 to be located on 
a large loop, but broken up by number of pseudoknots and single nucleotide 
interactions. Additional loping of the different structures could make this 
potentially hard to access by miRNA-155. The previously mentioned study 
showed that miRNA-155 was upregulated by treatment of cells with 
trastuzumab. MiRNA-155 in turn represses HER2 expression by targeting 
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HDAC2, a transcriptional activator of HER2 and by binding in the coding region 
of HER2 (He et al., 2016). Work in cell lines, showed Δ16HER2 to be resistant 
to trastuzumab treatment (Castiglioni et al., 2006; Mitra et al., 2009), however in 
vivo work has shown the opposite; that Δ16HER2 positive tumour cells are 
increasingly susceptible to trastuzumab (Castagnoli et al., 2014). Here we 
suggest that due to the absence of exon 16 the secondary structure of the 
miRNA-155 binding site in Δ16HER2 is obscured and Δ16HER2 is thereby less 
affected by miRNA-155 and thereby trastuzumab in in vitro models. 
3.5.1. Identification of the Δ16HER2 splicing event regulating 
factors 
 
The most prominent mechanism of splicing regulation is through RNA-binding 
proteins that affect the recognition of exons and introns by the spliceosome. 
Most regulatory signals are found in close proximity to the exon/intron 
boundaries [reviewed in (RNA and Cancer, 2013)]. Initially the intron boundary 
area of exon 16 and the exon itself was studied using three in silico predictive 
tools. These predicted 30 proteins to potentially bind the exon 16 splicing area. 
Comparing the results from the 3 software packages showed a list of ten 
splicing factors that were at least predicted by 2 tools for overlapping binding 
sites. These were hnRNP A1, hnRNP F, hnRNP H, SF2/ASF, sc35, SRp40, 
SRp55, SRSF3, CUG-BP and 9G8. A major limitation is that these programs 
have been produced at different times and are not all up to date in regard to 
more novel splicing factors and binding sites. In-silico predictions often differ 
strongly from what can be found in cells. To further narrow down the number of 
possible splicing regulators an experimental approach was used. The RNA 
chromatography assay combined with mass spectrometry and western blot 
confirmed some of the in-silico predicted splicing factors: hnRNP A1, hnRNP H, 
hnRNP F and SRSF3, as well as factors that were only predicted by one or 
none of the predictive programs. To verify if these proteins affect the splicing of 
Δ16HER2, transient knockdowns were performed. Besides Δ16HER2 the effect 
on p100, another HER2 splice variant was also measured. The close proximity 
is likely to link the splicing events; p100 is due to a partial intron 15 retention 
and Δ16HER2 is due to exon 16 skipping. The knockdowns showed that only 
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SRSF3 and the hnRNPs K, F and H affect the splicing of Δ16HER2. This could 
be observed in both HER2-high SKBR3 and HER2-low MCF-7 cells and 
supports previous findings by our group (Gautrey et al., 2015). The splicing 
factors SRSF3 and hnRNP K were shown to repress the recognition of exon 16 
and promote the production of Δ16HER2. HnRNPs F and H downregulate both 
Δ16HER2 and p100 production. As both p100 and Δ16HER2 are minor 
transcripts in the cell lines used, changes to their level only minimally affect the 
wild type HER2 levels. Interestingly, SRSF3 was found to upregulate the 
production of Δ16HER2, but downregulates the production of p100. Δ16HER2 
has been shown to promote tumour development and aggressiveness of the 
decease (Kwong and Hung, 1998; Siegel et al., 1999; Mitra et al., 2009; Sasso 
et al., 2011), whereas p100, although not extensively studied, has been 
associated with a tumour suppressing function (Aigner et al., 2001). Therefore 
in this model SRSF3 promotes a tumourigenic phenotype by promoting of 
Δ16HER2 and inhibition of p100 splicing.  
To show that these splicing factors act specifically on the exon 16 splicing 
region and to identify the mRNA binding sites, a Δ16HER2-minigene was 
constructed. When transfected into breast cancer cells the Δ16HER2-minigene 
gave rise to both wild type HER2-like and Δ16HER2-like transcripts. The 
knockdown of the hnRNPs, but not SRSF3 had an effect on the Δ16HER2-
minigene expression pattern.  As mentioned previously our group has identified 
a SRSF3 binding site in exon 15 (Gautrey et al., 2015). Given the size 
constraints of a minigene, the Δ16HER2-minigene only contains exon 15 and a 
small portion of intron 14 (Figure 3.20). This is expected to affect how exon 15 
and the binding site in it are recognised. Also no p100-like transcript is 
produced from the Δ16HER2-minigene (data not shown).  
 
 
Figure 3.22: The HER2 sequence of the Δ16HER2-minigene.  
The Δ16HER2-minigene contains a short segment of intron 14, followed by exon 15, intron 15, 
exon 16, intron 16, exon 17, intron 17 and exon 18. A large middle part of the introns 15 and 16 
were not included.  
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Comparing the combined in-silico predictions with the results from the RNA 
chromatography assay gave a starting point to identify binding sites of hnRNP 
F/H and hnRNP K. Four site-directed mutagenesis were performed for predicted 
binding sites. The mutations were carefully designed to not impair the normal 
exon recognition. However some additional predicted binding sites were also 
abolished: for hnRNP F/H mutant 2 binding motifs for RBM5, hnRNP P, KSRP 
and ZRANB2, for hnRNP K mutant 4 a potential Nova-1 binding motif and for 
hnRNP F/H mutant 5 potential binding motifs hnRNP P and RBM5. Additionally, 
hnRNP F/H mutant 2 gained a binding motif for MBNL1, hnRNP K mutant 4 
gained a potential binding motif for MBNL1 and hnRNP K mutant 6 gained a 
potential binding motif for ZRANB2. None of these splicing factors have been 
previously implied play a role in exon 16 splicing. However an effect of 
artificially produced binding motifs or deletion of potential binding sites could 
affect the splicing of the Δ16HER2-minigene. 
Of the two hnRNP F/H and two hnRNP K binding sites only mutation 4 had an 
effect on the splicing pattern. This binding site was located on intron 15 slightly 
upstream of the branch point. Similar to the knockdown of hnRNP K, the 
mutation of its biding site also causes the reduced expression of Δ16HER2-like 
products in favour of wild type HER2-like products. HnRNP F/H was found to be 
a factor that promotes the recognition of exons 16, but none of the mutated 
sites affected the alternative splicing pattern. A cluster of binding sites were 
predicted that overlap the branch point. It was not possible to mutate the 
binding site without also stopping exon 16 recognition.  
 
The role of SRSF3 in alternative splicing of Δ16HER2 
SRSF3 is a well-studied SR protein which is overexpressed and acts as an 
oncogene in a number of cancers including breast cancer (Jia et al., 2010; 
Silipo et al., 2015). One study showed an increase in SRSF3 expression to be 
positively correlated with the stage of breast cancer (Stickeler et al., 1999). If 
SRSF3 is elevated above the normal tissue specific threshold it can promote 
tumour development and tumour maintenance. This is mediated by SRSF3’s 
role in regulating the expression and alternative splicing of key proteins in the 
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cell cycle especially the G2/M phase transition and apoptosis (Jia et al., 2010). 
SRSF3 plays not only a role in alternative splicing, but also in transcription (Cui 
et al., 2008), RNA processing (Park and Jeong, 2016) and translation (Kim et 
al., 2014; Park and Jeong, 2016). One of its best studied targets is the tumour 
suppressor p53. Decreased levels of SRSF3 cause the increased inclusion of 
exon i9 which causes the production of the p53 splice variant p53β, which is 
responsible for cellular senescence activity (Tang et al., 2013). 
 
 
Figure 3.23: The effect of SRSF3 on the splicing of p100 and Δ16HER2.  
A, if SRSF3 is present and binds to the HER2 mRNA Δ16HER2 is produced. Binding site is 
based on (Gautrey et al., 2015). B, If SRSF3 does not bind to exon 15 the expression of p100 is 
increased. 
 
In this study previous findings of our research group, that showed SRSF3 
affects the alternative splicing of HER2 splice variants Δ16HER2 and p100 were 
reproduced (Gautrey et al., 2015). SRSF3 was shown to inhibit exon 16 
recognition and partial intron 15 retention (Figure 3.21). This is likely mediated 
by the previously identified SRSF3 binding site in exon 15 (Gautrey et al., 
2015). Although SRSF3 seemed to bind the exon 16 splice region in the RNA 
chromatography assay, SRSF3 had no effect on the Δ16HER2-minigene 
splicing. The reduced size of the Δ16HER2-minigene, the absence of chromatin 
factors or other factors associated with normal endogenous HER2 might cause 
SRSF3 to not interact with Δ16HER2-minigene. It is also possible that the 
binding of SRSF3 in the RNA chromatography assay was unspecific and 
SRSF3 act through the binding motif in exon 15. Indeed a similar mode of 
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action has been observed in Caspase 2 mRNA, were SRSF3 was shown to 
bind exon 8 and promote the skipping of downstream exon 9 (Jang et al., 2014).  
 
 
The role of hnRNP K in alternative splicing of Δ16HER2 
The ~66 kDa sized hnRNP K is comprised of three DNA-RNA binding homology 
domains, a K-protein-interactive region and a C-terminal protein kinase-binding 
domain (Dejgaard and Leffers, 1996) [reviewed in (Barboro et al., 2014)]. It also 
contains a nuclear-localisation signal and a nuclear shuttling domain that are 
important for its functions in the nucleus and cytoplasm (Barboro et al., 2014). 
HnRNP K has been shown to be highly expressed in a number of cancer types, 
the studied cancer types did not include breast cancer (Barboro et al., 2014). 
However, in a small cohort of human breast tumour samples hnRNP K was 
expressed at higher levels in high grade human breast tumours than in low 
grade tumours (Mandal et al., 2001). HnRNP K has been shown to play a role in 
transcription (Takimoto et al., 1993; Zheng et al., 2016), RNA processing 
(Venables et al., 2008; Song et al., 2016) and translation (Ostareck et al., 1997; 
Notari et al., 2006). Until 2008 only few hnRNP K regulated alternative splicing 
events had been described. In the large scale study by Venables and 
colleagues, they studied alternative splicing events that are regulated by hnRNP 
proteins (Venables et al., 2008). They found hnRNP K to be associated with the 
largest number alternative splicing events out of the studied hnRNP proteins. In 
general, downregulation of hnRNP K was shown to promote both exon skipping 
and exon inclusion events. Specific targets of hnRNP K include apoptotic 
peptidase activating factor 1 (APAF1) and protein tyrosine kinase 2 (PTK2B), 
where it acts as an exon recognition factor, and NLR family, pyrin domain 
containing 1 (NALP1) where it is an exon silencer (Venables et al., 2008). In the 
alternative splicing event producing Δ16HER2 hnRNP K was found to act as an 
exon silencer.  
Additionally, hnRNP K has been shown to regulate splice site selection of Bcl-x, 
were it inhibits the production of the pro-apoptotic Bcl-xs splice form (Revil et al., 
2009). Another study showed hnRNP K was able to regulate intron retention of 
glucose-6-phosphate dehydrogenase (G6PD) in response to starvation signals. 
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In this study hnRNP K was found to bind C-rich motifs in the exon and promote 
intron retention, leading to a G6DP alternative splice variant that is not 
translated. In our work hnRNP K was also shown to promote the retention of 
partial intron 15 and thereby the production of p100. However, exon 16 does not 
contain the type of C-rich motif that has been identified to bind hnRNP K. It was 
also shown that SRSF3 and hnRNP K can compete for the same motif (defined 
pre-mRNA sequence) (Cyphert et al., 2013). Indeed, the functional hnRNP K 
binding site (mutant 4) which was identified by mutagenesis, was also in-silico 
predicted to be a binding site of SRSF3. However SRSF3 does not affect 
splicing of the Δ16HER2-minigene model and therefore such a mechanism 
could not be detected in this system. It can only be speculated as to whether 
SRSF3 might be able to substitute hnRNPK at this binding site in endogenous 
HER2. 
 
The role of hnRNPs F and H in alternative splicing of Δ16HER2 
HnRNPs F and H are very closely related proteins, sized 53 and 56 kDa, 
respectively (Honore et al., 1995). They are expressed in most normal tissues. 
HnRNP F is predominantly found located in the cytoplasm and hnRNP H is 
more commonly found in the nucleus (Honore et al., 2004). HnRNPs H and F 
have been found overexpressed in some cancers (Honore et al., 2004; 
Balasubramani et al., 2006) and have been implied in malignant transformation 
(Balasubramani et al., 2006; Lefave et al., 2011). Not all studies agree that 
hnRNPs F and H are bad prognostic factors in cancer, in one study hnRNP H 
nuclear staining was correlated with good prognosis in colorectal cancer (Hope 
and Murray, 2011). These two splicing factors, like the previously discussed 
splicing factors, are not only involved in alternative splicing (Uren et al., 2016) 
but also in transcription (Wei et al., 2005), mRNA transport (White et al., 2012) 
and translation (Song et al., 2012). In the study by Venables it was found that 
only ~ 30% of alternative splice events that were regulated by one hnRNP (F or 
H) were also regulated by the second hnRNP (F or H). In 80% of hnRNP F/H 
mediated splicing events identified by this study, hnRNP F/H act as exon 
defining factors (Venables et al., 2008). This coincides with the findings of this 
thesis, where hnRNP F/H was observed to promote recognition of exon 16 in 
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HER2. In the initial work with Dr Gautrey, only knockdowns of hnRNP H were 
performed and an effect on p100 splicing was not observed (Gautrey et al., 
2015). However as the work was extended to also include hnRNP F, hnRNP 
F/H was found to not only inhibit Δ16HER2 but also p100 production. In the 
mutagenesis work it was not possible to identify the binding site of hnRNP F/H. 
Given the binding pattern observed in the RNA chromatography assay and the 
in-silico predictions hnRNP F/H was expected to bind in the intron surrounding 
the exon 16. As expected nothing indicates binding to the exon, as other studies 
have found binding to the exon to be associated with exon skipping (Rahman et 
al., 2015). HnRNP F/H has mostly been suggested to bind to the intron 
containing the 5’ss to promote the recognition of the upstream exon, but it has 
now also been found to act when binding to the upstream intron containing the 
3’ss (Wang et al., 2012b). Additionally, hnRNP F/H has been suggested to 
define an exon by binding to the beginning and end of an intron, thereby define 
the intron and promoting the correct splicing of both the intron and exon 
(Martinez-Contreras et al., 2006). Indeed there is a large cluster of hnRNP F 
and H binding sites predicted at the beginning of intron 15 (Figure 3.24). If 
hnRNP F/H bound the intron at these predicted binding sites as well as at the 
end of intron 15 it would possibly improve the intron 15 recognition and thereby 
also promote the recognition of exon 16. HnRNP F/H also inhibits the 
production of p100, therefore if hnRNP F/H acts through defining intron 15 it 
could impair both p100 and Δ16HER2 production.  
We suggest here that hnRNP F/H might bind to a sequence that overlaps with 
the branch point upstream of exon 16. One might assume that binding of 
hnRNP F/H at this site would mask the branch point and impair the assembly of 
the spliceosome. However, hnRNP F/H has been shown in the alternative 
splicing of RE1-silencing transcription factor (REST) to bind near the 5’ss of the 
alternative exon N50 and be displaced by the spliceosome assembly factor 
U2AF65 (Ortuno-Pineda et al., 2012). Therefore hnRNP F/H could similarly bind 
across the branch point and be displaced if necessary by SF1/BBP or U2AF. 
Here the most likely binding sites for hnRNP F/H based on experimental 
evidence, in-silico predictions and the current subject knowledge were studied. 
However there are also further potential binding sites further away in the introns 
15 and 16. 
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Figure 3.24: Splicing factor binding motifs at the exon 15/intron 15 boundary of HER2 
pre-mRNA. 
The image shows the splicing factors predicted to bind the boundary sequence of exon 15 and 
intron 15. The red line indicates the exon intron boundary. A large number of hnRNP H and F 
binding sites have been predicted for this part of intron 15. The image was generated by 
SpliceAid (http://www.introni.it/splicing.html). 
 
3.5.2. Feedback-loop between HER2 and its splicing regulators? 
 
HER2 is known to regulate a complex signalling network, the two main 
pathways being the ras-MAPK and the PI3K-AKT pathways. These pathways 
are known to have complex crosstalk and feedback mechanisms [reviewed in 
(Dittrich et al., 2014)]. Unpublished work by Dr Unal indicated the regulation of 
the hnRNP family of splicing factors through the ras-MAPK signalling pathway. 
This observation and studies showing hnRNP K could be induced by growth 
factor signalling, lead us to question whether HER2 mediated signalling could 
regulate the four identified splicing factors (SRSF3, hnRNP H, hnRNP F, 
hnRNP K) in our cell model (Mandal et al., 2001; Ciarlo et al., 2012). A transient 
knockdown of HER2 was performed to investigate the effect on the gene 
expression of the splicing factors. No change in the expression level of SRSF3 
could be observed, but for the expression of hnRNPs H, F and K a statistically 
significant increase was observed. Still the change was relatively small and 
should not be considered conclusive. They also contradict the previous 
observations in other cell lines that hnRNP K is induced by growth factor 
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signalling (Mandal et al., 2001; Ciarlo et al., 2012). SKBR3 cells were only used 
by Mandal et al. for initial experiments, where they observed that inhibiting 
HER2 with a monoclonal antibody decreased hnRNP K mRNA levels slightly. 
Due to the small changes observed, SKBR3 cells were not used in the further 
experiments in that study (Mandal et al., 2001). To study any changes to the 
protein level of the splicing factors, SKBR3 cells were treated with the HER2 
tyrosine kinase inhibitor lapatinib. As expected treatment with lapatinib inhibited 
ras-MAPK and PI3K-AKT signalling. The splicing factor protein levels were 
measured over 24 h and a small downregulation of all splicing factors after 24 h 
lapatinib treatment was observed. The work by Unal et al., suggested that the 
signalling pathways might additionally affect the phosphorylation status of the 
splicing factors. However, currently there is no phospho-hnRNP F/H antibody 
available. To assess the phosphorylation status of the splicing factors without 
specific antibodies, a column based phospho-protein separation kit could be 
used. As the last batch of hnRNP K and F/H antibodies showed a high number 
of unspecific bands, new antibodies would be needed to produce meaningful 
results in such an assay.  
From these findings it can be conclude that in the HER2-high SKBR3 cell line 
HER2 signalling might slightly downregulate the hnRNPs K, F and H at the 
mRNA level. However, it induces the expression of all four splicing factors at the 
protein level. It will be interesting to further study the effect of PI3K-AKT and 
ras-MAPK signalling on phosphorylation of splicing factors, as studies have 
shown that AKT mediated phosphorylation of splicing factors, namely hnRNP L 
and A2 can be an important step in alternative splicing regulation (Guha et al., 
2010; Vu et al., 2013). 
 
3.5.3. Progesterone induced expression of HER2 
 
Breast cancer as a predominantly female disease, has been closely linked to 
the two main female reproductive hormones oestrogen and progesterone 
(Breast Cancer, A Lobular Disease, 2011). Recent research, that showed PR to 
regulate the function of ER-α in favour of a tumour inhibiting signalling pathway 
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(Mohammed et al., 2015), has brought progesterone and progesterone receptor 
back into the focus of research. A number of studies have shown both 
oestrogen/ER and progesterone/PR to be part of a complex network of 
interactions and crosstalk with HER2 (Beguelin et al., 2010; Diaz Flaque et al., 
2013; Giuliano et al., 2013). As previously mentioned, recent research has 
shown oestrogen to affect the alternate splicing of the type 1 corticotropin-
releasing hormone receptor (Lal et al., 2013). This link between oestrogen and 
alternative splicing opens up a number of further possibilities as to how 
hormones might affect alternative splicing. Previous research in our group 
suggests that oestrogen does not affect HER2 mRNA expression in breast 
cancer cell lines (unpublished). In light of the role of the new findings on the 
roles of progesterone and PR in breast cancer, we wished to investigate 
whether progesterone affects HER2 expression and alternative splicing. 
It was determined that 100 nM progesterone is the optimal dose for treatment of 
the ER/PR positive cell line MCF-7. A time dependent effect of progesterone on 
the expression of HER2 and Δ16HER2 was observed. Progesterone induced 
the expression of both HER2 variants from 6 h to 24 h of treatment, roughly 
peaking at 12 h. Both wild type HER2 and Δ16HER2 followed the same trend. 
The ratio between wild type HER2 and Δ16HER2 did not significantly change. 
Taking these findings together, this work shows that progesterone induces the 
expression of HER2, but does not alter the alternative splicing pattern. MCF-7 
cells are rich in PR and low in HER2, therefore the significant, but relatively 
small effect on the expression raises the question of the importance of this 
interaction. This might be in part due to the dependence of the cell line on 
growth hormones and the extreme stress they suffer when starved in 
preparation to the progesterone treatment. Progesterone mediated effects on 
the transcription of splicing factors of HER2 are not likely to be observed in the 
24 h time frame of this experiment. Simply extending the time period cannot be 
considered a good solution, as this would prolong the stress situation and is 
very likely to cause unspecific effects on splicing and expression. 
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3.5.4. Summary 
 
In this chapter, four key splicing factors were identified, that regulate the 
Δ16HER2 splicing event. Of these SRSF3 and hnRNP K were shown to act as 
splicing silencers, inhibiting exon 16 recognition. At the same time SRSF3 
inhibits p100 production, but hnRNP K promotes p100 production. Knockdowns 
of hnRNPs F and H were shown to have an additive effect on the splicing 
events studied here. HnRNP F/H was shown to act as splicing enhancers for 
both exon 15 and 16, inhibiting Δ16HER2 and p100 production. A Δ16HER2-
minigene was successfully designed and constructed, and showed to be 
responsive to splicing factors hnRNPs K, F and H. However, the Δ16HER2-
minigene was not responsive to SRSF3. This is likely due to the lack of exons 
upstream of exon 15, which may also prevent Δ16HER2-minigene from 
producing p100. Through mutagenesis of the Δ16HER2-minigene a number of 
predicted splicing factor binding sites were eliminated and one binding site for 
hnRNP K was identified.  
Based on published (Mandal et al., 2001; Ciarlo et al., 2012) and unpublished 
(Dr. Unal) work it was decided to investigate a feedback loop between HER2 
and its splicing factors. HER2 knockdown was observed to increase the mRNA 
expression of hnRNPs F, H, and K. However, only very small changes to the 
protein level of the splicing factors were observed.  
At last, a potential effect of progesterone on HER2 expression and alternative 
splicing was investigated. This was brought on by a recent study highlighting a 
new role of PR in breast cancer (Mohammed et al., 2015). Indeed progesterone 
was observed to inducing HER2 expression, but there were no changes to the 
splicing ratio of Δ16HER2 and wild type HER2. The observed effect of 
progesterone on HER2 expression warrants further investigation. 
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3.5.5. Future work 
 
In this chapter it was possible to answer a number of questions, but it has also 
given rise to more questions and ideas. As has been discussed in the beginning 
of this chapter, all work on Δ16HER2 is based on the assumption that it is part 
of a full length HER2 transcript. However, the PCR work showed a very faint 
first exon. Verification of the promoter and transcription start site would be of 
great interest. Additionally, little is known about the 3’UTR of HER2 and any 
changes to its length and the poly(A) site used, could impact on its stability and 
processing. 
After identifying key splicing regulators of the Δ16HER2 splicing event, the 
binding sites of these factors was investigated by mutagenesis. One predicted, 
but unlikely binding site for hnRNP F/H has to still be tested. In the here 
described work the main focus was on the immediate area surrounding exon 
16. It would be of interest to further investigate G-tracts in introns 15 and 16, as 
those could act as hnNRP F/H binding sites. Further, investigation should be 
extended to the exon 15/intron 15 and intron 16/exon 17 boundaries. As exon 
16 recognition is dependent on intron 15 and 16 recognition. Additional, 
interesting factors to consider are SNPs in the splicing region and such that 
overlap with splicing factor binding sites. It would be of interest to observe if 
these have an effect on the splicing mechanism or binding of splicing factors.  
Although, the Δ16HER2-minigene used in this study has worked well it is an 
artificial system that cannot account for the more complex transcriptional 
processes and the normal working of cells. The next step would be to design 
antisense morpholino oligonucleotides that target splicing factor binding sites. 
There are a number of uses for this. Δ16HER2 has been extensively studied 
with regards to its function (Kwong and Hung, 1998; Siegel et al., 1999; Mitra et 
al., 2009; Sasso et al., 2011; Castagnoli et al., 2014), however in all studies 
cells were transfected with Δ16HER2 plasmids or Δ16HER2 transgenic mice 
models were used. To account for RNA-processing associated effects and to 
produce a less artificial system it would be suggested to use alternative 
techniques. Using antisense morpholino oligonucleotides or a CRISPR/Cas9 
system the HER2 splicing could be switched in favour of Δ16HER2 production. 
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This could be a less artificial model to use for studying downstream signalling 
and drug resistance as well as migration and its behaviour in a 3D environment. 
Switching the splicing from Δ16HER2 to wild type HER2 or even the tumour 
suppressor p100 on the other hand would be of great interest for a potential 
therapy. 
Further, the ability of HER2 signalling to regulate splicing factor expression was 
investigated. In a next step it would be of interest to study the impact of 
Δ16HER2 induced src signalling on the splicing factors, especially in regard to 
the Δ16HER2 splicing event regulating factors.  
For future work it would be very interesting to consider different models for 
HER2-positive breast cancer. In a recent publication Δ16HER2 levels were 
assessed in a number of breast cancer cell lines (Turpin et al., 2016). The 
SKBR3 cell line used for most of this study, was shown by Turpin and 
colleagues to have one of the lowest Δ16HER2/total HER2 ratios of all HER2-
positive breast cancer cell lines studied. The highest Δ16HER2/total HER2 ratio 
in a HER2-positive cell line was observed for ZR7530, where the level of 
Δ16HER2 was ~12% of total HER2 transcripts. In this study a number of basal 
and luminal cell lines showed similar levels of Δ16HER2. The overall highest 
Δ16HER2/total HER2 ratio was observed in the basal cell line SUM149PT. 
However, the total Δ16HER2 expression level was the highest in HER2-positive 
cell lines, especially in SUM225CWN (Turpin et al., 2016). The high 
Δ16HER2/total HER2 ratio in basal cell lines is  interesting, as Δ16HER2 
tumours in mice have shown a very heterogenous histology and their 
expression profile was found to be typical for ER-negative, high-grade 
metastatic primary tumours, not HER2 positive tumours (Alajati et al., 2013). 
This opens up the possibility of a new role of Δ16HER2 in triple negative breast 
cancers. 
Another avenue of research is based on the work by He et al., where it was 
shown that miRNA-155 binds in the coding region of the HER2 mRNA (He et 
al., 2016). This binding sequence is located in exon 17, within few nucleotides 
of exon 16. This study also showed that miRNA-155 expression is induced by 
the therapeutic antibody trastuzumab (He et al., 2016). Our work suggests that 
the secondary structure of Δ16HER2 might obscure the miRNA-155 binding 
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site. Δ16HER2 expressing cells have been shown to be resistant to 
trastuzumab treatment in cell line models (Castiglioni et al., 2006; Mitra et al., 
2009), the mechanisms however has remained unclear. The potential ability of 
Δ16HER2 to evade recognition by trastuzumab induced miR-155 could be a 
new mechanism of resistance in cell line models. 
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Chapter 4: Characterising HER2 in human breast tumours 
 
4.1. Introduction 
 
In the previous chapter the mechanisms that regulate Δ16HER2 mRNA splicing 
were studied. In this chapter the focus lies on linking HER2 alternative splice 
variants to more clinically relevant aspects. HER2, as an important biomarker 
for breast cancer, is routinely clinically assessed to determine the subtype of 
breast cancer and to accordingly plan therapy. The HER2 status can be 
determined by a number of methods. Immunohistochemistry (IHC) is the most 
commonly used technique. It determines the protein expression and localisation 
in breast tumour tissue sections. Alternatively, fluorescence/chromogenic in situ 
hybridization (FISH/CISH) can be performed to determine HER2 gene 
amplification. For all three methods a number of companies provide FDA 
approved reagents (Table 4.1). The methods can be performed on fresh, frozen 
or formalin-fixed paraffin-embedded (FFPE) tissue sections.  
Table 4.1: Table of FDA-approved HER2 assessment kits (FDA, 2016). 
Assay type Product name Company 
Immunohistochemistry 
Semi-quantitative 
IHC 
HercepTest™ DAKO 
IHC PATHWAY® Anti-HER2/Neu 
(4B5) Rabbit Monoclonal 
Primary antibody 
Ventana Medical Systems Inc 
IHC InSite® HER2/Neu Kit Biogenex Laboratories Inc 
Semi-quantitative 
IHC 
Bond Oracle™ HER2 IHC 
system 
Leica Biosystems 
Fluorescence in situ hybridization 
FISH INFORM HER2/Neu Ventana Medical Systems Inc 
FISH PathVysion® HER2 DNA Probe 
Kit 
Abbott Molecular Inc 
FISH HER2 FISH PharmDx™ Kit DAKO 
Chromogenic in situ hybridization 
CISH SPoT-Light® HER2 CISH kit Life Technologies Inc 
CISH INFORM HER2 dual ISH DNA 
probe cocktail 
Ventana Medical Systems Inc 
CISH HER2 PharmDx™ DAKO 
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Depending on the intensity and extent of IHC staining the tumours are grouped. 
If a tissue section is scored 0 or 1, the case is classified as HER2-negative. In 
case of a score of 2+, which is considered to be equivocal, the HER2 gene 
amplification status will be determined. The tumour is classified as HER2-
positive with a score of 3+. The majority of tumours are grouped accordingly 
and therapy can commence (Rakha et al., 2015).  
These current, and routinely used, methods of HER2 assessment have a 
relatively high rate of accuracy [reviewed in (Sapino et al., 2013)]. However two 
challenges remain, these are tumour heterogeneity and deviations between 
HER2 assessment methods (Miller et al., 2004; Vance et al., 2009; Sapino et 
al., 2013; Carvajal-Hausdorf et al., 2015)]. HER2 genetic heterogeneity in a 
tumour was defined as a tumour with 5-50% of infiltrating tumour cells with a 2.2 
ratio of HER2 gene amplification to chromosome 17 centromere (HER2/CEN-
17) (Vance et al., 2009). The HER2 genetic heterogeneity has been reported for 
5% (Vance et al., 2009) to 15% (Ohlschlegel et al., 2011) of tested tumours. 
They are most common in HER2 (2+) equivocal breast cancer cases and have 
been associated with an overall negative HER2 amplification status, but a 
significant number of cells with HER2 amplification (Ohlschlegel et al., 2011). It 
has been proposed that HER2 heterogeneity should be subdivided into 
categories (Sapino et al., 2013). The first group of tumours is characterised by 
the presence of two distinct populations of cells, one clearly HER2-negative and 
the other HER2-positive. This group would be associated with the discordant 
results between IHC and FISH results, observed by Miller and colleagues. They 
found focal HER2 amplification to be present in 21% of IHC 0-1/FISH-amplified 
and 30% of IHC 2+/FISH amplified breast tumour cases (Miller et al., 2004). 
The second group is characterized by dispersed presence of HER2-positive 
cells in HER2-negative breast tumours (Sapino et al., 2013). The implication of 
focal and diffuse HER2 amplification on trastuzumab therapy has been 
assessed in a sub-study of the N9831 study. They reported that trastuzumab 
therapy can be beneficial for some patients with both focal and diffuse HER2 
amplification [reviewed in (Oakman et al., 2010)]. 
In the introduction (section 1.10), the occurrence of HER2 therapy resistance 
and the lack of understanding the underlying mechanisms were discussed 
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(Vogel et al., 2002; Nagy et al., 2005; Junttila et al., 2009; Garrett and Arteaga, 
2011; Hurvitz et al., 2013). When HER2 status is clinically determined the 
expression of HER2 protein variants is not taken into consideration. A recent 
study showed antibodies for the extracellular domain (ECD) and intracellular 
domain (ICD) of HER2 to give discordant results in 15% of assessed breast 
tumours. This study was also able to associate expression ratios between ECD 
and ICD with the length of disease free survival. Showing a high ECD/ICD level 
to be associated with an increased disease free survival (Carvajal-Hausdorf et 
al., 2015). One could propose that increased levels of ECD mean high level of 
secreted HER2, such as HER2 splice variants p100 and Herstatin.  
Furthermore, one could hypothesize that there are cases of breast tumours 
which are classified as HER2-positive, but express a substantial amount of 
other HER2 protein variants that will not respond to anti-HER2 therapies. 
Alternatively, tumours with low levels of wild type HER2, but elevated levels of 
undetected HER2 protein variants could be classified as HER2-negative. This 
could prevent patients from being offered and treated with anti-HER2 therapies, 
although they might well benefit from receiving this treatment.  
The work presented in this chapter is part of a larger program of research 
investigating the importance of HER2 splice variants in breast cancer patients. 
To assist with the research we have obtained a well characterised cohort of 
breast tumour samples from the Breast Cancer Now Tissue Bank. The aim of 
the overall study is to assess differences between HER2 antibodies for different 
epitopes in IHC on breast tumours and compare these with the HER2 gene 
amplification status measured by CISH. Those observations will be combined 
with quantitative measurement of HER2 splice variant expression in the same 
cohort of breast tumours and correlated with the clinical data available for the 
patients. 
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4.2. Aims 
 
The aims of this chapter were to: 
 Characterise HER2 protein expression and localisation in a cohort of 
breast tumour samples 
 Assess HER2 gene amplification by CISH in a small cohort of breast 
tumour samples 
 Compare HER2 protein expression and HER2 gene amplification 
 Characterise breast tumours with discordant IHC and CISH results  
 Study the HER2 splice variants levels in discrepant breast tumour 
samples 
 
4.3. Specific methodology  
 
4.3.1. Immunohistochemistry (IHC) 
 
As part of a larger study, HER2 protein expression and localisation in human 
breast cancer tissue samples was assessed. Tissue sections from grade 3 
invasive ductal carcinomas were received from the Breast Cancer Now Tissue 
Bank, which collected them with full patient consent and ethical approval under 
the number: BCNTB000027. For each breast cancer group, ER+/HER2+, 
ER+/HER2-, ER-/HER2+ and ER-/HER2-, tumour sections from 10 cases were 
received. Additionally, tissue samples from reduction mammoplasty, 10 cases, 
were received. From each tumour block serial sections were received from the 
Breast Cancer Now Tissue Bank and stained with a C-terminal [HER2/ErbB2 
antibody #2242] (Cell Signalling) and an N-terminal HER2 antibody 
[HER2/ErbB2 (D8F12) XPTM Rabbit Antibody #4290)] (Cell Signalling) as well 
as the HercepTestTM (Dako). The formalin-fixed paraffin embedded (FFPE) 
sections were immunostained by Research Technician Grant Richardson and 
initially analysed by our collaborator clinical pathologist Dr Helen Kourea 
(Associate Professor of Pathology, University of Patras, Patras, Greece). 
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4.3.1.1. IHC with C- and N-terminal HER2 antibodies 
 
Forty cases were studied. For each tissue 4 µm thick sections were cut. Known 
HER2 3+ tumour section positive controls (provided by the Pathology 
Department at the University of Patras, Patras, Greece) as well as no primary 
antibody controls were included. As the Breast Cancer Now Tissue Bank 
sections were coated in a very thick layer of wax to preserve the tissue, the 
slides were incubated for 1 h at 60°C to help remove the wax. The sections 
were then dewaxed using xylene and rehydrated through graded ethanol (99%-
70%). They were then treated with a water/hydrogen peroxide block for 10 min 
and rinsed in water. Depending on the antibody the appropriate pre-treatment 
was used (Table 4.2.).  
Epitope retrieval: citrate buffer/microwave pre-treatment 
The slides were microwaved for 5 minutes in citrate buffer pH 6, the citrate 
buffer was exchanged for fresh hot citrate buffer and the slides microwaved 
again for 5 min. The sections were left to cool in fresh hot citrate buffer. After 
washing with water the slides were kept in TBS pH 7.6. 
Epitope retrieval: EDTA buffer/pressure cooker pre-treatment 
The pressure cooker was filled with 1.5 L of EDTA buffer pH 8. After the buffer 
was brought to a boil, the slides were immersed and the lid locked in place. The 
cooker was kept on heat for 2 min after pressure was reached. The pan was 
rapidly cooled under water and the slides were removed. The slides were 
washed under running water.  
Table 4.2: Table detailing the epitope retrieval method and dilution of the antibodies. 
 
 
C-terminal [HER2/ErbB2 
antibody #2242] Lot 8 
(Cell Signalling) 
N-terminal HER2 antibody 
[HER2/ErbB2 (D8F12) XPTM 
Rabbit Antibody #4290)] Lot 2 
(Cell Signalling) 
Pre-treatment Citrate microwave pre-treatment EDTA and pressure cooking 
Antibody 
concentration 
1/50 1/50 
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Antibody incubation and staining procedure 
For the following steps the rabbit IgG VECTASTAIN Elite® ABC kit (VECTOR 
Laboratories) was used. The sections were incubated in TBS pH 7.6 for 5 min, 
following this they were blocked with goat serum for 10 min. The blocking serum 
was replaced by the appropriate primary antibodies in TBS pH 7.6, except for 
the no primary antibody control, where the primary antibody was replaced by 
TBS and incubated, overnight. 
The slides were then washed in TBS pH 7.6 twice for 5 min. Next, all slides 
were covered with the anti-rabbit secondary antibody (VECTASTAIN ABC kit) 
for 30 min. The slides were washed as before and the tertiary antibody 
(VECTASTAIN ABC kit) was added and incubated for 30 min. The slides were 
washed again. 
The VECTOR® NovaRED™ peroxidase substrate kit (Vector Laboratories) was 
used to stain the tissue sections at RT. After 4 min staining, the slides were 
washed in water. Next they were counterstained in Mayers Haematoxylin 
(Hematoxylin 2g, Potassium alum 100g, Sodium alum 0.4g, Chloral hydrate 
100g, citric acid 2g in 2 L distilled water) for 30 sec. This was followed by 
washing of the slides under running water. The slides were dehydrated through 
graded alcohols (70%-99%) and mounted with DPX mounting medium (Sigma 
Aldrich). 
4.3.1.2. HercepTestTM 
 
The staining of the matched forty cases was performed using the HercepTestTM. 
As in the previous IHC staining protocol, HER2 3+ graded tumour section 
positive controls (provided by the Pathology Department at the University of 
Patras, Patras, Greece) and no primary antibody controls were included in 
every experiment. The staining was performed according to the manufacturers 
protocol. 
Briefly, the tissue slides were deparaffinised in xylene and then placed in 
absolute ethanol. Next they were incubated twice in 95% ethanol for 3 min and 
washed in distilled water. The sections were then immersed in the pre-heated 
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(to 95-99 °C) Epitope Retrieval Solution and incubated for 40 min at 95-99 °C. 
The slides were allowed to cool in the Epitope Retrieval Solution for 20 min at 
RT. They were then rinsed in diluted Wash Buffer. After tapping off excess 
buffer and carefully removing any remaining liquid around the tissue, the tissue 
section was encircled with a Dako Pen. Three drops of Peroxidase-Blocking 
Reagent were added to cover the specimen and incubated for 5 min. The 
specimens were gently rinsed with distilled water and placed in fresh buffer. 
Excess buffer was taped off and the slides wiped as before. Specimens were 
covered with 3 drops of Anti-HER2 Protein or Negative Control Reagent and 
incubated for 30 min. Again they were rinsed with Wash Buffer and placed in 
fresh buffer. The excess buffer was taped off and the slides wiped. The 
specimens were next covered with 3 drops of Visualization Reagent and 
incubated for 30 min. The slides were rinsed and wiped as before. The 
specimens were then covered with 3 drops of the Substrate-Chromogen 
Solution (DAB). After 10 min incubation, the slides were gently rinsed with 
distilled water. The slides were counterstained with hematoxylin and rinsed in 
distilled water. Lastly the slides were mounted and a coverslip applied. 
 
4.3.1.3. Scoring of immunohistochemistry (IHC) 
 
The sections were assessed according to the standard recommendation for 
HER2 assessment in breast cancer, depicted by figure 4.1 (Rakha et al., 2015). 
A score of 0 was assigned if no membrane staining or only incomplete 
membrane staining in <10% of invasive tumour cells was observed; 1+ was 
assigned for faint incomplete membrane staining of >10% of tumour cells. Both 
scores are considered HER2-negative. The score of 2+ was given when a weak 
to moderate complete membrane staining was observed in >10% of tumour 
cells or strong complete membrane staining in ≤ 10% of tumour cells. This 
score is considered borderline and a second test such as FISH or CISH for 
HER2 gene amplification should be performed. If the borderline scoring remains 
an alternative tumour section should be assessed. A HER2-positive or 3+ 
scoring was given to tumour sections with a strong (intense and uniform) 
complete membrane staining in >10% of invasive tumour cells.  
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The tissue sections were examined and scored by our collaborator Dr Helen 
Kourea (University of Patras, Patras, Greece). Images were taken at a number 
of magnifications in the clinical pathology at Royal Victoria Infirmary, Newcastle 
with a BX51 Olympus microscope, by Dr H. Kourea. Some images were also 
taken on a BX43 laboratory microscope (Olympus). 
Figure 4.1: Immunohistochemistry scoring scheme for HER2 status in breast tumours.  
Adapted from (Rakha et al., 2015). 
 
4.3.2. HER2 chromogenic in-situ hybridisation (CISH) 
 
A total of 19 slides were stained using the HER2 CISH pharmDx kit (Dako) 
(Table 4.3). These tissue sections were chosen as they had been identified as 
discrepant cases, in regard to the results obtained by the three different IHC 
antibodies, by Dr H. Kourea. Additionally, cases were included which showed 
no discrepancy to initial clinical assessment.  
The HER2 CISH pharmDx kit stains tissue sections for the HER2 gene with a 
red chromogenic signal and the centromeric region of chromosome 17 with a 
blue chromogenic signal. The HER2 probe is a Texas Red-labeled DNA probe 
that covers a 218 kb region which includes the HER2 gene on chromosome 17. 
A mixture of fluorescein-labeled peptide nucleic acid probes were used to target 
the centromeric region of chromosome 17 (CEN-17). The fluorescent probe 
signals were converted to chromogenic signals. The probes were bound by 
antibodies; anti-FITC conjugated with horseradish peroxidase (HRP) and anti-
Texas Red conjugated with alkaline phosphatase (AP). Incubation with the 
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substrates, Red and Blue Chromogen solutions yielded the red and blue signals 
at the probe site.  
The 19 stained tissue sections included a primary probe negative control and 
two HER2 3+ positive controls (provided by the Pathology Department of the 
University of Patras, Patras, Greece). The tissue sections used here were 
derived from the same tumours as used in section 4.3.1 for IHC. The tissue 
sections were provided by the Breast Cancer Now Tissue Bank and had been 
previously clinically assessed. Their original grading is indicated in table 4.3. 
Four samples were originally grouped as ER/HER2+ (group 2), 3 each were 
grouped ER/HER2- and ER+/HER2- (group 3 and 4). Five samples were 
grouped ER-/HER2+ (group 5). Additionally, one section from a reduction 
mammoplasty was included. Similar to the IHC staining here too 4 µm sections 
were used. 
 
Table 4.3: List of breast cancer tissue sections used for CISH. 
 
 
 
 
 
 
 
 
 
 
 
 
The ‘*’ sample was not considered discrepant by IHC. 
 
Group IHC-ID 
Group 2        ER+, HER2+   Grade 3     
Primary      NST/IDC 
IHC-1 
IHC-2 * 
IHC-3 
IHC-4 
Group 3                ER-,HER2-    Grade 
3     Primary     NST/IDC 
IHC-5 
IHC-6 
IHC-7 
Group 4             ER+, HER2-    Grade 3     
Primary     NST/IDC  
IHC-8 
IHC-9 
IHC-10 
Group 5              ER-, HER2+   Grade 3     
Primary     NS/IDC 
IHC-11 
IHC-12 
IHC-13 
IHC-14 
IHC-15 
Reduction mammoplasty   IHC-16 
Positive control 
IHC-C1 
IHC-C2 
No primary antibody IHC-N1 
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The staining was performed according to the manufacturer’s protocol. Briefly, 
the tissue slides were incubated at 60°C for 1h, then deparaffinised in a xylene 
bath and rehydrated stepwise in ethanol baths, last placed into Wash Buffer 1. 
For the pre-treatment a microwave oven was used. The slides were placed into 
a plastic jar filled with pre-treatment solution and microwaved 2 x 5 min. Then 
the slides were placed into a second preheated jar of pre-treatment solution and 
left to cool under light agitation for 15 min. The slides were then washed twice 
with Wash Buffer 1. After removal of any excess Wash Buffer 1 from the tissue 
sections, 5 drops of ice-cols pepsin were added to each slide. The slides were 
then incubated at 37°C for 2 min. The pepsin was removed and the tissue 
sections washed twice with Wash Buffer 1. Next the sections were dehydrated 
stepwise in ethanol baths from 70-95%. The slides were then left to air dry. 
Using a fume hood the HER2/CEN-17 Probe Mix was put onto the middle of the 
tissue section, a glass coverslip was placed on top and all air bubbles removed. 
Coverslip Sealant was used to seal the coverslip. The slides were then placed 
in a humid chamber and denatured for 15 min at 82°C. Hybridization with the 
probes was allowed to occur, with the slides incubating overnight at 45°C 
overnight in a humid chamber. 
Jars of Stringent Wash Buffer were preheated in a water bath to 65 (±2) °C. 
After removing the slides from the hybridisation chamber, the Coverslip Sealant 
and the cover slips were removed. The slides were then incubated in the 
Stringent Wash Buffer at 65 (±2) °C for exactly 10 min. The slides were then 
placed in Wash Buffer for 3 minutes at RT, the wash was repeated. The wash 
was then repeated with Wash Buffer 2. 
Excess buffer was removed and Peroxidase Block was added onto the slides. 
After 5 min incubation the slides were washed twice in Wash Buffer 2. Again, 
excess buffer was removed and CISH Antibody Mix was added onto the slides. 
After 30 min incubation in a humid chamber, the slides were washed twice in 
Wash Buffer 2. 
The excess buffer was removed and the tissue sections covered with Red 
Chromogen Solution. After 10 min incubation in a humid chamber, two washes 
in Wash Buffer 2 were performed. The specimen were covered with Blue 
Chromogen Solution and incubated for 10 min, after excess buffer was 
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removed. The slides were washed twice in Wash Buffer 2. The tissue sections 
were counterstained, by immersing them for 1min 10 sec in hematoxylin. The 
slides were then rinsed in Wash Buffer 2 and washed for 5 min in fresh Wash 
Buffer 2. This was followed by two 3 min washes in water. The sections were 
dried at 37°C for approximately 30 min. The coverslips were mounted with CISH 
Mounting Medium and left to dry at RT for ~ 1 h. The slides were stored under 
dry conditions until analysis. 
 
4.3.3. Scoring of HER2 CISH 
 
The whole tissue sections were scanned by the Leica SCN400 Slide Scanner 
and Autoloader system in the Newcastle Biobank facility. Areas of interest were 
identified and images up to 40 x magnification were gained from the scanning 
images. Matching images were taken to ones obtained by IHC. To count the 
exact number of stained probes per cell the slides were observed at 40 x 
magnification on a BX43 laboratory microscope (Olympus). The manufacturers 
signal counting guide (Figure 4.2) was used to guide scoring of tissue sections. 
Twenty distinct nuclei were counted from the main tumour area. For each the 
red HER2 gene signals and the blue chromosome 17 centromere signals were 
counted. The HER2/Cen-17 signal ratio is calculated. In addition the average 
HER2 signal was taken into consideration. 
The final HER2 score was assigned according to the updated (2013) 
recommendation for HER2 assessment in breast cancer in the UK and USA 
(Rakha et al., 2015). A HER2/Cen-17 signal ratio <2.0 and an average HER2 
copy number <4.0 signals per cell should be considered as HER2 negative. 
According to the HER2 CISH pharmDxTM (DAKO) signal counting guide, which 
is based on the pre-2013 recommendations, a HER2/Cen-17 signal ratio 
between 1.80 - 2.20 is considered borderline and another 20 nuclei were 
counted. Rakha et al. recommend additional cells to be counted for a ratio 
between 1.80 - 1.99. Additionally, they consider a ratio of <2.0 with an average 
HER2 copy number between 4.0 - 6.0 as borderline (Rakha et al., 2015). 
Borderline cases should be re-examined with a second method and possibly an 
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additional section of the tumour should be studied. The tumour is considered 
HER2 positive by the HER2 CISH pharmDxTM signal counting guide with a ratio 
above 2.2. The new guidelines suggest the cut off to be at 2.0. Furthermore, 
they suggest to consider cases with a HER2 copy number ≥6.0, independent of 
the HER2/Cen-17 ratio to be HER2-positive. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2: HER2 CISH pharmDx
TM
 (DAKO) signal counting guide.  
The red dots indicate the HER2 gene amplification signals and the blue dots the centromeric 
region of chromosome 17 (CEN-17) signals. The image was extracted from HER2 CISH 
pharmDx
TM
 signal counting guide (DAKO). 
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4.4. Results  
 
4.4.1. Immunohistochemistry for HER2 protein expression and 
localisation in human breast tumours 
 
The serial tissue sections from 40 tumours from the Breast Cancer Now Tissue 
Bank as well as HER2 3+ graded positive controls were stained with the C-
terminal and N-terminal antibodies as well as the HercepTestTM. The specific 
epitope for the N-terminal antibody has not been disclosed, although the 
product datasheet indicates it to bind near the N-terminus. The C-terminal 
HER2 antibody binds to an epitope around amino acid 1222 and the 
HercepTestTM was shown to bind to the C-terminus of HER2, at amino acids 
1244 to 1254 (Schrohl et al., 2011). The tissue sections were examined by a 
clinical pathologist Dr H. Kourea (Associate Professor of Pathology, University 
of Patras, Patras, Greece).  
 
Figure 4.3: C-terminal antibody controls. 
Examples of the controls used with each experiment are shown. A, shows the no primary 
antibody control. B, HER2-positive control on HER2 3+ graded tumour section. 
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Figure 4.3 A, shows the no primary antibody control and B, the 3+ positive 
control case with the C-terminal antibody. No staining was observed for the no 
primary antibody control, but a strong membrane staining was observed in the 
positive control. Similarly, figure 4.4 A, shows the no primary antibody control 
and B the positive control for the N-terminal antibody. The antibody worked as 
expected, giving a strong membrane staining in the positive control. The 
controls for the HercepTestTM are shown in figure 4.5. For the no primary 
antibody control a colon tissue section was used (provided by the Pathology of 
the Royal Victoria Infirmary, Newcastle). No unspecific staining can be 
observed in the no primary antibody control (Figure 4.5 A) and the positive 
control shows strong complete membrane staining (Figure 4.5 B). The 
manufacturer supplied controls were also used (Figure 4.5 C, D, E). The 
controls consisted of three cell lines. HER2-overexpressing SKBR3 cells 
showed complete membrane staining in all cells (Figure 4.5 C). In figure 4.5 D 
weak partial membrane staining of MDA-175 cells can be observed typical for 
1+ HER2 cells, and the MDA-231 cell line shows no HER2 staining. 
 
Figure 4.4: N-terminal antibody controls. 
Examples of the controls used with each experiment are shown. A, shows the no primary 
antibody control. B, HER2 3+ staining for the HER2 positive control tumour case. 
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Figure 4.5: HercepTest
TM
 controls. 
Examples of the controls used with each experiment are shown. A, shows the no primary 
antibody control performed on a colon tissue section. B, HER2-positive control on HER 3+ 
graded tumour section. C, D and E show the manufacturer supplied controls. C, HER2 3+ 
staining of SKBR3 cells. D, HER2 1+ staining of MDA-MB-175 cells. E, HER2 0 staining of 
MDA-MB-231 cells. 
 
The summary of Dr H Kourea’s assessment of the tissue sections is shown in 
table 4.4. It has to be noted that some background staining was observed in a 
few cases for all antibodies. Antibody concentrations were adjusted for 
optimisation where possible. The HercepTestTM was performed on all HER2-
positive tumours, but not yet on all HER2-negative tumours.  
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Group 3 (HER2/ER-negative) showed HER2 0 staining for all tumours with the 
C-terminal antibody and where performed also with the HercepTestTM. Only the 
N-terminal antibody showed some discrepancies. It stained G3S1 and G3S8 as 
HER2 1+. HER2 0 and 1+ cases are considered HER2 negative. Additionally, 
cases G3S7 and G3S10 showed HER2 2+ staining. As equivocal cases are 
reflex tested for HER2 gene amplification. These cases were tested with CISH 
and the results will be presented in the next section. Overall the results from 
IHC matched the initial clinical classification of the group 3 tumours. Similar 
observations were made for group 4 (HER2-negative/ER-positive). The C- and 
N-terminal antibodies showed HER2 negative (HER2 0) staining for all tumours 
except G4S3, which showed a slight HER2 1+ staining. The HercepTestTM was 
performed on 4 tumours, of these G4S5 was HER2 1+ and G4S5 focally HER2 
2+.  
The two HER2 positive groups showed more complex results. In group 2 
(HER2/ER-positive) the HercepTestTM showed HER2 3+ staining for 6 tumours, 
3 tumours were HER2 2+ and one tumour was HER2 0. With the other two 
antibodies no HER2 3+ staining was observed with the exception of G2S2, 
G2S3 and G2S7. G2S2 showed focal HER2 3+ staining with HercepTestTM, 
focal 2+ staining with the C-terminal antibody and 3+ with the N-terminal 
antibody. This tumour also showed HER2 3+ staining in tumour cells invading 
lymphatic vessels. In contrast G2S3 also showed focal HER2 3+ staining with 
the N-terminal antibody, however it only showed a HER2 2+ staining with the 
HercepTestTM and the C-terminal antibody. It should be noted that both G2S2 
and G2S3 showed a heterogeneous population of tumour cells in regard to 
HER2 status. G2S7 showed 3+ staining with the HercepTestTM and the C-
terminal antibody, but only a 2+ staining by the N-terminal antibody. Tumour 
heterogeneity was also observed in tumours G2S5 and 6. The tumour G2S10 
showed a clear HER2 3+ status with the HercepTestTM, however it the other 
antibodies showed no or only very weak staining. Additionally, one tumour 
G2S8 was assessed as HER2-negative by all antibodies.  
 
 
Chapter 4: Characterising HER2 in human breast tumours 
148 
 
Table 4.4: Results from immunohistochemistry of 40 human primary ductal carcinomas. 
 ID HercepTest
TM C-terminal 
antibody 
N-terminal 
antibody 
Comment IHC ID 
Group 2: 
ER+/HER2+ 
G2S1 3 2 2(F)  IHC-4 
G2S2 
3 (F) 
2 (F), LVI 
3+ 
3 
Tum. heter.  
G2S3 2(F) 2 3(F) Tum. heter.  
G2S4 2 1(F) 2 Tum. heter.  
G2S5 3 2 2 Tum. heter. IHC-2 
G2S6 2 2 2 Tum. heter.  
G2S7 3 3 2   
G2S8 0 1 2  IHC-3 
G2S9 3 2 2   
G2S10 3 1 0  IHC-1 
Group 3: 
ER-/HER2- 
G3S1 NA 0 1   
G3S2 NA 0 0   
G3S3 NA 0 0  IHC-5 
G3S4 NA 0 0   
G3S5 0 0 0   
G3S6 0 0 0   
G3S7 0 0 2  IHC-6 
G3S8 NA 0 1   
G3S9 NA 0 0   
G3S10 NA 0 2  IHC-7 
Group 4: 
ER+/HER2- 
G4S1 NA 0 0   
G4S2 NA 0 0   
G4S3 0 0 1  IHC--8 
G4S4 0 0 0   
G4S5 2 (F) 0 0  IHC-9 
G4S6 1 0 0  IHC-10 
G4S7 NA 0 0   
G4S8 NA 0 0   
G4S9 NA 0 0   
G4S10 NA 0 0   
Group 5: 
ER-/HER2+ 
G5S1 3 1 3   
G5S2 0 0 0  IHC-11 
G5S3 3 2 3   
G5S4 1 0 2 Tum. heter. IHC-13 
G5S5 3 3 3   
G5S6 3 1 3  IHC-12 
G5S7 3 0 3 Tum. heter. IHC-14 
G5S8 2 2 2   
G5S9 3 2 3   
G5S10 1 0 3  IHC-15 
“LVI”, lymphovascular space invasion; “F”, focal staining and “Tum. heter.”, tumour 
heterogeneity. 
In group 5, six tumours were stained as HER2 3+ by the HercepTestTM. These 
tumours also showed 3+ staining with the N-terminal antibody. However the C-
terminal antibody only confirmed the 3+ staining for G5S5, the other tumours 
only showed weak staining. The other case of concordant staining was 
observed for G5S8, which showed HER2 2+ staining with all three antibodies. 
G5S2 showed no HER2 staining with any of the antibodies. HER2 negative 
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staining was observed with the HercepTestTM and the C-terminal antibody, but 
equivocal staining was observed with the N-terminal antibody for G5S4. G5S10 
was also stained HER2 negative with the HercepTestTM and the C-terminal 
antibody, but it showed HER2 3+ staining with the N-terminal antibody. The 
HER2 staining of the tumour was heterogeneous in G5S4 and 7. 
Some tumours showed borderline (HER2 2+) results or discrepancy between 
the staining results of the 3 antibodies. These discrepant cases as well as some 
HER2-negative tumours were used for further studies. For ease of use new ID’s 
were assigned, these are indicated in table 4.4. 
 
4.4.2. HER2 gene amplifications in human breast tumours 
 
This was the first time the HER2 CISH pharmDxTM kit was successfully 
performed in our laboratory. To verify that the CISH worked and no unspecific 
staining took place different controls were used. Figure 4.6 shows the primary 
probe negative control for which an ER-negative, HER2-positive grade 3 ductal 
carcinoma section was used. It was part of the same Breast Cancer Now Tissue 
Bank cohort as the tested tissue sections. The negative control showed no 
HER2 gene or centromere 17 signals. A normal breast tissue section is shown 
in figure 4.7. Both the HER2 and CEN-17 probe are shown to bind specifically. 
Cells of normal ducts show two HER2 gene and CEN-17 signals per nucleus. 
To further verify the correct positive staining with the assay two HER2 3+ ductal 
carcinomas (provided by the Department of Pathology of Unversity of Patras, 
Patras, Greece) were included. Figure 4.8 shows images of the two positive 
controls. IHC-C1 was assessed to have a HER2 gene amplification of 6.55 with 
a CEN-17 signal of 2.3 and thereby a HER2/CEN-17 ratio of 2.85. The second 
positive control, IHC-C2 was assessed to have a HER2 gene amplification of 
9.6 with a CEN-17 signal of 2.15 and thereby a HER2/CEN-17 ratio of 4.47. 
Both are clearly HER2-positive and confirm the previous clinical assessment 
and thereby our assay. 
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Figure 4.6: HER2 CISH pharmDx
TM
: no primary probe control 
A, shows the whole tumour section stained without the primary probes. B, tumour is magnified 
and nuclei can be seen, but no staining for HER2 or CEN-17 can be observed. 
 
 
. 
Figure 4.7: HER2 CISH staining on normal breast tissue.  
A, shows the whole tissue section. B, in the ductal cells both HER2 and Cen-17 signals can be 
observed. Normal diploid signals can be observed. A few stromal cells nuclei can be observed, 
but they are too small to determine HER2 gene status. 
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Figure 4.8: HER2 CISH staining showing HER2 gene amplification on the HER2 3+ 
positive control tumours.  
A, shows the whole tissue section. B, in the ductal cells both HER2 and Cen-17 signals can be 
observed. Normal diploid signals for centromere 17 (blue dots) can be observed, while large 
clusters of red signals corresponding to the HER2 gene are seen, indicating HER2 gene 
amplification. 
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Following the assessment of the controls, the staining of the 15 tumour cases 
was observed. The tissue sections from the Breast Cancer Now Tissue Bank 
originate from different hospitals throughout the UK. Although, the preservation 
of the tissue sections follows strict guidelines by the Breast Cancer Now Tissue 
Bank minor variations remain (Breast Cancer Now Tissue Bank, 2010). All 
samples were stained at the same time, but differences in tissue integrity and 
digestion of nuclei between tissues were observed. This could have impacted 
the assessment of borderline cases.  
 
Table 4.5: Results of the HER2 CISH staining for the human invasive ductal carcinomas. 
 
 
 
 
 
 
 
 
 
 
Table 4.5 summarises the CISH scores of the grade 3 invasive primary ductal 
carcinomas studied in this chapter. Four samples were originally grouped as 
ER/HER2-positive (group 2), 3 each were grouped as ER/HER2-negative and 
ER-positive/HER2-negative (group 3 and 4) and 5 samples were grouped as 
ER-negative/HER2-positive (group 5). The original HER2 status for the samples 
of group 2, 3 and 4 was confirmed by our CISH scoring, except for IHC-1, which 
was clinically assessed to be a HER2-positive tumour, but was HER2-negative 
to borderline in our CISH assay. However in group 5, only IHC-12 and ICH-14 
Group 
IHC-ID HER2 gene 
amplification 
CEN-17 HER2/CEN-17 HER2 status 
Group 2: 
ER+/HER2+ 
IHC-1 2.98 1.65 1.95 B/- 
IHC-2 5.58 2.48 2.25 + 
IHC-3 5.2 2.3 2.26 + 
IHC-4 8.35 2.05 4.07 + 
Group 3: 
ER-/HER2-   
IHC-5 1.7 1.65 1.03 - 
IHC-6 2.7 1.75 1.5 - 
IHC-7 2 1.9 1.05 - 
Group 4: 
ER+/HER2-     
IHC-8 2.75 2.15 1.3 - 
IHC-9 3.05 2.05 1.49 - 
IHC-10 2.35 1.65 1.42 - 
Group 5: 
ER-/HER2+    
IHC-11 1.3 1.2 1.08 - 
IHC-12 5.2 1.7 3.06 + 
IHC-13 2.3 1.85 1.24 - 
IHC-14 4.13 1.9 2.43 + 
IHC-15 2.83 1.25 2.02 B/+ 
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were scored as HER2-positive by our CISH. The tumour sections IHC-11, 13 
and 15 were originally assessed as HER2-positive, however by CISH IHC-11 
and 13 were classified as HER2-negative. The tumour IHC-15 shows a 
HER2/CEN-17 ratio of 2.02, which would make this a HER2 positive case, 
however this ratio is caused by loss of chromosome 17 centromere signals 
(CEN-17: 1.25). The HER2 gene count is only 2.83 and with a normal CEN-17 
signal of 2, a tumour would be clearly HER2 negative.  
 
4.4.3. Comparison of HER2 protein levels and HER2 gene 
amplification in a cohort of human breast tumours 
 
In the two previous sections the outcomes from the IHC staining of tumour 
sections for the expression and localisation of HER2 proteins, and the outcome 
from the HER2 CISH pharmDxTM assay for HER2 gene amplification were 
discussed. Here the tumours that have been scored by IHC and CISH were 
more closely examined. As was mentioned before, the tissue sections had been 
clinically assessed for their HER2 status before they were received from the 
Breast Cancer Now Tissue Bank. Table 4.5 shows an overview of the IHC and 
CISH results grouped according to the original tumour classification.  
Group 2 are tumours that have been clinically assessed as HER2- and ER-
positive. The CISH results for tumours IHC-2, 3 and 4 matched the clinical 
HER2-positive status. IHC-1 was HER2-negative to borderline by CISH. Figure 
4.9 shows representative images of the IHC and CISH assays for IHC-1. A 
borderline case is generally assessed by a second method. It should be noted 
that although the HER2/CEN-17 ratio was 1.95 - borderline, the HER2 gene 
copy number per cell was actually less than 3 and this was suggested to be 
considered HER2-negative (Rakha et al., 2015). The HercepTestTM confirmed 
the tumour as HER2-positive status (Figure 4.9, A). However the other two 
antibodies (C-and N-terminal) also showed a weak cytoplasmic positivity but no 
membranous staining, a finding that is scored as HER2-negative. IHC-2 and 4 
are clearly HER2 positive by both CISH and HercepTestTM, although the other 
antibodies only gave a score of HER2 2+. For IHC-2 tumour heterogeneity was 
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observed in the IHC experiments. IHC-4 is a case of strong HER2-gene 
amplification with a HER2 copy number of 8.35 per nucleus, this is also clearly 
visible in figure 4.11 III. Initial observation of the C-terminal staining (Figure 4.11 
A) would indicate strong staining, however clinical HER2 scores are assigned 
according to the extent of complete membranous HER2 staining. It should be 
noted that the HercepTestTM also showed some diffuse cytoplasmic staining 
(Figure 4.11 A). IHC-3 is a very interesting case as it shows a clear HER2-
positive score by CISH, but is HER2-negative by IHC (Figure 4.10). A general 
HER2-gene amplification was observed, however the strongest amplification 
was observed in clusters of tumour cells surrounded by stromal cells (Figure 
4.10 IV). The tissue morphology is very similar to the area which showed HER2 
2+ staining with the N-terminal antibody.  
The group 3 (HER2/ER-negative) tumours were confirmed by CISH to be 
HER2-negative. The HercepTestTM has not yet been performed on IHC-5 and 7. 
All three tumours were scored HER2-negative for the C-terminal antibody. Only 
with the N-terminal antibody was a stronger HER2 2+ staining observed for 
IHC-6 and 7. Group 4 contains tumours with a HER2-negative and ER-positive 
status. IHC-8 and 10 were classified as HER2-negative by both CISH and IHC. 
They showed no more than a 1+ staining with one antibody. IHC-9 was also 
scored as HER2-negative by CISH and IHC, however it should be noted that 
the HercepTestTM showed focal HER2 2+ staining. 
The tumours in group 5 were clinically assessed to be HER2-positive, but ER-
negative. All three antibodies used showed no or minimal HER2 staining for 
IHC-11. The CISH assay also scored this tumour as HER2-negative (Figure 
4.12 B). There is no indication in the tissue sections on why this tumour was 
initially assessed as HER2-positive. Similarly, IHC-13 was also graded 1+ by 
HercepTestTM and 0 with the C-terminal antibody. Only the N-terminal antibody 
gave a higher score of 2+ (Figure 4.13 A). The HER2-negative IHC staining 
matched the score of the CISH assay. The HER2 gene was present at a normal 
level in most nuclei, however as can be observed in figure 4.13, IV in a few 
tumour cells HER2-gene amplification was shown. This matches the 
observation of tumour heterogeneity by IHC. The tumour IHC-15 only stained as 
HER2 3+ with the N-terminal antibody. Both the C-terminal antibody and the 
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HercepTestTM only stained the tumour weakly (Figure 4.15 A). The CISH score 
for this case was borderline to HER2 positive. Only a minor HER2-gene 
amplification was observed in some cells and the CEN-17 average indicated 
chromosome 17 monosomy. However some dispersed nuclei showed stronger 
HER2-gene amplification. An example is shown in 4.15 IV. IHC-12 and 14 had a 
HER2-positive CISH score. The results for IHC-14 are shown in figure 4.14. 
Both tumours showed HER2 3+ staining with the HercepTestTM and the N-
terminal antibody. In contrast both only showed weak staining with the C-
terminal antibody. It should be noted that IHC-14 showed focal staining with 
HercepTestTM and diffuse staining with the N-terminal antibody (Figure 4.14). 
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Figure 4.9: IHC and CISH images for the human breast cancer case IHC-1. 
The table summarises the findings from IHC and CISH experiments. A, shows images of serial 
sections of the same tissue stained with the HercepTest
TM
, C-terminal and N-terminal HER2 
antibody. HER2 status is indicated for each image. B, shows images from CISH staining. I, 
shows the whole tissue section and the arrow indicates the area from which the images were 
taken. II, and III, show the same area at different magnifications. 
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Figure 4.10: IHC and CISH images for the human breast cancer case IHC-3. 
The table summarises the findings from IHC and CISH experiments. A, shows images of serial 
sections of the same tissue stained with the HercepTest
TM
, C-terminal and N-terminal HER2 
antibody. HER2 status is indicated for each image. B, shows images from CISH staining. I, 
shows the whole tissue section and the arrow indicates the area from which the images were 
taken. II, and III, show the same area at different magnifications. IV, shows high magnification of 
HER2-gene amplified cells. 
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Figure 4.11: IHC and CISH images for the human breast cancer case IHC-4. 
The table summarises the findings from IHC and CISH experiments. A, shows images of serial 
sections of the same tissue stained with the HercepTest
TM
, C-terminal and N-terminal HER2 
antibody. HER2 status is indicated for each image. “F”, indicates focal staining. B, shows 
images from CISH staining. I, shows the whole tissue section and the arrow indicates the area 
from which the images were taken. II, and III, show the same area at different magnifications. 
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Figure 4.12: IHC and CISH images for the human breast cancer case IHC-11. 
The table summarises the findings from IHC and CISH experiments. A, shows images of serial 
sections of the same tissue stained with the HercepTest
TM
, C-terminal and N-terminal HER2 
antibody. HER2 status is indicated for each image. B, shows images from CISH staining. I, 
shows the whole tissue section and the arrow indicates the area from which the images were 
taken. II, and III, show the same area at different magnifications displaying absence of 
amplification. 
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Figure 4.13: IHC and CISH images for the human breast cancer case IHC-13. 
The table summarises the findings from IHC and CISH experiments. A, shows images of serial 
sections of the same tissue stained with the HercepTest
TM
, C-terminal and N-terminal HER2 
antibody. HER2 status is indicated for each image. B, shows images from CISH staining. I, 
shows the whole tissue section and the arrow indicates the area from which the images were 
taken. II, and III, show the same area at different magnifications. IV, shows nuclei with an 
increased HER2 gene copy number. 
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Figure 4.14: IHC and CISH images for the human breast cancer case IHC-14. 
The table summarises the findings from IHC and CISH experiments. A, shows images of serial 
sections of the same tissue stained with the HercepTest
TM
, C-terminal and N-terminal HER2 
antibody. HER2 status is indicated for each image. “F”, indicates focal staining. B, shows 
images from CISH staining. I, shows the whole tissue section and the arrow indicates the area 
from which the images were taken. II, and III, show the same area at different magnifications. 
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Figure 4.15: IHC and CISH images for the human breast cancer case IHC-15. 
The table summarises the findings from IHC and CISH experiments. A, shows images of serial 
sections of the same tissue stained with the HercepTest
TM
, C-terminal and N-terminal HER2 
antibody. HER2 status is indicated for each image. B, shows images from CISH staining. I, 
shows the whole tissue section and the arrow indicates the area from which the images were 
taken. II, and III, show the same area at different magnifications. IV, shows an example of one 
single cell at high magnification with HER2-gene amplification. 
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4.4.4. HER2 splice variant expression in selected, discrepant breast 
tumour cases 
 
In the previous sections a cohort of primary invasive ductal carcinomas were 
characterised. Discrepancies were observed between IHC and CISH results in 
a few tumour cases. To determine if these discrepancies might be due to HER2 
splice variants PCRs were performed. From the HER2-/ER-positive breast 
tumour group samples IHC-1, 3 and 4 were used and from the HER2-
positive/ER-negative breast tumour group samples IHC-13, 14 and 15 were 
used. The RNA quality of IHC-11 was not good enough to produce cDNA that 
could be used in this study. SKBR3 cDNA was included in each experiment as 
a control and for comparison. The levels of HER2 splice variants Herstatin, 
p100 and Δ16HER2 were determined by conventional PCR. Additionally, PCRs 
for wild type HER2 and the housekeeping gene β-actin were performed.  
 
 
Figure 4.16: HER2 splice variant levels in discrepant primary invasive ductal carcinoma 
cases. 
Three samples from group 2 and three samples from group 5 were used. PCRs used were 
performed for HER2 splice variants Herstatin, p100 and Δ16HER2, as well as wild type HER2 
and the housekeeping gene β-actin. 
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Figure 4.16 shows the levels of the HER2 splice variants. The β-actin levels 
were comparable, only IHC-4 showed a decreased level of β-actin. Wild type 
HER2 was strongly expressed in IHC-1, 4, 14 and 15, but only weakly 
expressed in IHC-3 and IHC-13. Δ16HER2 was weakly expressed in all 
tumours and in a consistent ratio with wild type HER2. Herstatin is present in all 
samples, with the highest levels in IHC-1, 4 and 15. Similarly, p100 can also be 
observed in every tumour. The level is increased compared to the other 
tumours in IHC-1, but the strongest band can be observed for IHC-15. It should 
be noted that the PCRs for all three HER2 splice variants were carried out at 
the same cycle number.  
 
Table 4.7: Summary of CISH and IHC results for samples used in PCR. 
  HER2 
gene 
HER2/ 
CEN-17 
HER2 
status 
Hercep 
TestTM 
C-term. 
Antibody 
N-term. 
Antibody 
Group 2: 
HER2+/
ER+ 
IHC-1 2.98 1.95 B/- 3 1 0 
IHC-3 5.2 2.26 + 0 1 2 
IHC-4 8.35 4.07 + 3 2 2(F) 
Group 5: 
HER2+/
ER- 
IHC-13 2.3 1.24 - 1 0 2 
IHC-14 4.13 2.43 + 3 0 3 
IHC-15 2.83 2.02 B/+ 1 0 3 
 “B”, borderline. “F”, focal staining. 
 
Comparing the PCR results to the results from the previous sections (Table 4.6) 
showed the following trends. The wild type HER2 levels detected by PCR 
roughly matched the observations made with the HercepTestTM. Interesting 
observations can be made for levels of p100 and Herstatin. IHC-3 and 13 
showed clear bands for p100 and Herstatin as well as a HER2 2+ score with the 
N-terminal antibody, but not the other antibodies. The highest level of p100 
could be observed for IHC-15, which by IHC showed a 3+ score with the N-
terminal antibody. Although wild type HER2 is expressed at the mRNA level, the 
HercepTestTM gave a very weak staining in this tumour. 
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4.5. Discussion 
 
This chapter is part of a larger study that investigates the importance of HER2 
splice variants in the assessment of breast cancer. For an optimal treatment of 
patients suffering from breast cancer, an accurate assessment of the main 
biomarkers (ER, PR and HER2) has to be made. The HER2 status is routinely 
clinically assessed and the methods used show a relatively high rate of 
accuracy [reviewed in (Sapino et al., 2013)]. However tumour heterogeneity and 
deviations between HER2 assessment methods can still be observed (Miller et 
al., 2004; Vance et al., 2009; Sapino et al., 2013; Carvajal-Hausdorf et al., 
2015). As was discussed in the introduction, HER2 genetic heterogeneity is 
defined as 5-50% of infiltrating tumour cells with a HER2/CEN-17 ratio of ≥2.2 
(Vance et al., 2009). Tumour heterogeneity can be subdivided in tumours with a 
localized subpopulation of HER2 overexpressing cells and in tumours which 
have two populations of cells that are present throughout the tumour (Sapino et 
al., 2013).  
 
4.5.1. Discrepant IHC and CISH staining in invasive ductal 
carcinomas 
 
In this study a cohort of primary invasive ductal carcinomas provided by the 
Breast Cancer Now Tissue Bank was characterised for their HER2 status with 
two clinically used tests. The HercepTestTM was used to study protein 
expression and localisation, and the HER2 CISH pharmDxTM assay was used to 
measure HER2-gene amplification. Additionally, two HER2 antibodies with 
differing epitopes were utilised and compared to the HercepTestTM. The 
tumours were characterised with the help of experienced clinical pathologist Dr 
H. Kourea. The findings in this study matched the initial clinical assessment for 
all HER2-negative tumours. Only IHC-9 showed a focal HER2 2+ score with the 
HercepTestTM and IHC-6 and 7 showed HER2 2+ staining with the N-terminal 
antibody. As is undertaken in clinic, these tumours were assessed for their 
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HER2-gene amplification status by CISH. They were clearly scored as HER2-
negative, confirming their clinically determined HER2 status.  
The two groups of HER2-positive tumours (group 2 and 5) showed more 
complex results. Twelve tumours showed HER2 3+ staining with the 
HercepTestTM, but only one tumour showed 3+ staining with all antibodies. In 
the other breast tumours the antibodies gave mixed results. Seven HER2 
positive tumours showed tumour heterogeneity. This might partially account for 
the different staining results with the 3 antibodies on the serial sections, as 
different parts of the heterogeneous tumour might be dominant in the different 
sections. HercepTestTM is a C-terminal antibody with an epitope only 20 amino 
acids downstream of the C-terminal antibody’s epitope, however the other C-
terminal antibody showed a weaker staining for most tumours. In all cases, 
except G2S7, the N-terminal antibody stained equally or stronger than the C-
terminal antibody. Interestingly, two tumours stained 3+ with the N-terminal 
antibody but less with the other two antibodies. Concerning was the observation 
that some of the tumours were not HER2-positive by the IHC staining. 
Additionally, when HER2 status is evaluated in the clinic by IHC, only the HER2 
membrane staining is taken into account. Dependent on the completeness of 
membrane staining and the extent in the tissue the HER2 score is determined. 
It is also important to note that HER2 has been shown to localise within the 
cytoplasm and the nucleus [reviewed in (Mills, 2012)]. In the present study no 
nuclear staining was observed. Cytoplasmic staining was observed to different 
extends in the majority of HER2 positive tumours. The strongest cytoplasmic 
staining was observed with the N-terminal antibody. 
Next the HER2-gene amplification was assessed for part of the cohort. These 
included the tumour samples which were flagged up as discrepant by the IHC 
experiments. The HER2-negative tumours were also scored HER2-negative by 
the CISH assay. Five of nine originally HER2-positive tumours showed HER2-
gene amplification by CISH. Two tumours showed borderline scoring (IHC-1, 
IHC-15) and two were scored HER2-negative. One of the tumours, IHC-3 was 
confirmed by CISH to have a HER2-positive score, however it showed no HER2 
overexpression with the C-terminal antibodies and only a 2+ score with the N-
terminal antibody. This patient was originally scored HER2-positive and would 
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have been accordingly treated. However, the protein level data suggests no 
overexpression of wild type HER2. The 2+ score with the N-terminal antibody 
might indicate the increased presence of truncated proteins such as p100 or 
Herstatin. As discussed in the main introduction p100 and Herstatin are HER2 
protein variants that cannot induce downstream signalling and are considered 
tumour suppressors (Jackson et al., 2013). Tumours with a HER2-positive CISH 
score, but HER2-negative IHC score are a minor group. Work by Kurozumi et 
al. found such a pattern in 1.8% of tested tumours. They correlated this 
observation with a worse survival rate than HER2 gene and protein negative 
patients (Kurozumi et al., 2016). It has not been sufficiently tested how HER2-
negative patients respond to anti-HER2 therapy, it is likely that in this case the 
patient did not respond as expected to a HER2 targeting therapy; no follow up 
data for these patients is currently available. 
In two cases the CISH assay clearly scored HER2-positive tumours as HER2-
negative. These tumours, IHC-11 and 13 were also assessed as HER2 
negative by IHC. IHC-11 showed no signs of HER2 genetic heterogeneity. For 
IHC-13 a few dispersed nuclei with a low-level HER2-gene amplification could 
be observed. This tumour stained 2+ with the N-terminal antibody, again 
suggesting the presence of truncated HER2 protein variants.  
The two borderline cases IHC-1 and 15 are difficult to assess. They showed 
only very minimal HER2-gene amplification in combination with chromosome 17 
monosomy. Dependent on assessment criteria they could also be classed as 
HER2-negative (Rakha et al., 2015). IHC-1 was also stained HER2-negative 
with the C-and N-terminal antibody. However the HercepTestTM scored the 
tumour as HER2 3+. Dr Kourea reported tumour heterogeneity for the IHC 
stained tumour sections. This tumour might contain focal HER2-positive tumour 
areas that were not part of all serial sections. Furthermore this tumour might not 
contain HER2-gene amplification, but overexpress HER2 through alteration at 
the transcriptional and translational level. In the IHC-15 tumour dispersed nuclei 
with a stronger HER2-gene amplification could be observed on a background of 
HER2-negative tumour cells. This tumour showed weak staining with the C-
terminal antibodies, but a 3+ staining with the N-terminal antibody; again 
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suggesting a tumour which might express other forms of HER2 proteins such as 
the HER2 splice variants p100 and Herstatin. 
One major concern is that the tumour sections assessed are not representative 
of the whole breast tumours. This might be one of the reasons for discrepancies 
between findings in this study and the original clinical HER2-status, if a tumour 
is focally heterogeneous in regard to its HER2 status and different areas are 
assessed. In the here studied cohort of tumours some tumour heterogeneity 
was observed. However more concerning was the variability between the IHC 
results. One could argue that the C-and N-terminal antibodies have not been 
tested and optimised for clinical use like the HercepTestTM and might therefore 
give less reliable results. The results should still not be disregarded, as both 
antibodies worked on the positive controls of each experiment, although less 
intensely. The results for the N-terminal antibody are most interesting, as they 
might indicate the expression of HER2 splice variants. A study showed 
antibodies for the extracellular domain/N-terminus and intracellular domains/ C-
terminus of HER2 to give discordant results in 15% of assessed breast tumours. 
They associated high extracellular domain/ intracellular domain levels with an 
increased disease free survival (Carvajal-Hausdorf et al., 2015). Increased 
levels of extracellular domain are likely to indicate HER2 protein variants with a 
truncated C-terminus, such as p100 and Herstatin. Furthermore, absence of N-
terminal staining with strong C-terminal staining could indicate the presence of 
HER2 C-terminal fragments. 
 
4.5.2. Possible role of HER2 splice variants in discrepant breast 
cancer cases 
 
The discrepant IHC staining results indicat that these tumours may well express 
other HER2 protein variants. To address this question PCRs were performed to 
study the expression of the well-studied splice variants p100, Herstatin and 
Δ16HER2 in the same tumour samples. PCRs were performed on 6 tumours 
(IHC-1, 3, 4, 13, 14 and 15). The wild type HER2 mRNA levels matched the 
results from the HercepTestTM for most tumours. The exception was IHC-15 
Chapter 4: Characterising HER2 in human breast tumours 
170 
 
which showed a strong band in the PCR, but a 0 sore with the HercepTestTM. 
Δ16HER2 was present in all tumours, but only at a consistently low level. Both 
Herstatin and p100 could be observed in all tumours. As suggested in the 
above sections variations to the levels of p100 and Herstatin could be observed. 
Herstatin was most pronounced in IHC-1, 4 and 15. In the tumours IHC-3 and 
13 where the N-terminal antibody gave the strongest staining with HER2 2+ 
scores, p100 and Herstatin were clearly present. Tumour IHC-15 showed the 
highest level of p100. Additionally, the PCR band for wild type HER2 was also 
strong. However, the mRNA level of wild type HER2 does not translate to the 
protein level, as the HercepTestTM only scores this tumour as 1+. In contrast the 
N-terminal antibody showed a 3+ staining and might indicate that p100 is 
translated. It can only be cautiously suggested that membranous N-terminal 
HER2 staining might be due to p100 or Herstatin. These two proteins are not 
anchored in the cell membrane, however they might interact and dimerize with 
wild type HER2 or another member of the ErbB protein family. 
 
4.6. Summary 
 
In this chapter a cohort of invasive primary ductal carcinomas was 
characterized using IHC and CISH. The IHC results showed discordance 
between the three HER2-specific validated antibodies. Although the controls of 
the antibodies were consistently accurate, the C-terminal antibody did not stain 
most tumours that were stained by the other antibodies. Some discrepancies 
were also observed with the N-terminal antibody, however staining was more 
similar to the HercepTestTM. Interestingly in two tumours the N-terminal antibody 
stained more strongly than the HercepTestTM. Tumour heterogeneity could be 
observed in four of twenty HER2-positive tumours. In addition to IHC, CISH was 
performed to determine the HER2-gene amplification status in a subset of 
tumours. It confirmed the clinical HER2 status for most tumours. For four 
tumours CISH gave a borderline or HER2-negative score although they had 
been clinically assessed as HER2-positive. Of these one tumour (IHC-1) was 
scored HER2 3+ by HercepTestTM therefore confirming its clinical status. 
However the other two tumours (IHC-13 and IHC-15) were also HER2-negative 
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by HercepTestTM. Interestingly IHC-15 is scored HER2 3+ with the N-terminal 
antibody. As the different results between N- and C-terminal antibodies might 
indicate the presence of HER2 protein variants. Through conventional PCR the 
levels of HER2 splice variants p100, Herstatin and Δ16HER2 was assessed. 
Indeed, when taking the housekeeping gene and the level of wild type HER2 
into consideration, the levels of p100 and Herstatin mRNA were elevated in a 
few cases. Most notable is the strongly elevated level of p100 in IHC-15, which 
as mentioned above had a HER2 3+ score with the N-terminal antibody, but 
none of the C-terminal antibodies. 
 
4.7. Further work 
 
This chapter discussed the first findings of a larger study undertaken by our 
research group to investigate the importance of HER2 splice variants in breast 
cancer. For completeness the HercepTestTM should be performed on the 
remaining HER2-negative cases. This work showed differences in IHC results 
depending on the antibodies used. As the differences between the antibodies 
might indicate the increased levels of HER2 protein variants, conventional 
PCRs were performed to measure their levels. Although this gave first indicative 
results, in a next step TaqManTM qPCR will be performed to quantify the 
expression of HER2 splice variants in all tumours. Additionally, it would be 
useful if RNA could be derived from laser-capture sections of the serial sections 
characterized by IHC and CISH. Furthermore, western blots should be carried 
out with samples from these tumours to determine the presence of HER2 
protein variants that are not due to the main HER2 splice variants. The 
experimental results should then be correlated to patient therapy and follow up 
information to identify any possible connections. This is of great interest, as it 
could be hypothesized that some breast tumours which are assessed as HER2-
positive, but express a substantial amount of HER2 protein variants that will not 
respond to anti-HER2 therapies. Conversely, tumours with low levels of wild 
type HER2, but elevated levels of undetected HER2 protein variants could be 
classed as HER2-negative. This could prevent patients from being treated with 
anti-HER2 therapy, although they might benefit from receiving it.  
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For further studies it could be of interest to employ a gene-protein assay such 
as used by Kurozumi et al. to measure IHC and CISH on the same samples 
(Kurozumi et al., 2016). Additionally, it would be interesting to extend work to 
include metastatic tumours with tissue biopsies from secondary tumours. In this 
chapter tumours were discussed that showed discordance between HER2-gene 
and protein status. It is not known how this pattern will change in secondary 
tumours and whether HER2-negative tumour cells with HER2-gene 
amplification might change their phenotype to express HER2 proteins. The 
need for such studies was further highlighted by a systematic review showing 
the lack of sufficient knowledge (Turner and Di Leo, 2013). 
Furthermore, it would be of great interest to determine where HER2 splice 
variants occur in a tissue. For this an mRNA-FISH assay should be developed. 
This FISH assay would need to be very specific to distinguish between wild type 
HER2 and its splice variants. First steps have been performed for such an 
assay. It is based on the FISH Tag RNA Multicolor kit (Thermo Scientific). This 
kit could allow the detection of multiple mRNAs in parallel. Plasmids carrying 
templates for wild type HER2 and Δ16HER2 probes have been generated. It 
would be suggested to develop this method for the use in cell lines and adapt it 
for tissue sections. Performing this assay successfully on human breast tumour 
sections would give insight into the localization and extend of splice variant 
expression, which cannot be assessed from qPCR. 
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Chapter 5: Identification of novel HER2 splice variants 
 
5.1. Introduction 
 
The proto-oncogene HER2 is located on chromosome 17q12. On the sense 
strand HER2 is preceded by phenylethanolamine N-methyltransferase (PNMT) 
and followed by growth factor bound protein 7 (GRB7). The antisense strand 
encodes post-GPI attachment to protein 3 (PGAP3) which partially overlaps 
with the reading frame of some HER2 transcripts. The reading frame of 
migration and invasion enhancer 1 (MIEN1) also partially overlaps with the 3’ 
end of some HER2 transcripts (Figure 5.1). As mentioned in chapter 1, HER2 
has two promoters, with the more recently discovered 2nd promoter initiating 
transcription of 4 (novel) exons, upstream of the normal exon 1. Additionally, 
one transcript has been described that starts from the novel exon 4 instead of 
normal exon 1 or novel exon 1 (Figure 5.2: ErbB2-201). The NCBI database 
considers the HER2 gene to have 32 exons. The transcript on which most 
studies, including ours, are based is 27 exons long and uses the 1st promoter 
(Figure 5.2: ErbB2-008). 
 
Figure 5.1: Chromosomal location of HER2 and surrounding genes.  
Derived from http://www.ncbi.nlm.nih.gov/gene/2064. 
 
The web archive Ensembl (http://www.ensembl.org/) contains 22 HER2 mRNA 
transcripts (Examples in figure 5.2) and NCBI AceView 
(http://www.ncbi.nlm.nih.gov/IEB/Research/Acembly) 23 HER2 mRNA 
transcripts. Some of these are un-spliced and very short, others deviate by the 
length of the untranslated region. In some cases the evidence comes from only 
one clone from a tissue that is high in splicing events, such as the brain or 
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testis. Most of the variants found in the databases have not been studied 
further. Interestingly, of the three well studied HER2 splice variants, supporting 
transcripts can only be found for Herstatin (AceView: ERBB2, variant iAug10) 
and p100 (Ensemble ID: ENST00000578199) but not Δ16HER2. Of the 22 
HER2 mRNAs in Ensembl, 12 have been shown, or are predicted. to be 
translated into proteins. In western blot experiments our group detected more 
HER2 protein bands than can be attributed to known HER2 protein variants 
(Gautrey et al., 2015). Also, C- and N-terminal antibodies gave different 
spectrums of protein bands ranging from 55 kDa to 185 kDa. Knockdown 
experiments using HER2 specific siRNAs caused the disappearance of these 
bands, confirming their identity as HER2 protein variants. The potential number 
of functionally different HER2 proteins could have a major impact on the role of 
HER2 in cancer such as breast carcinoma. 
 
Figure 5.2: Transcript profile of the HER2 (ErbB2) gene.  
A snapshot of the Ensembl database shows the annotated HER2 mRNA transcripts. Reference 
mRNA transcript is ErbB2-008. 
In the previous chapters the focus was on the HER2 splice variant Δ16HER2. 
Here the existence of novel HER2 mRNA transcripts was experimentally 
investigated. It was decided to use a PCR based approach to study possible 
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alternative splice variants of HER2 in breast cancer. Most HER2 protein 
variants studied so far, contain changes to the extracellular domain, therefore 
the focus of this study was on detecting changes to the mRNA sequence 
encoding the transmembrane and intracellular domain. Furthermore, the 
stability of any novel HER2 mRNA transcript and the likelihood of translation 
into a novel HER2 protein variant were also investigated.   
 
5.2. Aims 
 
The aims of this chapter were to: 
 Identify novel HER2 transcripts  
 Characterise the novel HER2 splice variant I25HER2 
 Study the mRNA stability of I25HER2 
 Observe the expression of I25HER2 in different normal human tissues 
 Observe the expression of I25HER2 in a cohort of human breast tumours 
 
5.3. Specific methodology 
 
5.3.1. In-silico predictions of I25HER2 
 
To predict the characteristics of potential protein product from any newly 
identified HER2 transcripts, in-silico protein tools from the Swiss Bioinformatics 
Institute’s Bioinformatics Resource Portal were used. The used mRNA 
sequences were translated into an amino acid sequence with the ExPASy 
translate tool (http://web.expasy.org/cgi-bin/translate/dna_aa). For the 
prediction of the molecular weight and isoelectric point, the ExPASy ProtParam 
(http://web.expasy.org/protparam/) was used. 
The secondary structure of wild type HER2 and I25HER2 was predicted using 
the web resource of the Pôle BioInformatique Lyonnais: https://npsa-
prabi.ibcp.fr/cgi-bin/secpred_gor4.pl [based on (Garnier et al., 1996)]. The 
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whole mRNA sequence was used for the prediction. The poly(A)-tail was not 
included, as its length is unknown. 
 
5.3.2. RNA stability assay 
 
The rate of mRNA decay was studied using an RNA stability assay. For the 
RNA stability assay 3 x 105 SKBR3 cells per well were seeded in 6 well plates 
with normal complete McCoy’s medium. A 1 mg/mL Actinomycin D (Sigma) 
solution was prepared in DMSO. After 20 hours the medium was exchanged for 
complete McCoy’s medium with 5 µg/mL of Actinomycin D. The plates were 
immediately swirled for an even distribution of Actinomycin D on the cells. For 
time point 0 cells were harvested directly. Further cells were collected after 1, 2, 
4, 6 and 8 hours. Cells were lysed in the ReliaPrepTM Cell Miniprep lysis buffer 
and stored overnight at -80C. RNA was collected and reverse transcription 
performed as described before in sections 2.5.1 and 2.6.1. 
 
5.3.3. Northern blot using NorthernMax®-Gly 
 
To determine to what extent intron 25 is retained in full length HER2 mRNA, 
northern blots were performed. The experiments were performed using the 
NorthernMax®-Gly kit (Life Technologies), based on the manufacturers 
recommendations. For details please refer to the manufacturer’s instructions. 
This kit uses non-isotopic biotin labelled RNA probes to detect specific RNAs in 
RNA extracts from cells. Throughout the process RNase free conditions were 
ensured. 
 
Generation of biotin labelled RNA probes 
Initially 83 bp long probes were used, but as these were found to not yield 
results, new longer probes were designed. PCRs were performed to produce 
templates for the generation of the new RNA probes, using cDNA from SKBR3 
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cells. Two probes were generated; one to capture general HER2 with a probe 
spanning exon 5 (size: 313 bp) and a second which encompasses parts of exon 
25 and intron 25 (size: 311 bp) to detect intron 25 retention transcripts. The 
PCR was performed using the Pfu DNA Polymerase as described in section 
3.3.6. Instead of 200 ng, 500 ng of cDNA were used in the PCR reactions. The 
primers used contain T7 promoter sequences. The T7 promoters are 
incorporated into the cDNA templates in an orientation that allows the 
production of RNA probes which are complementary to the mRNAs which were 
to be detected (Table 5.1). The PCR products were purified after separation on 
a 1% agarose gel (section 2.8.1) and used as a template for RNA synthesis.  
 
Table 5.1: Primers for the northern blot RNA probe DNA template. 
Name of Primer Sequence 
I25HER2_F TCCCTCAACTGTCACCTCTCA 
I25HER2_R with T7 promoter 
TAATACGACTCACTATACAAATACATCGGA
GCCAGCC 
Wild type HER2_F CTCCGATGTGTAAGGGCTCC 
Wild Type HER2_R with T7 promoter 
TAATACGACTCACTATAGGACAGGCAGTCA
CACAGC 
 
In the RNA synthesis step biotinylated CTP nucleotides (Invitrogen) were 
incorporated into the RNA probes. A reaction mix was prepared for each probe 
as described in table 5.2. The synthesis was carried out for 5 h at 37C. The 
template DNA was degraded by TURBOTM DNase (Ambion) for 30 min at 37C 
and the RNA was purified by phenol-chloroform extraction. 
 
Table 5.2: The T7 reaction mix for Northern blot RNA probe generation. 
Reagents For a volume of 40 µL 
10xBuffer 4 µL 
RNAseOUT 2 µL 
25 mM ATP, GTP and UTP mix 0.6 µL 
10 mM CTP (1:4) mix 2 µL 
T7 polymerase 4 µL 
cDNA 0.3 to 1 µg 
Nuclease free H2O Fill up to 40 µL 
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Northern blot 
RNA from SKBR3 cells was used to detect the expression of HER2 transcripts. 
To minimalize unspecific interactions the GenElute Direct mRNA Mini prep kit 
(Sigma) was used, as it isolates the poly-adenylated mRNA fraction using oligo 
(dT) (for details see section 2.5.2). The mRNA (3 µg/lane) was mixed 1:1 with 
the glycoxal loading dye and denatured. The mRNA was size separated (5 V / 
cm electrode to electrode) on a 1% agarose gel together with a MilleniumTM 
RNA marker (Ambion). The integrity and appropriate separation was briefly 
observed under UV light. Exposure was minimalised to keep damage to the 
mRNA minimal. For a size reference an image of the trans-illuminated gel and a 
ruler was taken. The assembly of the transfer is described in figure 5.1. A 
downward transfer of the mRNA onto a positively charged nylon BrightStar-Plus 
membrane (Life Technologies) was carried out for 2.5 h (Figure 5.3). After the 
transfer the mRNA was crosslinked at 254 nm UV light for 1 min with the 
membrane. During crosslinking of the mRNA, the successful transfer of mRNA 
can be observed.  
 
 
Figure 5.3: Depiction of the northern blot transfer assembly.  
A stack (3 cm) of thick paper towels was prepared onto which 5 sheets of chromatography 
paper were placed. Three were pre-wet in the transfer buffer. Onto this the nylon BrightStar-
Plus membrane was placed. Next the gel, followed by three pre-wet chromatography papers 
and the chromatography paper bridges were added. A tray with evenly spaced small weights 
(total 200 g) was placed on top. The buffer reservoir (0.5 mL/cm
2
 of gel) is elevated to roughly 
the level of the membrane. 
 
The membrane was cut into strips, so each ‘mRNA lane’ could be hybridized 
with the correct probe. The membranes were pre-hybridized at 68°C in 
ULTRAhyb buffer (10 mL/100 cm2) for 30 min in a hybridization oven. Next a 
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~16 h hybridization was performed. To optimise the binding of the probes to the 
mRNA, different concentrations of probes were used. The optimised 
concentrations were 10 ng (0.1 pmol) for the general HER2 probe and 30 ng 
(0.3 pmol) for the intron 25 retention probe. The probes were mixed with 1 mL 
of ULTRAhyb buffer and added to the membrane strips. Using the Low 
Stringency Wash Solution #1 (20 mL/100 cm2) a 10 min wash at RT and under 
agitation was performed. This was followed by two washes with High Stringency 
Wash Solution #2 (20 ml/100 cm2) for 15 min each at 68°C using agitation in a 
hybridization oven. 
 
Detection of hybridization 
The Chemiluminescent Nucleic Acid Detection Module (Thermo Scientific) was 
used to detect the hybridized probes. The blocking and washing steps were 
carried out in 50 mL tubes (Greiner). The blocking and wash buffers were pre-
warmed to 37°C. The membrane was blocked with 8 mL blocking buffer for 15 
min. The blocking reagent was removed and fresh blocking buffer (8 mL) with 
Streptavidin/Horseradish peroxidase (25 µL) was added to the membrane strips 
and incubated for 15 min under agitation at RT. Next the membrane strips were 
washed 4 times with 4 x Wash Buffer. The membranes were then incubated in 
Substrate Equilibrium Buffer for 5 min at RT under agitation. Equal amounts of 
Luminol/Enhancer Solution and Substrate Working Solution were mixed. 
Excess liquid was removed from the membrane, the ECL mix was applied to it 
and incubated for 5 min. The ECL was then removed, and the films exposed to 
the chemiluminescence for 1 h. 
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5.4. Results 
 
5.4.1. Identification of novel HER2 splicing events by PCR  
 
As mentioned in section 5.1, the HER2 gene has been reported to have two 
promoters and alternative first exons. The initial experiments were performed in 
the breast cancer cell line SKBR3, as these overexpress HER2 and produce all 
well studied HER2 splice variants. None of the 2nd promoter associated exons 
could be detected by PCR under these experimental conditions. However, a 
very short exon (51 bp) was found to be expressed in SKBR3 cells (Figure 5.4). 
This novel exon 6 is situated shortly upstream of the conventional exon 1.  
 
 
Figure 5.4: Expression of exons upstream of normal 
exon 1.  
PCRs were performed on SKBR3 cDNA to amplify 
HER2 transcripts spanning from the upstream (novel) 
exon 1 or 6 to normal exon 3. 
 
In the next step the existence of HER2 alternative splice variants was 
investigated. As all the established HER2 splice variants are generated by 
variations in the first 17 exons, this work focused on exons 17 to 27, which 
encode the transmembrane and intracellular domain. For completeness fellow 
PhD student M. Silipo investigated the first 16 exons. Specific forward and 
reverse primers covering exons 17 to 27 were used in a series of PCRs to 
amplify any intron retentions, exon skipping events or novel exons (Figure 5.5 A 
and B). The PCRs were performed on cDNA from SKBR3 cells. The reverse 
primer in exon 21 did not work, but the primers in the surrounding exons worked 
and should therefore amplify any variations in this area. In figure 5.5 A, two faint 
upper bands could be observed for the PCRs with forward primer in exon 25 
and reverse primers in exons 26 and 27. Figure 5.5 B, the PCR with forward 
primer in exon 24 and reverse primer in exon 26 also shows a very faint band at 
~ 650 bp. The upper bands were sequenced and confirmed to be due to the 
retention of the 291 bp sized intron 25. PCRs on cDNA from three separate 
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nuclear and cytoplasmic RNA fractions showed that intron 25 is present in the 
cytoplasm; opposed to transcripts containing both intron 25 and 26, which are 
only found in the nuclear fraction suggesting an only partially spliced transcript 
(Figure 5.5 C).  
 
 
Figure 5.5: The retention of intron 25 in HER2 transcripts. 
All PCRs were carried out using cDNA from SKBR3 cells. A, PCR based mapping of splicing 
events between exons 17 and the last exon 27. Reverse primer in exon 21 did not work. B, 
Three PCRs from exon 19 to 22, exon 22 to 24 and exon 24 to 26. C, Expression of wild type 
HER2 and intron 25 retention with or without intron 26 in cDNA from nuclear (N.) and 
cytoplasmic (C.) RNA fraction. 
 
To understand the nature of the intron 25 containing mRNA, PCRs were 
performed using a reverse primer in intron 25 in combination with forward 
primers spanning the exons upstream, until conventional exon 1. The PCR with 
a forward primer in exon 1 did not yield a PCR product and amplifications from 
exon 2 and 3 were very faint. Two bands were observed for all PCRs with 
forward primers upstream from exon 12 (Figure 5.6 A and B), the upper bands 
were attributed to intron 12 (361 bp) retention, which was identified by fellow 
PhD student M. Silipo. The retention of intron 12 was also confirmed with a 
forward primer in intron 12 and a reverse primer in intron 25 (Figure 5.6 B and 
C), the intron 12 retention band was stronger in SKBR3, than MCF-7 cDNA. 
Intron 25 is not retained in transcripts skipping exon 16, therefore not part of 
Δ16HER2 (Figure 5.6 B and C).  
C 
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Figure 5.6: Presence of intron 25 in HER2 mRNA transcripts.  
PCR based mapping of the inclusion of intron 25 was performed. In A, and B, SKBR3 cDNA 
was used. A, Using forward primers in exons 1 to 12 with a reverse primer in intron 25. B, Using 
forward primers in intron 12 and exons 14 to 24 and exon 16 skipping (Δ16) in combination with 
a reverse primer in intron 25. C, PCR using forward primers in exons 12 to 24, including exon 
16 skipping (Δ16) with intron 25 reverse primers performed on MCF-7 cDNA.  
 
A very diffuse range of PCR products were amplified between exons 20 and 24, 
if a reverse primer in intron 25 was used (Figure 5.6 B and C). The bands above 
1.5 kb match the predicted sizes of intron 23 (708 bp) retention. The strongest 
bands are due to intron 24 (155 bp) retention. However, this intron retention 
was not observed in the initial experiments (Figure 5.5 A). Figure 5.6 C shows 
the same area amplified with MCF-7 cDNA. A similar if not more complex range 
of PCR products were amplified. The additional fainter bands in both SKBR3 
and MCF-7 were due to the sequential retention of introns. Surprisingly, 
compared to the expression profile in SKBR3 cells, in MCF-7 cells the PCRs 
that amplify from forward primers upstream of exon 20 are much fainter.  
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Figure 5.7: Presence of intron 25 in HER2 mRNA transcripts.  
PCR based mapping of the inclusion of intron 25 was performed. PCRs with forward primers in 
exon 18 to exon 24 with reverse primers in intron 25 were performed. A, for these PCRs cDNA 
from poly(A) enriched SKBR3 mRNA was used. B, for these PCRs cDNA from cell compartment 
fractioned nuclear and cytoplasmic SKBR3 mRNA was used.  
 
To separate intermediate splice products from mature mRNAs, PCRs were 
performed on a three different RNA preparations. PCRs for the region of exon 
18 to 24 were performed with cDNA from poly(A) enriched as well as nuclear 
and cytoplasmic fractions of SKBR3 mRNAs (Figure 5.7). The poly(A) enriched 
RNA, should primarily contain polyadenylated mRNA. The number of bands is 
strongly reduced in the PCRs using this cDNA, only the intron 24 retention band 
can be observed in the PCRs with forward primers in exons 22 and 24, and very 
faintly with the forward primer in exon 20 (Figure 5.7 A). PCRs performed on the 
nuclear RNA fraction show a very strong band for the retention of intron 24 
when using a forward primer in exon 24, as well as additional fainter bands as 
previously observed with normal cDNA (Figure 5.7 B). The PCR products from 
the reactions using the cytoplasmic RNA fraction are faint. In the cytoplasmic 
fraction a number of bands that could be seen before totally disappear (Figure 
5.7 B). However retention of intron 24 in combination with intron 25 can still be 
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observed, but only if amplified from exon 24 to intron 25. The cytoplasmic 
fraction was expected to only contain mature mRNAs and for any intermediate 
splicing products to not be present. 
 
5.4.2. In-silico predictions for I25HER2 mRNA and protein 
 
The PCR-based mapping of intron 25 retention indicated it to be primarily 
retained in an otherwise normal full length HER2 transcript. Intron 25 is 291 bp 
long and does not change the reading frame of the transcript. The intron also 
encodes a premature stop codon, which could cause this transcript to be a 
target of nonsense-mediated decay. An in-silico prediction of the mRNA 
secondary structure of I25HER2 and wild type HER2 was performed to assess 
the impact of the retained intron 25 on the overall secondary structure. As for 
the prediction of Δ16HER2, both the MFE and the centroid plain model were 
used. The MFE model predicted secondary structure of I25HER2 shows 
differences in some areas of the structure compared to the prediction for wild 
type HER2. The main differences are observed in the bottom half of the images 
in figure 5.8. The centroid model predicted a secondary structure for I25HER2 
which is very different compared to wildtype HER2.  
In the next step in-silico predictions for a translated I25HER2 protein was 
performed. The I25HER2 mRNA is predicted to translate into an 1110 amino 
acid long protein (ExPASy Bioinformatics Resource portal). Due to the stop 
codon in intron 25 it is predicted to lack the last 202 amino acids of the normal 
HER2 C-terminus and to instead contain a novel 57 amino acid long C-terminus 
(Figure 5.9, A). No sequence similarity can be observed when aligning the two 
C-termini. 
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Figure 5.8: In-silico predicted secondary structure of wild type HER2 and I25HER2 mRNA.  
Secondary mRNA structure predictions from two methods are shown, the minimum free energy 
(MFE) model and the centroid plain model. The predicted secondary structure for the full length 
mRNA transcripts are shown, but lacking the poly(A)-tail. Images were generated by the 
RNAfold web server, based on (Lorenz et al., 2011). 
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Figure 5.9: Protein predictions for 
I25HER2.  
A, The C-terminus of wild type HER2 
and I25HER2 is shown. I25HER2 
protein sequence encoded by intron 
25 was predicted by ExPASy 
translation tool 
(http://web.expasy.org/cgi-
bin/translate/dna_aa). B, The 
phosphorylation and binding sites in 
wild type HER2 and I25HER2 are 
shown. It is indicated for which protein 
the phosphorylation sites function as 
binding motifs. Image was adapted 
from (Roskoski, 2013).  
 
I25HER2 is predicted to have a molecular weight of 123.1 kDa and isoelectric 
point (pI) of 6.25 (ExPASy ProtParam). Wild type HER2 without post-
translational modifications is 137.9 kDa in size and has a basal pI of 5.58. Due 
to extensive post-translational modifications of wild type HER2, it is normally 
185 kDa in size. Therefore I25HER2 can be expected to be closer to 170 kDa in 
size. The C-terminus of wild type HER2 is highly phosphorylated especially at 
the tyrosines, which act as important binding sites for downstream effectors. 
The predicted I25HER2 protein lacks five of these binding sites and only 
contains 1 instead of 6 tyrosines in the alternate sequence (Figure 5.9, B). 
A 
B 
B 
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Protein secondary structure predictions were performed for wild type HER2 and 
I25HER2 (web resource of the Pôle BioInformatique). The secondary structure 
predicted for I25HER2 differs in its C-terminus from wild type HER2. The 
shorter I25HER2 sequence lacks an alpha helix and has a shorter random coil 
structure broken up by extended strands compared to wild type HER2 (Figure 
5.10). 
 
 
Figure 5.10: Predicted secondary structures of wild type HER2 and I25HER2.  
Bellow the amino acid sequence the predicted secondary structure is indicated. The table 
indicates the secondary structures, their abbreviations and percentage of the total protein 
sequence. The purple bar indicates the start of the alternative C-terminal sequences. Based on 
the online prediction by: https://npsa-prabi.ibcp.fr/cgi-bin/secpred_gor4.pl; (Garnier et al., 1996). 
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5.4.3. Expression of I25HER2 in cell lines and tissue 
 
To understand whether the expression of intron 25 retention is just a by-product 
of the aberrant overexpression of HER2 in the SKBR3 cancer cell line or if it is 
expressed more commonly the following experiments were performed. The 
level of intron 25 was observed in a number of breast cancer cell lines. Intron 25 
retention was found to be present in all tested breast cancer cell lines and 
mostly in the same ratio to wild type HER2 (Figure 5.11, A). Except for one 
sample of normal breast tissue in which the intron 25 level was increased 
compared to wild type HER2.  
 
Figure 5.11: Expression of I25HER2 in a panel of human breast cancer cell lines (A) and 
normal human tissues (B).  
Conventional PCR was performed to amplify Intron 25 HER2, wild type HER2 and the 
housekeeping genes GAPDH. A second housekeeping gene ß-actin was included for the 
normal tissues, as GAPDH is differentially expressed in tissues.  
 
A panel of normal human tissues was used to further study the splicing of intron 
25. PCRs for intron 25 retention, wild type HER2 and two housekeeping genes 
were performed (Figure 5.11, B). The primers for intron 25 were located in exon 
25 and intron 25. The intron retention could be observed in all of the studied 
tissue samples. The level of intron 25 did not correspond directly to the level of 
wild type HER2. In the heart sample intron 25 is only faintly expressed, whereas 
wild type HER2 is strongly expressed. In the cerebellum intron 25 is present 
nearly at the same level as wild type HER2. Overall the intron 25 retention is the 
most abundant in testis and cerebellum. 
B A 
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Furthermore, samples from the Breast Cancer Now Tissue Bank were used to 
study the relationship of intron 25 retention within breast cancer subtypes 
(Figure 5.12). A forward primer in exon 23 and a reverse primer in intron 25 
were used to detect intron 25 retention. This combination was used not only to 
detect intron 25 or intron 24 and 25 retention, but to also show genomic DNA 
contamination which would be characterised by the additional inclusion of intron 
23. The focus is on the intron 25 retention band, as combined intron retention of 
intron 24 and 25 could be caused by incompletely spliced mRNAs. No genomic 
bands were detected. Additionally, PCRs for wild type HER2 and the 
housekeeping gene ß-actin were performed. Samples from two groups (Group 
5 and 9) of HER2-positive/ER-negative grade 3 ductal carcinomas and one 
group (Group 3) of HER2/ER-negative grade 3 ductal carcinomas, as well as 
one group (Group 1) of normal breast tissue from breast reduction surgery were 
used.  PCRs on five samples for each group were performed and SKBR3 was 
included as a positive control. It should be noted that although the same 
amounts of RNA were used to generate cDNA, fluctuations in expression of the 
housekeeping gene β-actin impair normalisation between samples. For most 
samples the ratio between wild type HER2 and intron 25 expression was 
consistent. 
In the two groups of HER2 positive breast tumours four samples (G5-3, G5-4, 
G9-3, G9-4) showed a lower expression of wild type HER2 then expected for 
HER2 positive tumours. When comparing the tumour samples to SKBR3 and 
normalising by ß-actin, the ratio between intron 25 retention and wild type HER2 
seems consistent. In contrast variations in the ratio between intron 25 retention 
and wild type HER2 in both normal breast and ER/HER2-negative tumour 
samples were observed. As expected the level of wild type HER2 was very low 
in normal breast and HER/ER-negative tumour samples. In some HER2/ER-
negative tumour samples (G3-3, G3-4, G3-5) wild type HER2 could not be 
detected. One normal breast sample, G1-4 had a slightly increased expression 
of wild type HER2. However in all samples of group 1 and 3 intron 25 retention 
could be observed. The samples G3-3, G3-4 and G3-5 should be noted as they 
show intron 25 retention, but wild type HER2 levels remain below detection 
limit. In most samples the retention of intron 24 and 25 remains in the same 
ratio to intron 25 retention and wild type HER2. Interesting exceptions are the 
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normal breast samples G1-1, G1-3 and G1-4 as well as the HER2/ER-negative 
tumour samples G3-3 and G3-4, which show no double intron retention.  
 
 
Figure 5.12: Expression of I25HER2 in breast tumour and breast reduction samples.  
Conventional PCR was performed to amplify the retentions of HER2 introns 24 and double 
intron 24 and 25 retention.  Wild type (WT) HER2 and the housekeeping gene β-actin were also 
amplified. Tissue samples were provided by the Breast Cancer Now Tissue Bank. The sample 
groups shown here are: Group 5 - grade 3, ER-negative, HER2-positive ductal carcinoma; 
Group 9 - grade 3, ER-negative, HER2-positive ductal carcinoma; Group 1 – normal breast from 
reduction surgery; Group 3 - grade 3, ER-negative, HER2-negative ductal carcinoma. The 
PCRs were performed on five samples of each sample group. SKBR3 was included as a 
positive control for HER2 expression. 
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5.4.4. Stability of I25HER2 mRNA 
 
The novel HER2 transcript I25HER2 is likely to undergo nonsense-mediated 
decay as the retained intron encodes a premature stop codon (Silva and 
Romao, 2009). To study how stable the I25HER2 transcript is, a RNA stability 
or RNA decay assay was performed. Using Actinomycin D the transcription of 
mRNAs was impaired and the degradation of mRNAs observed over a time 
period of 8 hours. One representative experiment of three biological replicates 
is shown here (Figure 5.13). The levels of wild type HER2 and GAPDH stay 
relatively unaffected by the Actinomycin D treatment until 8 h after treatment. 
The levels of Δ16HER2 and intron 25 stay relatively stable for the first four 
hours and then decrease. Opposed to this, the levels of intron 12 retention 
decrease strongly within the first hour and are only very slightly detectable 
afterwards. This increased stability of intron 25 compared to intron 12 indicates 
that I25HER2 might evade the normal nonsense-mediated mRNA decay. 
 
 
 
 
 
 
 
 
 
 
Figure 5.13: RNA stability assay for HER2 transcripts.  
SKBR3 cells were treated with 5 µg/mL Actinomycin D. At 0, 1, 2, 4, 6 and 8 hours post-
treatment RNA was collected. Following reverse transcription PCRs were performed to detect 
the expression levels of intron 25 retention, intron 12 retention, Δ16HER2, wild type HER2 and 
GAPDH. One representative experiment of 3 biological replicates is show. 
 
Next, a non-isotopic northern blot was designed to study the expression of 
intron 25 and to better understand what HER2 transcript it is part of. The 
positive control provided in the NorthernMax®-Gly kit was used, alongside the 
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HER2 specific probes. A strong band at ~ 1.5 kb was detected. This matches 
with the expected 1.4 kb of mouse GAPDH mRNA. One representative 
experiment is shown in figure 5.14. Very faint additional bands can be observed 
at stronger exposures. Given their size, these are expected to be due to 
unspecific binding to the RNA of the 28S and 18S ribosomal subunits.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.14: Mouse GAPDH positive control for northern blot.  
Results of the positive control experiment for the northern blot is shown (n=2). The first panel 
shows the RNA ladder with a ruler aligned for comparison. The second panel shows the mouse 
RNA size separated on an agarose gel. The last panel show the northern analysis using the 
company provided mouse GAPDH RNA probe.  
 
After establishing this basic northern blot in our laboratory, a series of 
optimisation steps were undertaken to detect human general HER2 and intron 
25 retention. A RNA probe was designed to bind to exon 5 to detect all HER2 
transcripts and a second probe was designed to target intron 25. To prevent 
unspecific binding of the RNA probes to ribosomal RNA and partially spliced 
pre-mRNAs, poly(A) enriched mRNA from the HER2 overexpressing SKBR3 
cell line was used. A number of optimisation steps were carried out to detect 
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both general HER2 and intron 25 retention. Two experiments were performed in 
which the same pattern with the general HER2 probe was observed. However 
the assay had to be further optimized for intron 25 detection. In figure 5.15 the 
results from the last optimisations are shown. The first panel of figure 5.15 
shows the size separated mRNA. The most abundant mRNAs are visible at 
approximately 9, 3, 2.4 and 1.4 kb. As poly(A) enriched mRNA was used in the 
assay no ribosomal RNAs (18S - 1.9 kb, 28S - 5 kb) can be observed. As no 
biotin-labelled RNA ladder of appropriate size exists, a ruler was aligned to later 
assign the correct size to the northern blot. The two northern blots in figure 5.14 
show the corresponding hybridization of probes for general HER2 and intron 25. 
In the intron 25 blot two bands (8-9 kb and 2.8kb) were detected. With the 
general HER2 probe multiple bands were detected at 9, 4.5, 3 and 2.5 kb. Due 
to the signal strength of the dominant bands, fainter bands are difficult to 
determine. However there seems to be a faint band at 2.8 kb and one at 2 kb. 
The 9 kb bands are roughly the size of the main mRNA bands on the agarose 
gel and do not match any known HER2 transcript. The 4.5 kb band detected by 
the general HER2 probe matches the size of wild type HER2. The 3 and 2.5 kb 
bands of the general HER2 plot, similar to the 9 kb band are very close in size 
to the most abundant RNAs on the agarose gel. The HER2 splice variant p100 
was determined to be 2.3kb of size and could possibly correspond to the 2.5 kb 
band (Doherty et al., 1999a). Additionally, with the intron 25 probe a second 
band that does not seem to match any of the mRNA bands of the agarose gel 
was detected. This band is 2.8 kb of size and could match a very faint band on 
the general HER2 blot. An intron 25 band was expected to overlap with a 
general HER2 band, as the general HER2 probe binds exon 5, which was 
shown in PCR to be part of I25HER2. 
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Figure 5.15: Northern blot for I25HER2 and wild type HER2.  
Results of northern blot for general HER2 and intron 25 retention are shown. The first panel 
shows the agarose gel with the RNA ladder and two lines of poly(A) isolated RNA. For 
comparison a ruler was aligned. The next panels show the northern analysis with the general 
HER2 and intron 25 probes. For general HER2 4 bands can be detected and for intron 25 two 
bands. 
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5.5. Discussion  
 
Currently about 30% of breast cancers are diagnosed as HER2-positive. This 
subset of breast tumours is associated with a poor prognosis, although 
treatment with anti-HER2 drugs has improved the survival rates. As detailed in 
the introduction, resistance can occur both in adjuvant and neo-adjuvant HER2 
targeted therapy in both primary and advanced metastatic breast cancer 
(Guarneri et al., 2010). In chapter four breast cancer cases with discordant 
HER2 status profiles were discussed. The differences observed when using 
different HER2 antibodies highlight the importance of re-evaluating the clinical 
assessment of HER2 positivity. This highlights the need for a detailed analysis 
of the HER2 variants. In this chapter the existence of previously undescribed 
HER2 splice variants was investigated. A large number of HER2 mRNA 
transcripts can be found in online databases (NCBI AceView and Ensembl), but 
they have not been studied further.  
 
5.5.1. Intron 25 retention 
 
Our research group decided to re-investigate HER2 transcript variants. In this 
thesis the focus was on the mRNA sequence encoding the transmembrane and 
intracellular domain of HER2, as the known three splice variants arise from 
changes to the first 16 exons. The retention of intron 25 (I25HER2) was 
detected in a number of cell lines and tissues. Intron retentions are often 
dismissed as intermediates of pre-mRNA splicing or unimportant by-products of 
aberrant splicing. This is a narrow view has been disputed by a number of intron 
retaining mRNAs that give rise to functional proteins [reviewed in (Hube and 
Francastel, 2015)]. HER2 itself has two functional splice variants that arise due 
to intron retention, p100 and Herstatin (Gebhardt et al., 1998; Doherty et al., 
1999a). 
Intron 25 encodes a premature stop/termination codon (PTC). PTCs are a main 
signal on mRNAs to initiate nonsense-mediated mRNA decay (NMD). NMD is 
normal cellular mechanism that limits the translation of C-terminally truncated 
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proteins with dominant-negative or gain-of-function variations [reviewed in (Silva 
and Romao, 2009)]. A transcript with a PTC more than 50-55 nts upstream of 
the last exon-exon junction will be recognised as a target of RNA decay (Nagy 
and Maquat, 1998). Therefore the recognition of a PTC is dependent on the 
recognition of exon-exon junctions and the splicing associated assembly of the 
exon junction complex (EJC). The EJC is a protein complex assembled 20-24 nt 
upstream of each exon-exon junction (Le Hir et al., 2000). NMD takes place in 
the first round of translation from an mRNA. At this stage the cap-binding 
complex is still associated with the mRNA [reviewed in (Maquat, 2004)]. Each 
EJC is displaced from the mRNA as it is translated in the ribosome. If a PTC 
terminated the translation early, the remaining EJCs interact with the 
terminating ribosome and the SURF complex is formed which tigers the 
degradation of the mRNA [reviewed in (Popp and Maquat, 2013)]. In the case of 
intron 25 retention the next EJC is expected to be located more than 55 nt 
downstream of the PTC in intron 25. However there are cases where the 
transcripts are translated in spite of a premature stop codon. One example is 
the HER2 splice variant Herstatin, which retains the PTC containing intron 8 
(Doherty et al., 1999a). Another example is ß-globulin in the disease ß-
thalassemia. There mutations to ß-globulin have been identified that result in a 
PTC in exon 1. These ß-globulin variants are translated at a comparable level to 
the wild type (Romao et al., 2000). 
Figure 5.16: Transcript profile of the HER2 gene. 
 A snapshot of two HER2 mRNA transcripts from the NCBI AceView database are shown; 
variant “h” and “n”. Exons and retained introns are indicated on the images. 
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Through PCRs performed on cDNA from different RNA preparations, it was 
possible to confirm the presence of intron 25 mRNA in the cytoplasm and as 
part of polyadenylated transcripts. Intron 25 retention is part of an mRNA 
transcript that is, as far as could be assessed, full length. Due to the length of 
the transcript, the PCR from exon 1 to intron 25 was not successful. 
Amplification was only possible from exon 3 to intron 25. The finding that intron 
25 is not retained in exon 16 skipping (Δ16HER2) transcripts, further supports 
the assumption that intron 25 retention is not only a late spliced intron, but a 
specific transcript. The incorporation of intron 12 in a portion of intron 25 
mRNAs was also observed. Intron 12 retention was observed by fellow PhD 
student M. Silipo in a number of cell lines and normal tissues (unpublished 
data). The retention of intron 12 has also been reported previously to Ensembl 
and NCBI AceView databases. Members of our research group, M. Silipo and 
MRes student S. Satam, also showed protein expression from this transcript 
using an intron 12 containing HER2 plasmid construct (manuscript under 
preparation).  
 
Figure 5.17: Promoter related signatures around HER2 exons 17 to 19.  
A, shows a snapshot from the Ensembl database, which shows transcription factor binding sites 
in the region of HER2 exons 17 to 19. B, shows a snapshot from the UCSC Genome browser, 
which indicates acetylation of the lysine 27 of histone H3 (H3K27Ac) and DNase I 
hypersensitivity clusters for the region of HER2 exons 17 to 20 is shown. 
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Less clear are the results for PCRs covering the region downstream of exon 18 
to intron 25, for which a diffuse band pattern is observed. These multiple bands 
may be partially spliced pre-mRNAs, as PCRs performed on cDNA from poly(A) 
enriched mRNA of HER2-positive SKBR3 cells show only a retention of intron 
24 and 25. A similar pattern was observed in the HER2-low MCF-7 cells. It 
should be noted that the band intensity was stronger for amplifications from 
exon 20 onward. This is very interesting as a transcript, “n” has been described 
that, although incomplete in regard to the 3’ end of the sequence, has a 5’UTR 
starting in exon 21 (Figure 5.65). The region from exon 17 to exon 19 has also 
been annotated as a transcription factor binding site in the Ensembl database 
(Figure 5.17 A). For the same region an increased acetylation of the lysine 27 of 
histone H3 (H3K27Ac) and DNase I hypersensitivity clusters can be found on 
the UCSC Genome browser, which are associated with transcription initiation 
(Figure 5.17 B). This could support the transcription start site of variant ‘n’ in 
exon 21 and possibly a similar transcript in MCF-7 that also incorporates intron 
25. 
Another previously described transcript that might be linked to I25HER2 is 
variant “h”, which had been identified as a polyadenylated and caped transcript 
in trachea (NCBI AceView). Initially it was presumed that the PCR from exon 1 
to intron 25 did not work because the large amplicon size impaired the PCR. 
Therefore I25HER2 was expected to still contain exon 1 although only 
amplification from exon 2 to intron 25 could be observed. A HER2 variant “h” 
described in the AceView database was described to starts in intron 2. This 
raises the question if I25HER2 might also have a later start point. Similar to 
variant “h” a subset of I25HER2 also retains intron 12. Lastly, increased 
retention of introns between exon 21 and 25 in I25HER2 was observed, which 
has also been described in variant “h”. Due to the start of transcript “h” being in 
intron 2 it was predicted to have a 2484 bp long 5’UTR and to only initiate 
translation in intron 12. Its translation was also predicted to be terminated in 
intron 21, giving rise to a 3955 bp long 3’UTR. Interestingly it was also shown to 
contain a partially spliced exon 27. A partially spliced exon 27 in I25HER2 could 
not be verified. Variant “h” has been suggested to have impaired protein 
translation efficacy, due to the presence of a shorter translated product 
upstream of the main open reading frame. The predicted protein “h” lacks both 
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the majority of the ligand binding domains and the last 271 amino acids of 
conventional HER2. Its predicted molecular weight is 41.3 kD (NCBI AceView).  
 
5.5.1.1. In-silico predictions for I25HER2 
 
The previously described mRNA transcripts (variants “n” and “h”) and our 
finding regarding the different ways in which intron 25 can be incorporated into 
mRNAs show that there is possibly more than one I25HER2 transcript. 
Retention of additional introns or the use of a not previously described promoter 
are possibilities, but are unlikely to be the main, stable I25HER2 transcript. 
Therefore a transcript from exon 1 to exon 27 was used with only intron 25 
retention for our in-silico predictions. Secondary mRNA structure predictions 
show that the retention of intron 25 causes an extensive change to the mRNA 
structure, especially in the centroid plain model. This could indicate I25HER2 
mRNA to be differently processed, shuttled to the ribosomes and translated. A 
full length I25HER2 protein would be expected to only differ from wild type 
HER2 by its shorter alternative C-terminal tail. This could have a major impact 
on the downstream signalling ability of I25HER2, as the phosphorylation sites in 
the normal C-terminus are not part of I25HER2. These phosphorylated 
tyrosines are the main docking sites for downstream signalling molecules, so 
that neither the PI3K-AKT nor the ras-MAPK pathways are likely to be initiated 
in I25 HER2. In addition the I25HER2 C-terminus is short and has a slightly 
different secondary structure, which could impact not only its own downstream 
signalling, but also the transactivation of its dimerization partner. In the 
introduction it was described how the ErbB family members need to dimerise 
after ligand binding to induce downstream signalling [reviewed in (Roskoski, 
2014)]. Considering the intricate interaction between the intracellular domains of 
the two ErbB interacting proteins (Collier et al., 2013) such a drastic shortening 
of the C-terminus is very likely to impair that interaction. 
 
 
Chapter 5: Identification of novel HER2 splice variants 
200 
 
5.5.1.2. HER2 intron 25 retention levels in human tissues 
 
In this study it was shown that intron 25 is retained in breast cancer cell lines as 
well as normal breast tissue. Additionally, intron 25 was observed to be retained 
in other normal tissues. An indicator that I25HER2 is not only a by-product of 
HER2 splicing, is that the ratio between wild type HER2 and intron 25 retention 
is dependent on the tissue. Overall the intron 25 retention is the most abundant 
in testis and cerebellum. These tissues are known for a high level of alternative 
splicing (de la Grange et al., 2010). Additionally, the expression of I25HER2 
was studied in a small cohort of human grade 3 ductal breast carcinomas and 
normal breast tissues. In the HER2-positive breast tumour samples the ratio 
between wild type HER2 and intron 25 retention was mostly consistent. For 
three HER2-positive breast tumour samples HER2 (G5-2, G5-3, G5-4) IHC and 
CISH data is available from chapter 4 (Table 5.3). G5-3 and G5-4 showed a 
lower wild type HER2 expression than expected. For G5-3 this matches the IHC 
and CISH scoring. In case of G5-4 CISH score as well as two of three IHC 
methods indicated HER2 overexpression. 
Table 5.3: HER2 IHC and CISH score for four tumour samples used in intron 25 PCRs.  
Sample 
ID 
CISH 
ID 
HercepTest 
C-term. 
Antibody 
N-term 
Antibody 
HER2 CISH 
score 
G3-1 IHC-5 NA 0 0 1.03 
G5-2 IHC-12 3 1* 3 3.06 
G5-3 IHC-13 1* 0 2 1.24 
G5-4 IHC-14 3(F) 0 3(D)* 2.42 
 
In contrast variations in the ratio between intron 25 retention and wild type 
HER2 was observed in both normal breast and ER/HER2-negative tumour 
samples. As expected the level of wild type HER2 was very low or not 
detectable in normal breast and HER/ER-negative tumour samples. Only one 
normal breast sample (G1-4) showed a slightly increased level of wild type 
HER2. However in all normal breast and ER/HER2-negative tumour samples 
intron 25 retention could be observed. The samples G3-3, G3-4 and G3-5 
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should be noted as they show intron 25 retention, but wild type HER2 levels 
remain below detection limit.  
 
5.5.1.3. Intron 25 stability 
 
To further assess if I25HER2 is likely to be translated into a protein an mRNA 
decay assay was performed. There it was shown that I25HER2 is degraded 
slowly, at a similar rate to Δ16HER2. A member of our group, MRes student S. 
Satam successfully transfected a HER2 construct containing intron 12 into 
breast cancer cells and showed its protein expression (unpublished data). 
Given that intron 25 was more stable than intron 12 in the RNA decay assay, it 
is very likely that I25HER2 mRNA will also be translated.  
Before trying to detect I25HER2 at the protein level we wished to further 
understand the type of HER2 transcript that intron 25 is retained in. For this a 
non-isotopic northern blot was established. The positive control experiment 
supplied by the manufacturer of the northern blot kit was carried out 
successfully. However, problems were encountered when adapting the protocol 
for the detection of general HER2 and intron 25. In two experiments the same 
binding pattern for general HER2 was observed. A number of bands sized: 9, 
4.5, 3 and 2.5 kb were detected. Multiple bands were expected as all known 
HER2 splice variants are expected to contain exon 5, the binding site of the 
general HER2 probe. The 4.5 kb band corresponds to wild type HER2. 
Furthermore, HER2 splice variant p100 was determined to be 2.3 kb of size and 
could possibly correspond to the 2.5 kb band detected in the northern blot 
(Doherty et al., 1999a). However, the specificity of the probes has to be put in 
question as three bands (9, 3 and 2.5 kb) are close in size to the main RNA 
bands observed on the agarose gel. The RNA used was enriched for poly(A) 
mRNA and the main bands in the agarose gel were therefore the most strongly 
expressed mRNAs in SKBR3 cells. Although HER2 is strongly overexpressed in 
SKBR3 cell, the ~9 kb sized band does not correspond to any known HER2 
transcript. Only in one study in the ovarian cancer cell line SKOV-3, was a 
HER2 variant detected that had a similar size (Doherty et al., 1999b). That 
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transcript also contained a very long 3’UTR. The sequence provided by the 
paper showed HER2 to be translocated, as the 3’UTR contained elements from 
chromosome 3q26.2. HER2 gene amplification can also be observed in SKBR3 
cells, but there is no information on a similar translocation and associated 
increase in 3’UTR length. 
The results from the northern blot for intron 25 are not conclusive. The process 
has undergone a number of optimisation steps. The result from the last 
optimized experiment was shown here. Two bands (8-9 kb and 2.8 kb) were 
detected in the intron 25 northern blot. One is very similar in size to the before 
discussed 9 kb band detected with the general HER2 probe. The other, 2.8 kb 
band does not share the size with the RNA bands, but matches a very faint 
general HER2 band. This was expected as the general HER2 probe binds exon 
5, which was shown by PCR to be part of I25HER2. However the band size of 
2.8 kb was unexpected, as the PCR work indicated I25HER2 to be part of a full 
length transcript of approximately 4.5 kb. Previously the possibility of an 
I25HER2 variant in MCF-7 cells, which starts around exon 20 was discussed. 
Depending on the 3’UTR length such a transcript could potentially account for 
the 2.8 kb northern blot band. The similar size of this band to the general HER2 
band could be a coincident and the general HER2 band could actually 
correspond to Herstatin.  
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5.5.2. Summary 
 
In this study a novel intron retention variant of HER2 was identified. As 
I25HER2 is expressed in a number of tissues and its mRNA is stable, it is likely 
to be translated into a protein. Although the sample size was small, it is very 
interesting to note that I25HER2 expression is increased in normal breast tissue 
and HER2-negative breast tumours, as well as some HER2-positive tumours. It 
could be suggested that due to the truncated c-terminus I25HER2 is a 
functionally impaired HER2 protein variant. 
 
5.5.3. Further work  
 
The main aim of any future work would be to identify any other novel HER2 
variants and to better characterise I25HER2. It would be necessary to optimise 
the northern blot assay further. Plasmids with templates for human GAPDH, 
general HER2 and I25HER2 northern blot probes have been generated and will 
be used in future studies. A main issue is the lack of a biotinylated RNA ladder 
of the appropriate size to accurately determine the size of northern blot bands. 
A pre-stained RNA ladder (DynaMarker® Prestained Marker for RNA High, 
BioDynamics Laboratory) that can be transferred onto the nitrocellulose 
membrane was acquired, to be used in future work. To verify if the bands 
observed in the northern blot are specific different sources of mRNA should be 
tested. It would also be best to use previously tested HER2 probes, to see if the 
pattern observed in this work is reproducible with a different probe and possibly 
northern blot system. If the probes were for identical regions, the results would 
indicate how specific this non-isotopic northern blot was. An optimised northern 
blot assay would also be of use for the study of other novel splice variants. 
To better understand HER2 transcripts in general, we would suggest to perform 
a 3’/5’ RACE (rapid amplification cDNA ends). The basic method has been 
modified and improved by some companies (e.g. FirstChoice® RLM-RACE kit 
by Thermo Scientific) and could be adapted to identify novel HER2 variants as 
well as the exact 3’ and 5’ usage of known HER2 variants, including I25HER2. 
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The existence of alternative promoters and first exons was discussed 
previously. A 5’ RACE would be especially interesting in regard to alternative 
poly(A) sites, which have not been previously investigated in HER2. Work in 
recent years have shown them to be important for the splicing of the transcript 
in general and the further processing of mRNAs (Elkon et al., 2013; Li et al., 
2015a). 
Once I25HER2 transcript has been sufficiently characterised, an I25HER2 
plasmid construct should be designed. It could then be expressed in cells and 
the translated protein could be studied in regard to its localisation, ability to 
dimerize and induce downstream signalling. Depending on the results, an 
antibody could be designed and further expression studies in human tumour 
samples would be performed. A similar approach would be used if other HER2 
mRNA transcripts were identified. 
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Chapter 6: Conclusion and outlook 
 
6.1.  Conclusion 
 
The topic of the research presented in this thesis is the breast cancer proto-
oncogene and therapy target HER2. Different interlinking aspects were studied 
in this project. The focus of the first result chapter was Δ16HER2. A number of 
studies have indicated that the oncogenic HER2 splice variant Δ16HER2 might 
be a driver of breast tumour formation (Castiglioni et al., 2006; Marchini et al., 
2011; Alajati et al., 2013). In-vitro and in-vivo experiments have suggested that 
Δ16HER2 driven breast tumours show an expression profile similar to ER-
negative, high grade metastatic breast tumours (Alajati et al., 2013). It has been 
further suggested that these tumours have a histology and karyotype distinct 
from wild type HER2 driven tumours (Castagnoli et al., 2014).  
To better understand this driver of tumour formation the mechanisms regulating 
its production were investigated. Four key splicing factors (SRSF3, hnRNPs F, 
H & K) were identified that regulate the splicing process yielding Δ16HER2, as 
well as a hnRNP K binding site in the Δ16HER2 spice region. These splicing 
factors were also found to affect the splicing process of the tumour suppressor 
HER2 splice variant p100. Part of the work presented here indicated that 
hnRNP F/H might not only enhance exon 16 inclusion in the HER2 mRNA, but 
itself be induced by HER2 signalling.  
HER2 as well as HER2 signalling has been shown to interact with the other 
main biomarkers of breast cancer, ER and PR (Oh et al., 2001; Beguelin et al., 
2010; Diaz Flaque et al., 2013; Giuliano et al., 2013; Grabinski et al., 2014). In 
chapter three an additional possible way of interaction was studied. The aim 
was to investigate whether progesterone induced HER2 expression and 
affected the alternative splicing pattern of HER2. Progesterone was observed to 
induce HER2 expression but not affect the alternative splicing pattern. 
Most studies only focus on studying one HER2 protein variant. However, to 
understand the impact that the coexistence of HER2 protein variants and how 
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they interact might have on therapy success, different approaches have to be 
considered. As an initial step, in chapter four a cohort of invasive primary ductal 
carcinomas was characterized by IHC and CISH. A N- and a C-terminal 
antibody were used in addition to clinically used HercepTestTM. Some 
discrepancies were observed between the IHC staining’s as well as between 
the initial clinical assessment and the results of the IHC and CISH study. 
Tumour heterogeneity was observed in 35% of HER2-positive tumours. Four 
HER2-positiv tumours showed HER2-negative to borderline scores by CISH. Of 
these only one was scored 3+ by the HercepTestTM. The other two were HER2-
negative on the protein level however one, tumour IHC-15 was interesting as it 
scored HER2 3+ with the N-terminal antibody. To investigate whether some of 
these discrepant results are due to HER2 splice variants, conventional PCRs 
were performed. Indeed, p100 and Herstatin levels were elevated in some 
tumours, most strongly in IHC-15. 
As mentioned above, all HER2 protein variants arising from alternative mRNA 
processing, translation initiation as well as proteolytic cleavage, should be 
investigated in conjunction. Moreover, in the final results chapter of this thesis 
the existence of novel HER2 splice variants was investigated. An intron 
retention splice variant, named I25HER2 was identified. It was found to be 
present in both normal tissues and human breast tumour tissues. Interestingly, 
although the sample size was small I25HER2 levels were elevated in normal 
and HER-negative tumours. Additionally, experimental evidence suggests the 
mRNA stability of I25HER2 to be similar to Δ16HER2. I25HER2 is therefore 
likely to be translated into a protein, which is likely to be functionally impaired 
and could possibly downregulate the function of wild type HER2. 
In conclusion, this work identified key splicing regulators through which the 
production of HER2 splice variants Δ16HER2 and p100 is regulated. The 
research also identified a novel HER2 splice variant.  
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6.2. Outlook 
 
Taking the findings of this PhD thesis forward, the main aim will be to device a 
study that characterizes HER2 in all its forms in breast cancer. This will be of 
relevance to define potential breast cancer subtypes and inform clinical HER2 
assessment methods. Such a study would also show at what levels and in what 
combinations HER2 protein variants can be found in human breast tumours. 
This could be explored by studying the mechanistic of HER2 splice variant 
interactions in basic cell line models. Here key splicing regulators of Δ16HER2 
were identified. In future studies this work would be expanded to include the 
other HER2 splice variants. Understanding the role of HER2 protein variants 
and how they are produced would give an opportunity to potentially develop 
new treatment strategies.  
As research in tumour biology expands new aspects have to be considered. Of 
particular interest for future work would be the microenvironment of breast 
tumour cells and their interaction with the immune system. Functional studies 
are mostly done in cell line models and to some extend in mice. However, 
alternative splicing has been shown to be affected by environmental influences 
(Pagliarini et al., 2015) and therefore findings in 2D cell line models might not 
translate directly into 3D-models or actual mechanisms in human tumours. In 
future work it would be very interesting to investigate different tumour cell line 
models, their interaction with stromal cells and the effect on expression and 
alternative splicing of HER2. 
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